

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrRIABNI™

rituximab for injection
10 mg/mL Intravenous Infusion

Professed Standard

Antineoplastic

Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, ON L5N 0A4

Date of Initial Authorization:
March 11, 2021

Submission Control Number: 237814

© 2021 Amgen Canada Inc., All Rights Reserved.

RECENT MAJOR LABEL CHANGES

N/A	
-----	--

TABLE OF CONTENTS

RECENT MAJOR LABEL CHANGES 2

PART I: HEALTH PROFESSIONAL INFORMATION 4

1 INDICATIONS 4

 1.1 Pediatrics 5

 1.2 Geriatrics 5

2 CONTRAINDICATIONS 5

3 SERIOUS WARNINGS AND PRECAUTIONS BOX 5

4 DOSAGE AND ADMINISTRATION 7

 4.1 Dosing Considerations 7

 4.2 Recommended Dose and Dosage Adjustment 7

 4.3 Reconstitution 9

 4.4 Administration 10

 4.5 Missed Dose 11

5 OVERDOSAGE 11

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING 11

7 WARNINGS AND PRECAUTIONS 12

 7.1.1 Pregnant Women 21

 7.1.2 Breast-feeding 21

 7.1.3 Pediatrics 22

 7.1.4 Geriatrics 22

8 ADVERSE REACTIONS 22

 8.1 Adverse Reaction Overview – Hemato-Oncology 22

 8.2 Clinical Trial Adverse Reactions 23

 8.3 Less Common Clinical Trial Adverse Drug Reactions (< 1%) 27

 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other
Quantitative Data 71

 8.5 Post-Market Adverse Drug Reactions 71

 Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA, also known as
Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) Patients 71

9 DRUG INTERACTIONS 74

 9.1 Serious Drug Interactions 74

 9.2 Drug Interactions Overview 74

 9.3 Drug-Behavioural Interactions 74

 9.4 Drug-Drug Interactions 74

 9.5 Drug-Food Interactions 74

 9.6 Drug-Herb Interactions 75

 9.7 Drug-Laboratory Test Interactions 75

10 CLINICAL PHARMACOLOGY 75

 10.1 Mechanism of Action 75

10.2	Pharmacodynamics.....	75
10.3	Pharmacokinetics	75
11	STORAGE, STABILITY AND DISPOSAL.....	78
12	SPECIAL HANDLING INSTRUCTIONS.....	79
PART II: SCIENTIFIC INFORMATION.....		80
13	PHARMACEUTICAL INFORMATION	80
14	CLINICAL TRIALS	81
14.1	Trial Design and Study Demographics.....	81
14.2	Study Results	83
14.3	Comparative Bioavailability Studies	83
14.4	Immunogenicity.....	85
14.5	Clinical Trials - Reference Biologic Drug.....	85
15	MICROBIOLOGY	110
16	NON-CLINICAL TOXICOLOGY	110
16.1	Comparative Non-Clinical Pharmacology and Toxicology.....	112
16.1.1	Comparative Non-Clinical Pharmacodynamics	112
16.1.2	Comparative Toxicology	112
PATIENT MEDICATION INFORMATION		113
PATIENT MEDICATION INFORMATION		121

RIABNI™ (rituximab for injection) is a biosimilar biologic drug (biosimilar) to Rituxan®

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Indications have been granted on the basis of similarity between RIABNI™ and the reference biologic drug Rituxan®.

Non-Hodgkin's Lymphoma (NHL)

RIABNI (rituximab) is indicated for:

- the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma.
- the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.
- the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.
- the maintenance treatment of patients with follicular non-Hodgkin's lymphoma who have responded to induction therapy with either CHOP or CHOP plus rituximab.
- single-agent maintenance treatment of previously untreated patients with advanced follicular non-Hodgkin's lymphoma with high tumour burden and who have responded to induction therapy with either CHOP plus rituximab or CVP plus rituximab.

Chronic Lymphocytic Leukemia (CLL)

RIABNI (rituximab) is indicated for:

- the treatment of patients with previously untreated or previously treated B-cell chronic lymphocytic leukemia (B-CLL), Binet Stage B or C, in combination with fludarabine and cyclophosphamide.

The use of rituximab in CLL is based on an improvement in progression-free survival. Overall survival benefit has not been demonstrated in patients with previous treatment for CLL. The efficacy of treatment with R-FC (rituximab -fludarabine and cyclophosphamide) in CLL patients who were previously treated with rituximab in combination with fludarabine and cyclophosphamide has not been studied (see **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG** for details).

Rheumatoid Arthritis (RA)

RIABNI in combination with methotrexate is indicated in adult patients:

- to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.

Rituximab in combination with methotrexate has been shown to reduce the rate of progression of joint damage as measured by x-ray.

Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

RIABNI in combination with glucocorticoids is indicated for:

- the induction of remission in adult patients with severely active Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).

Consideration should be given to current treatment guidelines for vasculitis.

1.1 Pediatrics

The safety and efficacy of rituximab have not been studied in pediatric patients (see **7 WARNINGS AND PRECAUTIONS, Pediatrics**).

1.2 Geriatrics

Geriatrics (≥ 65 years of age): In the CLL setting, exploratory subgroup analysis indicates that use in the geriatric population is associated with differences in efficacy and safety. See **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG** and **8 ADVERSE REACTIONS** for details.

2 CONTRAINDICATIONS

RIABNI (rituximab) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see **6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING**.

- RIABNI (rituximab injection) is contraindicated in patients with known Type I hypersensitivity or anaphylactic reactions to murine proteins, Chinese Hamster Ovary (CHO) cell proteins, or to any component of this product (see **7 WARNINGS AND PRECAUTIONS**).
- RIABNI is also contraindicated in patients who have or have had progressive multifocal leukoencephalopathy (PML).
- RIABNI is not recommended for use in patients with severe, active infections.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

- **General**

RIABNI (rituximab) is a potent drug. Several adverse reactions are associated with rituximab, some of which are severe and life-threatening (see **7 WARNINGS AND PRECAUTIONS**). This drug should only be used by health professionals experienced in treating Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). Patients should be treated in a setting where full resuscitation facilities are immediately available, and where medications and supportive care measures for the treatment of hypersensitivity reactions (eg, epinephrine, antihistamines, glucocorticoids) are immediately available in the event of an allergic reaction during administration (see **4 DOSAGE AND ADMINISTRATION**).

- **Infusion Reactions**

Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Carefully monitor patients during infusions. Discontinue RIABNI infusion and provide medical treatment for Grade 3 or 4 infusion reactions (see **7 WARNINGS AND PRECAUTIONS, Infusion-Related Events**).

- **Progressive Multifocal Leukoencephalopathy (PML)**

Patients with RA, NHL and CLL who received treatment with rituximab may have an increased risk of PML. PML can cause disability or death. Healthcare professionals should monitor patients on RIABNI for any new sign or symptom that may be suggestive of PML. Further treatment with RIABNI should be withheld immediately at the first sign or symptom suggestive of PML (see **7 WARNINGS AND PRECAUTIONS, Progressive Multifocal Leukoencephalopathy**).

- **Tumor Lysis Syndrome (TLS)**

Acute renal failure requiring dialysis with instances of fatal outcome has been reported in the setting of TLS following treatment of NHL patients with rituximab (see **7 WARNINGS AND PRECAUTIONS, Infusion-Related Events**).

- **Hepatitis B Virus (HBV) Reactivation**

HBV reactivation has occurred in patients treated with rituximab, in some cases resulting in fulminant hepatitis, hepatic failure, and death. All patients should be screened for HBV infection before treatment initiation, and should be monitored during and after treatment with RIABNI. In the event of HBV reactivation, RIABNI and concomitant medications should be discontinued.

- **Mucocutaneous Reactions**

Severe, including fatal, mucocutaneous reactions including Toxic Epidermal Necrolysis (TEN) and Stevens Johnson Syndrome (SJS) have occurred in patients treated with rituximab. Patients experiencing a severe mucocutaneous reaction should discontinue treatment with RIABNI and seek prompt medical evaluation (see **7 WARNINGS AND PRECAUTIONS, Skin**).

- **Infections**

Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during or following the completion of rituximab -based therapy. RIABNI treatment should not be initiated in patients with severe active infections. Patients should be screened for infectious disease history (see **7 WARNINGS AND PRECAUTIONS, Infections**).

- **Cardiovascular**

Serious and potentially fatal cardiovascular events have been reported rarely following administration of rituximab (see **7 WARNINGS AND PRECAUTIONS**).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

RIABNI (rituximab) infusions should be administered in a setting where full resuscitation facilities (see **3 SERIOUS WARNINGS AND PRECAUTIONS BOX**) are immediately available, and under the close supervision of someone experienced and capable of dealing with severe infusion-related reactions. RIABNI should be administered as an IV infusion through a dedicated line. **Do not administer as an intravenous push or bolus** (see **4.4 Administration**).

Hypersensitivity reactions and severe infusion-related reaction may occur with administration of RIABNI (see **7 WARNINGS AND PRECAUTIONS**). Since transient hypotension may occur during infusion with RIABNI, consideration should be given to withholding anti-hypertensive medications 12 hours prior to and throughout infusion with RIABNI.

Patients who develop clinically significant arrhythmias should undergo cardiac monitoring during and after subsequent infusions of RIABNI. Patients with pre-existing cardiac conditions such as angina and arrhythmias should be monitored during and after the infusion of RIABNI.

Amgen Entrust™ Patient Support Programs will facilitate the administration of RIABNI through the Entrust™ Infusion Network with clinics staffed by qualified healthcare professionals specially trained in the administration of RIABNI infusions. Information about Entrust™ Patient Support Programs can be obtained by calling:

- Enliven® by Amgen Entrust™ at 1.877.936.2735 for Inflammation
- Victory® by Amgen Entrust™ at 1.888.706.4717 for Oncology

4.2 Recommended Dose and Dosage Adjustment

Non-Hodgkin's Lymphoma (NHL)

Usual Dose

Low Grade or Follicular Non-Hodgkin's Lymphoma

Premedication

Premedication consisting of an analgesic or anti-pyretic (eg, acetaminophen) and an antihistaminic drug (eg, diphenhydramine) should always be administered before each infusion of RIABNI.

Premedication with glucocorticoids should also be considered, particularly if RIABNI is not given in combination with steroid-containing chemotherapy (see **7 WARNINGS AND PRECAUTIONS, Non-Hodgkin's Lymphoma** and **Chronic Lymphocytic Leukemia, Infusion- Related Events**).

Initial treatment

The recommended dosage of RIABNI as a single agent is 375 mg/m² given as an IV infusion once weekly for four doses (on days 1, 8, 15, and 22).

The recommended dosage of RIABNI in combination with CVP chemotherapy is 375 mg/m² for 8 cycles (21 days/cycle), administered as an IV infusion on day 1 of each chemotherapy cycle after IV administration of the corticosteroid component of CVP.

Maintenance treatment

In previously untreated patients with advanced high-tumour burden follicular lymphoma, after complete or partial response to induction treatment the recommended dose of RIABNI maintenance therapy is 375 mg/m² body surface area. RIABNI maintenance therapy should be

initiated eight weeks following completion of RIABNI in combination with chemotherapy. RIABNI as a single agent should be administered every 8 weeks for a maximum of 12 doses (two years).

The recommended dose of RIABNI for relapsed or refractory patients after response to induction treatment is 375 mg/m² every 3 months until disease progression or for a maximum period of two years.

Diffuse Large B-cell Non-Hodgkin's Lymphoma

Premedication

Premedication consisting of an analgesic/anti-pyretic (eg, acetaminophen) and an antihistaminic drug (eg, diphenhydramine) should always be administered before each infusion of RIABNI.

Premedication with glucocorticoids should also be considered, particularly if RIABNI is not given in combination with steroid-containing chemotherapy (see **7 WARNINGS AND PRECAUTIONS, Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Infusion-Related Events**).

RIABNI should be used in combination with CHOP chemotherapy. The recommended dosage of RIABNI is 375 mg/m² administered on day 1 of each chemotherapy cycle after IV administration of the glucocorticoid component of CHOP. The other components of CHOP (cyclophosphamide, doxorubicin, vincristine) should be given after the administration of RIABNI.

Chronic Lymphocytic Leukemia (CLL)

Premedication

Premedication consisting of an analgesic or anti-pyretic (eg, acetaminophen) and an antihistaminic drug (eg, diphenhydramine) should always be administered before each infusion of RIABNI.

Premedication with glucocorticoids should also be considered, particularly if RIABNI is not given in combination with steroid-containing chemotherapy (see **7 WARNINGS AND PRECAUTIONS, Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Infusion-Related Events**).

The recommended dosage of RIABNI in combination with chemotherapy for previously untreated and previously treated patients is 375 mg/m² body surface area administered on day 1 of the first treatment cycle followed by 500mg/m² body surface area administered on day 1 of each subsequent cycle for 6 cycles in total. The chemotherapy should be given after RIABNI infusion.

Prophylaxis with adequate hydration and administration of uricostatics (such as allopurinol) starting 48 hours prior to start of therapy is recommended for CLL patients to reduce the risk of tumour lysis syndrome. For CLL patients whose lymphocyte counts are > 25 x10⁹/L it is recommended to administer methylprednisolone IV shortly before infusion with RIABNI to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome. In study ML17102 an equivalent of 80mg of methylprednisolone (100 mg prednisone IV) was given prior to infusions with rituximab. Seventy-four percent (74%) of patients in the R-FC arms of study ML17102 received at least one dose of corticosteroids, with 27% receiving two or more doses.

Dosage Adjustments During Treatment

No dose reductions of RIABNI are recommended but 47% of patients in the clinical trial ML17102 for CLL required a delayed and/or slowed infusion, and 17% required their first dose split over two days. When RIABNI is given in combination with CHOP chemotherapy, standard dose reductions for the chemotherapeutic drugs should be applied. When RIABNI is given as maintenance treatment, treatment should be delayed in case of significant clinical toxicity according to standard practice.

RIABNI as a Component of ZEVALIN® (Ibritumomab Tiuxetan) Therapeutic Regimen

As a required component of the ZEVALIN therapeutic regimen, rituximab is administered twice. The first administration of RIABNI is a single infusion of 250 mg/m² and should precede the second administration by 7-9 days. At the second administration, RIABNI 250 mg/m² should be infused within 4 hours prior to the administration of 90Y-ibritumomab tiuxetan. Refer to the ZEVALIN product monograph for full prescribing information.

Rheumatoid Arthritis (RA)

Premedication

Premedication consisting of an analgesic or anti-pyretic (eg, acetaminophen) and an antihistaminic drug (eg, diphenhydramine) should always be administered before each infusion of RIABNI.

Premedication with glucocorticoids should also be administered in order to reduce the frequency and severity of infusion-related reactions. Patients should receive 100 mg IV methylprednisolone to be completed 30 minutes prior to each RIABNI infusion (see **7 WARNINGS AND PRECAUTIONS, Rheumatoid Arthritis, Infusion-Related Events**).

Usual Dose

A course of RIABNI consists of two 1000 mg IV infusions. The recommended dosage of RIABNI is 1000 mg by IV infusion followed two weeks later by the second 1000 mg IV infusion.

Retreatment in Patients with RA

The need for further courses should be evaluated 24 weeks following the previous course with retreatment given based on residual disease or disease activity returning to a level above a DAS28-ESR of 2.6 (treatment to remission). Patients may receive further courses no sooner than 16 weeks following the previous course.

Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

The recommended dosage of RIABNI for treatment of GPA/MPA is 375 mg/m² body surface area, administered as an IV infusion once weekly for 4 weeks.

Glucocorticoids administered as methylprednisolone 1000 mg intravenously per day for 1 to 3 days followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day and tapered per clinical need) are recommended to treat severe vasculitis symptoms. This regimen should begin within 14 days prior to or with the initiation of RIABNI and may continue during and after the 4 week course of RIABNI treatment.

The efficacy and safety of subsequent courses of rituximab have not been established (see **7 WARNINGS AND PRECAUTIONS** and **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG**).

4.3 Reconstitution

Not applicable.

4.4 Administration

Preparation for administration:

Use appropriate aseptic technique. RIABNI does not contain any preservative or bacteriostatic agent. Withdraw the necessary amount of RIABNI and dilute to a final concentration of 1 to 4 mg/mL into an infusion bag containing either 0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP. To avoid foaming, gently invert the bag to mix the solution. Discard any unused portion left in the vial. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. For in-use stability information see **11 STORAGE, STABILITY AND DISPOSAL**.

Non-Hodgkin's Lymphoma

Do not administer as an intravenous push or bolus. Premedication with glucocorticoids should be considered, particularly if RIABNI is not given in combination with steroid-containing chemotherapy. Premedication may attenuate infusion-related events. In the clinical trial ML17102 for CLL, the equivalent of 80 mg methylprednisolone (100 mg prednisone IV) was given to most patients prior to each infusion.

First Infusion

The RIABNI solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. RIABNI should not be mixed or diluted with other drugs. If hypersensitivity or infusion-related events do not occur, escalate the infusion rate in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr. This rate corresponds to an administration time of 4.25 hours. If hypersensitivity or an infusion-related event develops, the infusion should be temporarily slowed or interrupted (see **7 WARNINGS AND PRECAUTIONS**). The infusion can continue at one-half the previous rate upon improvement of patient symptoms.

Subsequent Infusions

Subsequent infusions of RIABNI can be administered at an initial rate of 100 mg/hr and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated. This rate corresponds to an administration time of 3.25 hours.

Rheumatoid Arthritis

First infusion of each course

The recommended initial rate for infusion is 50 mg/hr; after the first 30 minutes, it can be escalated in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr. This rate corresponds to an administration time of 4.25 hours.

Second infusion of each course

Subsequent doses of RIABNI can be infused at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30 minutes intervals, to a maximum of 400 mg/hr. This rate corresponds to an administration time of 3.25 hours.

Alternative 120-minute subsequent infusions with the concentration of 4 mg/mL in a 250 mL volume (Rheumatoid Arthritis Only)

If patients did not experience a serious infusion-related adverse event during the previous infusion administered using the standard administration schedule, an alternative 120-minute infusion of a concentration at 4 mg/mL in a 250 mL volume can be administered for the second infusion. Initiate at a rate of 62.5 mL/hr (125 mg) given in the first 30 minutes and 150 mL/hr (875 mg) given over the next 90 minutes. If the 120-minute infusion is tolerated, the same alternative 120-minute infusion rate can be used when administering subsequent infusions and courses.

Patients who have clinically significant cardiovascular disease including arrhythmias or previous serious infusion reactions to any prior biologic therapy or to rituximab, should not be administered the alternative 120-minute infusion.

Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

First infusion

The recommended initial infusion rate for RIABNI is 50 mg/hr; subsequently, the rate can be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. This rate corresponds to an administration time of 4.25 hours.

Subsequent infusions

Subsequent infusions of RIABNI can be started at a rate of 100 mg/hr and increased by 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. This rate corresponds to an administration time of 3.25 hours.

Pneumocystis Jiroveci Pneumonia (PCP) prophylaxis is recommended for patients with GPA/MPA during and following treatment.

4.5 Missed Dose

Missed or delayed doses should not be omitted but administered at a later time point, based on professional judgment observing the total number of planned cycles and the planned interval between doses.

5 OVERDOSAGE

There has been no experience with overdosage in human clinical trials. Single doses higher than 1000 mg have not been tested in controlled clinical studies. The highest dose tested to date is 5 g in patients with chronic lymphocytic leukemia. No additional safety signals were identified. Patients who experience overdose should have immediate interruption of their infusion and be closely monitored. Consideration should be given to the need for regular monitoring of blood cell count and for increased risk of infections while patients are B-cell-depleted.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

To help ensure the traceability of biologic products, including biosimilars, health professionals should recognise the importance of recording both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

Table 1. Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Intravenous	100 and 500 mg vials (10 mg/mL)	hydrochloric acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection

RIABNI is a sterile, clear to slightly opalescent, colourless to slightly yellow, preservative-free liquid concentrate for intravenous (IV) administration.

RIABNI is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials.

Description

RIABNI (rituximab) is a chimeric mouse/human monoclonal antibody that binds specifically to the transmembrane antigen CD20.

7 WARNINGS AND PRECAUTIONS

Please see **3 SERIOUS WARNINGS AND PRECAUTIONS BOX**.

NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Infusion-Related Events

RIABNI is associated with infusion-related reactions, which may be related to release of cytokines and/or other chemical mediators. Severe infusion-related reactions might be clinically indistinguishable from hypersensitivity reactions or cytokine release syndrome. Severe infusion-related reactions with fatal outcome have been reported during post-marketing use. Severe infusion-related reactions usually manifested within 30 minutes to 2 hours after starting the first infusion with rituximab. These reactions were characterized by pulmonary events, and included, in some cases, rapid tumour lysis and features of tumour lysis syndrome in addition to fever, chills, rigors, hypotension, urticaria, bronchospasm, acute respiratory distress syndrome, angioedema and other symptoms (see **8 ADVERSE REACTIONS, Clinical Trial Adverse Reactions, Experience From Clinical Trials in Hemato-Oncology**).

Infusion related deaths (death within 24 hours of infusion) have been reported at a rate of approximately 0.04 - 0.07% (4-7 per 10,000 patients treated). Nearly all fatal events occurred in association with the first infusion.

Patients with a high number ($> 25 \times 10^9/L$) of circulating malignant cells or high tumour burden such as patients with CLL and mantle cell lymphoma, who may be at higher risk of especially severe cytokine release syndrome, should only be treated with extreme caution and when other therapeutic alternatives have been exhausted. These patients should be very closely monitored throughout the first infusion. Consideration should be given to the use of a reduced infusion rate for the first infusion in these patients or a split dosing over two days during the first cycle and any subsequent cycles if the lymphocyte count is still $> 25 \times 10^9/L$; in the CLL ML17102 trial, 47% of patients required a delayed and/or slowed infusion, and 17% of patients required split dosing.

Premedication consisting of an anti-pyretic and an antihistaminic (eg, acetaminophen and diphenhydramine) should always be administered before each infusion of RIABNI. Premedication with glucocorticoids should also be considered, particularly if RIABNI is not given in combination with steroid-containing chemotherapy (see **4 DOSAGE AND ADMINISTRATION**).

Medications for the treatment of hypersensitivity reactions, eg, epinephrine, antihistamines and glucocorticoids should be available for immediate use in the event of a reaction during administration. In the CLL clinical trials, most patients received high-dose boluses intravenous corticosteroids [100 mg Prednisone IV] before each RIABNI infusion.

Patients should be monitored closely throughout the infusion. Patients with a high tumour burden or with a high number ($> 25 \times 10^9/L$) of circulating malignant cells such as patients with CLL and mantle cell lymphoma may be at higher risk of developing severe infusion-related reactions. If mild, the symptoms are usually reversible with interruption of RIABNI infusion. Treatment of infusion-related symptoms with diphenhydramine and acetaminophen is recommended. Additional treatment with bronchodilators or IV saline or IV corticosteroids may be indicated and should be immediately available. In patients with severe reaction, the infusion should be interrupted immediately (see **4 DOSAGE AND ADMINISTRATION**) and they should receive aggressive symptomatic treatment. Since initial improvement may be followed by deterioration, these patients should be closely monitored until Tumour Lysis Syndrome (TLS) and pulmonary infiltration have been ruled out. In most cases, the infusion can be resumed at a 50% reduction in rate (eg, from 100 mg/hr to 50 mg/hr) when symptoms have completely resolved. Most patients who have experienced non-life-threatening reactions have been able to complete the full course of therapy (see **4 DOSAGE AND ADMINISTRATION**). Further treatment of patients after complete resolution of signs and symptoms has rarely resulted in repeated severe infusion-related reactions. In the patients with a severe reaction, the decision to administer further infusions should be made by the treating physician on a case-by-case basis after assessing the risk versus benefit to the patient.

Pulmonary Events

Pulmonary events have included hypoxia, lung infiltration and acute respiratory failure. Some of these events have been preceded by severe bronchospasm and dyspnea. Patients with a history of pulmonary insufficiency or those with pulmonary tumour infiltration may be at greater risk of poor outcome and should be treated with increased caution.

Acute respiratory failure may be accompanied by events such as pulmonary interstitial infiltration or edema, visible on a chest x-ray. The syndrome usually manifests itself within one or two hours of initiating the first infusion. Patients who experience severe pulmonary events should have their infusion interrupted immediately (see **4 DOSAGE AND ADMINISTRATION**) and should receive aggressive symptomatic treatment. In some cases, symptoms worsened over time, while in others initial improvement was followed by clinical deterioration. Therefore, patients experiencing pulmonary events or other severe infusion-related symptoms should be closely monitored until complete resolution of their symptoms.

Tumour Lysis Syndrome

RIABNI mediates the rapid lysis of benign and malignant CD20 positive cells. Signs and symptoms (eg, hyperuricemia, hyperkalemia, hypocalcemia, hyperphosphatemia, acute renal failure, elevated LDH, high fevers) consistent with Tumour Lysis Syndrome (TLS) have been reported to occur within 1 to 2 hours though initial reports of TLS were not diagnosed until 12-24 hours after the first infusion in NHL patients with high numbers of circulating malignant lymphocytes. Acute renal failure requiring dialysis with instances of fatal outcome has been

reported in the setting of TLS in NHL patients. Prophylaxis for TLS should be considered for patients at risk of developing rapid tumour lysis (eg, patients with a high tumour burden or with a high number ($> 25 \times 10^9/L$) of circulating malignant cells such as patients with CLL and mantle cell lymphoma). These patients should be followed closely and appropriate laboratory monitoring should be performed. Appropriate medical therapy should be provided for patients who develop signs and symptoms consistent with rapid tumour lysis. Following treatment for and complete resolution of signs and symptoms, subsequent rituximab therapy has been administered in conjunction with prophylactic therapy for TLS in a limited number of cases.

Anaphylaxis

Anaphylactic reactions, including fatalities, have been reported in patients treated with rituximab. These reactions may be clinically indistinguishable from severe infusion-related reactions, other hypersensitivity reactions or cytokine release syndrome. True hypersensitivity reactions typically occur after starting the second or subsequent infusion of rituximab. Epinephrine, antihistamines and glucocorticoids should be available for immediate use in the event of a hypersensitivity reaction to RIABNI.

Carcinogenesis and Mutagenesis

No long-term animal studies have been performed to establish the carcinogenic or mutagenic potential of rituximab, or to determine its effects on fertility in males or females. Individuals of childbearing potential should use effective contraceptive methods during treatment and for up to 12 months following therapy with RIABNI.

Cardiovascular

Since transient hypotension may occur during infusion with RIABNI, consideration should be given to withholding anti-hypertensive medications 12 hours prior to and throughout infusion with RIABNI. Serious and potentially fatal cardiovascular events have been reported rarely following administration of rituximab. These events included: angina pectoris, cardiac arrhythmias such as atrial flutter and fibrillation, heart failure, myocardial infarction and cardiogenic shock. Infusions with RIABNI should be discontinued in the event of serious or life-threatening cardio-pulmonary events. Patients who develop clinically significant cardiovascular events should undergo cardiac monitoring during and after subsequent infusions of RIABNI. Patients with pre-existing cardiac conditions including arrhythmias and angina have had recurrences of these events during therapy with RIABNI and should be monitored throughout the infusion and immediate post-infusion period.

Driving and Operating Machinery

It is not known whether rituximab has an effect on the ability to drive and operate machines, though the pharmacologic activity and adverse events reported to date do not indicate that such an effect is to be expected.

Gastrointestinal

Abdominal pain, bowel obstruction and perforation, in some cases leading to death, were observed in patients receiving rituximab in combination with chemotherapy for DLBCL. A causal association with rituximab has not been established.

In post-marketing reports, which include both patients with low-grade or follicular NHL and DLBCL, the mean time to onset of symptoms was 6 days (range 1-77) in patients with documented gastrointestinal perforation. Complaints of abdominal pain, especially early in the course of treatment, should prompt a thorough diagnostic evaluation and appropriate treatment.

Hematologic

Myelosuppression

Although RIABNI is not myelosuppressive in monotherapy, caution should be exercised when considering treatment of patients with neutrophil counts $< 1.5 \times 10^9/L$ and/or platelet counts of $< 75 \times 10^9/L$, as clinical experience with such patients is limited. Rituximab has been used in patients who underwent autologous bone marrow transplantation and in other risk groups with a presumable reduced bone marrow function without inducing myelotoxicity.

Grade 3-4 neutropenia and decreased white blood cell counts were very common in ML17102 with combination therapy of rituximab with fludarabine and cyclophosphamide. Grade 4 lymphopenia was not captured. Neutropenia and febrile neutropenia occurred in higher frequencies in the R-FC arm. This increase did not result in a statistically significant increase in hospitalization rates.

Immune

HAMA/HACA Formation

Human anti-murine antibody (HAMA) was not detected in 67 patients evaluated. Of 356 patients evaluated for human anti-chimeric antibody (HACA), 1.1% (4 patients) were positive. Patients who develop HAMA/HACA titers may have allergic or hypersensitivity reactions when treated with rituximab or other murine or chimeric monoclonal antibodies.

Immunization

The safety of immunization with live viral vaccines, following therapy with rituximab has not been studied. Therefore, vaccination with live virus vaccines is not recommended while receiving RIABNI or during peripheral B-cell depletion.

Patients treated with RIABNI may receive non-live vaccinations. However, with non-live vaccines response rates to the vaccination could be reduced. In a non-randomized study, patients with relapsed or refractory low-grade NHL who received rituximab monotherapy when compared to healthy untreated controls had a lower rate of response to vaccination with tetanus recall antigen (16% vs 81%) and Keyhole Limpet Hemocyanin (KLH) neoantigen (4% vs 76%) when assessed for > 2 -fold increase in antibody titer.

Mean pre-therapeutic antibody titers against a panel of antigens (*Streptococcus pneumoniae*, influenza A, mumps, rubella, varicella) were maintained for at least 6 months after treatment with rituximab.

Infections

Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia > 11 months after rituximab exposure).

Hepatitis B Reactivation with Related Fulminant Hepatitis

Cases of Hepatitis B virus (HBV) reactivation, occasionally with fulminant hepatitis, hepatic failure, and death has been reported in some patients with hematologic malignancies treated with rituximab. The majority of patients received rituximab in combination with chemotherapy. Isolated cases have been reported in patients who either had evidence of antibodies against Hepatitis B surface antigen before treatment or did not have any such antibodies. The median time to diagnosis of hepatitis was approximately 4 months after the initiation of rituximab and approximately one month after the last dose (see **8 ADVERSE REACTIONS**).

Hepatitis B reactivation can occur in oncology patients even if Hepatitis B surface antigen status is normal. HBV screening should be performed in all patients before initiation of treatment with RIABNI. At minimum, this should include HBsAg-status and HBcAb-status. These can be complemented with other appropriate markers as per local guidelines. Reactivation of HBV infection is a well-known complication in patients with chronic hepatitis B, especially in those receiving cytotoxic or immunosuppressive therapy. In addition, non-Hodgkin's lymphoma of itself may be an independent risk factor for HBV reactivation. Patients with active hepatitis B disease should not be treated with RIABNI. Patients with positive hepatitis B serology should consult liver disease experts before start of treatment and should be monitored and managed following local medical standards to prevent hepatitis B reactivation.

In patients who develop reactivation of viral hepatitis B, RIABNI and any concomitant chemotherapy should be discontinued and appropriate treatment including antiviral therapy initiated. There are insufficient data regarding the safety of resuming therapy with RIABNI in patients who develop hepatitis subsequent to HBV reactivation.

Additional Serious Viral Infections

The following additional serious viral infections, either new, reactivated or exacerbated, have been identified in clinical studies or post-marketing reports. The majority of patients were profoundly immune-suppressed. These viral infections included JC virus [progressive multifocal leukoencephalopathy (PML) (see **7 WARNINGS AND PRECAUTIONS, Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Progressive Multifocal Leukoencephalopathy**), cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis C. In some cases, the viral infections occurred up to one year following discontinuation of rituximab and have resulted in death. RIABNI treatment should not be initiated in patients with an active and/or severe infection or severely immunocompromised patients.

Tuberculosis Reactivation

In the CLL clinical trial ML17102, one patient treated with rituximab plus fludarabine and cyclophosphamide experienced reactivation of tuberculosis. Patients who develop reactivation of tuberculosis should be treated as per current medical practice and RIABNI should be discontinued. There are no data regarding the safety of resuming therapy with RIABNI in patients who develop tuberculosis reactivation.

Pneumocystis Jiroveci Pneumonia

Cases of Pneumocystis Jiroveci Pneumonia (PJP) have been reported in patients receiving rituximab in combination with chemotherapy. These cases included patients with multiple risk factors for PJP, including the underlying disease state and other immunosuppressive therapies. The use of PJP prophylaxis should be considered according to local guidelines.

Monitoring and Laboratory Tests

Complete blood counts (CBC) and platelet counts should be obtained at regular intervals in patients with hematologic malignancies during therapy with RIABNI and more frequently in patients who develop cytopenias (see **8 ADVERSE REACTIONS**).

Neurologic

Four cases of stroke or cerebral ischemia originated from a clinical study (GELA, LNH98-5) and concerned patients from 72 to 79 years of age, who had received rituximab in combination with

CHOP chemotherapy, all with a history of cardiovascular disease or cardiovascular risk factors. In particular, lacunar lesions were seen in two patients, both of whom had a medical history of hypertension, the major risk factor of such small vessel disease. In 2 of these reports, the events were fatal and in the other two, the events were reported to have resolved. Furthermore, if the accepted definition of transient ischemic attack (TIA) (duration of signs/symptoms < 24 hours) is applied, then one of the four patients with reported stroke experienced a TIA.

Progressive Multifocal Leukoencephalopathy

Cases of Progressive Multifocal Leukoencephalopathy have been reported during the use of rituximab in hematologic malignancies (NHL, CLL) (see **8 ADVERSE REACTIONS**). The majority of patients had received rituximab in combination with chemotherapy or as part of a hematopoietic stem cell transplant.

Patients being treated with RIABNI should be instructed to report any new neurological signs or symptoms to their physician. Physicians treating patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia should be alert to any new signs or symptoms that may be suggestive of PML and consider PML in the differential diagnosis of patients reporting new onset neurological symptoms. Consultation with a neurologist should be considered as clinically indicated. Symptoms of PML are diverse, progress over days to weeks, and can include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory and orientation leading to confusion and personality changes. Further treatment with RIABNI should be withheld immediately at the first sign or symptom suggestive of PML and an evaluation that includes a magnetic resonance imaging (MRI) scan without and, where clinically indicated, with gadolinium-enhancement of the brain should be performed. Cerebrospinal fluid analysis for JC viral DNA is recommended to confirm a diagnosis of PML. Discontinue RIABNI and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients with confirmed PML.

The absolute risk for PML in patients treated with RIABNI cannot be precisely estimated and factors that might increase an individual patient's risk for PML have not been identified. There are no known interventions that can reliably prevent or adequately treat PML if it occurs. It is not known whether early detection of PML and discontinuation of RIABNI will mitigate the disease. The relationship between the risk of PML and the duration of treatment is unknown.

Skin

Severe mucocutaneous reactions including Stevens Johnson Syndrome (SJS), lichenoid dermatitis, vesiculobullous dermatitis, Toxic Epidermal Necrolysis (TEN) and paraneoplastic pemphigus have been reported rarely. Some of these cases were fatal. The onset varied from days to several months following exposure to rituximab. Patients experiencing a severe mucocutaneous reaction should discontinue treatment with RIABNI and seek prompt medical evaluation. In case of such an event, with a suspected relationship to RIABNI, treatment should be permanently discontinued. Skin biopsy may help to establish a diagnosis and guide subsequent treatment.

RHEUMATOID ARTHRITIS (RA) AND GRANULOMATOSIS WITH POLYANGITIS (GPA, ALSO KNOWN AS WEGENER'S GRANULOMATOSIS) AND MICROSCOPIC POLYANGITIS (MPA)

Infusion-Related Events

Rituximab is associated with infusion-related reactions, which may be related to release of cytokines and/or other chemical mediators. For RA patients, premedication consisting of an antipyretic and an antihistaminic (eg, acetaminophen and diphenhydramine) should always be

administered before each infusion of RIABNI. For RA patients, premedication with glucocorticoids should also be administered before each infusion of RIABNI, in order to reduce the frequency and severity of infusion-related reactions (see **8 ADVERSE REACTIONS, Rheumatoid Arthritis** and **4 DOSAGE AND ADMINISTRATION, Rheumatoid Arthritis**).

For GPA/MPA patients, rituximab was given in combination with higher doses of IV glucocorticoids (see **4 DOSAGE AND ADMINISTRATION, GPA/MPA**), which may reduce the incidence and severity of these events. Infusion related reactions (IRRs) in the GPA/MPA clinical study were defined as any adverse event occurring within 24 hours of an infusion and considered to be infusion-related by investigators in the safety population. Ninety-nine patients were treated with rituximab and 12% experienced at least one IRR. All IRRs were CTC Grade 1 or 2. The most common IRRs included cytokine release syndrome, flushing, throat irritation, and tremor.

Rituximab has caused severe infusion reactions. In spontaneous reports, fatal infusion reactions were reported very rarely in patients with autoimmune diseases and other co-morbidities (eg, pulmonary fibrosis and Systemic Lupus Erythematosus [SLE]). The co-morbidities may have contributed to the fatal outcome (see **7 WARNINGS AND PRECAUTIONS, Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia**).

Severe infusion-related reactions with fatal outcome have been reported in the post-marketing setting (see **8 ADVERSE REACTIONS, Rheumatoid Arthritis, Post-Market Adverse Drug Reactions**) and co-morbidities may have contributed to the fatal outcome. Closely monitor patients with pre-existing cardiac conditions and those who experienced prior cardiopulmonary adverse reactions.

In clinical studies, 10/990 (1%) patients with rheumatoid arthritis who received a first infusion of rituximab at any dose experienced a serious reaction during the infusion. Four out of ten patients that experienced serious infusion reactions did not receive premedication with IV steroids. No infusion reactions in the RA population were fatal. Most infusion events reported were mild to moderate in severity. The most common symptoms were headache, pruritus, throat irritation, flushing, rash, urticaria, hypertension, and pyrexia. In general, the proportion of patients experiencing any infusion reaction was higher following the first infusion of any treatment course than following the second infusion. Subsequent rituximab infusions were better tolerated by patients than the initial infusion. Less than 1% of patients experienced serious IRRs, with most of these reported during the first infusion of the first course (see **8 ADVERSE REACTIONS, Rheumatoid Arthritis**). The infusion-related reactions reported with rituximab were usually reversible with a reduction in rate, or interruption, of the infusion and administration of appropriate symptomatic treatment, if required. In most cases, the infusion can be resumed at a 50% reduction in rate (eg, from 100 mg/hr to 50 mg/hr) when symptoms have completely resolved.

Depending on the severity of the infusion-related reaction and the required interventions, temporarily or permanently discontinue RIABNI.

Anaphylaxis

Anaphylactic and other hypersensitivity reactions have been reported following the IV administration of proteins to patients. Medicinal products for the treatment of hypersensitivity reactions; eg, epinephrine, antihistamines and glucocorticoids, should be available for immediate use in the event of an allergic reaction during administration of RIABNI.

Carcinogenesis and Mutagenesis

See **7 WARNINGS AND PRECAUTIONS, Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia**.

Cardiovascular

Since hypotension may occur during infusion with RIABNI, consideration should be given to withholding anti-hypertensive medications 12 hours prior to the infusion of RIABNI.

Angina pectoris, cardiac arrhythmias such as atrial flutter and fibrillation, heart failure or myocardial infarction have occurred in patients treated with rituximab. Patients who develop clinically significant arrhythmias should undergo cardiac monitoring during and after subsequent infusions of RIABNI. Patients with a history of cardiac disease such as angina and arrhythmias should be monitored closely (see **4 DOSAGE AND ADMINISTRATION**).

Concomitant use with Biologic Agents and Disease-Modifying Antirheumatic Drugs (DMARDs) other than Methotrexate in RA

Limited data are available on the safety of the use of biologic agents or DMARDs other than methotrexate in patients exhibiting peripheral B-cell depletion following treatment with rituximab. Patients should be closely observed for signs of infection if biologic agents and/or DMARDs are used concomitantly.

Effects on Ability to Drive and Use Machines

See **7 WARNINGS AND PRECAUTIONS, Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia**.

Immune

A total of 96/1039 (9.2%) patients with rheumatoid arthritis tested positive for HACA in clinical studies. The emergence of HACA was not associated with clinical deterioration or with an increased risk of reactions to subsequent infusions in the majority of patients. The presence of HACA could be associated with worsening of infusion or allergic reactions after the second infusion of subsequent courses. Such events could include hypersensitivity or anaphylactic reactions or anaphylactic shock. Failure to deplete B-cells after receipt of further treatment courses has also been observed rarely.

A total of 23/99 (23%) rituximab-treated patients with GPA/MPA tested positive for HACA by 18 months. The clinical relevance of HACA formation in rituximab-treated patients is unclear.

Immunization

Physicians should review the patient's vaccination status and patients should, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating RIABNI therapy. Vaccinations should be completed at least 4 weeks prior to first administration of RIABNI.

The safety of immunization with live viral vaccines following rituximab therapy has not been studied. Therefore, vaccination with live virus vaccines is not recommended while on RIABNI or while peripherally B-cell depleted.

Patients treated with RIABNI may receive non-live vaccinations. However, response rates to non-live vaccines may be reduced. In a randomized study, patients with RA treated with rituximab and methotrexate had comparable response rates to tetanus recall antigen (39% vs 42%), reduced rates to pneumococcal polysaccharide vaccine (43% vs 82% to at least 2 pneumococcal antibody serotypes), and KLH neoantigen (47% vs 93%), when given at least 6 months after rituximab as compared to patients only receiving methotrexate. Should non-live vaccinations be required while receiving RIABNI therapy, these should be completed at least 4 weeks prior to commencing the next course of RIABNI.

In the overall experience of rituximab repeat treatment over one year, the proportions of patients with positive antibody titers against S. Pneumoniae, influenza, mumps, rubella, varicella and tetanus toxoid were generally similar to the proportions at baseline.

Infections

Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).

Serious infections can occur during therapy with RIABNI. Based on the mechanism of action of rituximab and the knowledge that B-cells play an important role in maintaining normal immune response, patients may have increased risk of infection following RIABNI therapy (see **10 CLINICAL PHARMACOLOGY**). RIABNI should not be administered to patients with an active and/or severe infection or severely immuno-compromised patients (eg, AIDS where levels of CD4 or CD8 are very low). Physicians should exercise caution when considering the use of RIABNI in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection (see **8 ADVERSE REACTIONS, Rheumatoid Arthritis**). Patients who develop infection following therapy with RIABNI should be promptly evaluated and treated appropriately.

Hepatitis B Reactivation

Cases of hepatitis B reactivation including those with a fatal outcome, have been reported in RA and GPA/MPA patients receiving rituximab.

Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with RIABNI. At minimum, this should include HBsAg-status and HBcAb-status. These can be complemented with other appropriate markers as per local guidelines. Patients with active hepatitis B disease should not be treated with RIABNI. Patients with positive hepatitis B serology should consult liver disease experts before start of treatment and should be monitored and managed following local medical standards to prevent hepatitis B reactivation.

Progressive Multifocal Leukoencephalopathy

Cases of fatal progressive multifocal leukoencephalopathy (PML) have been reported following use of rituximab for the treatment of autoimmune diseases (including RA). Several, but not all of the reported cases had potential risk factors for PML, including the underlying disease, long-term immunosuppressive therapy or chemotherapy. PML has also been reported in patients with autoimmune disease not treated with rituximab.

Patients being treated with RIABNI should be instructed to report any new neurological signs or symptoms to their physician. Physicians treating patients with autoimmune diseases should be alert to any new signs or symptoms that may be suggestive of PML and consider PML in the differential diagnosis of patients reporting new-onset neurological symptoms. Consultation with a neurologist should be considered as clinically indicated. Symptoms of PML are diverse, progress over days to weeks, and can include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory and orientation leading to confusion and personality changes. Further treatment with RIABNI should be withheld immediately at the first sign or symptom suggestive of PML and an evaluation that includes a magnetic resonance imaging (MRI) scan without and, where clinically indicated, with gadolinium-enhancement of the brain should be performed. Cerebrospinal fluid analysis for JC viral DNA is recommended to confirm a diagnosis of PML. Discontinue RIABNI and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients with confirmed PML.

The absolute risk for PML in patients treated with RIABNI cannot be precisely estimated and factors that might increase an individual patient's risk for PML have not been identified. There are no known interventions that can reliably prevent or adequately treat PML if it occurs. It is not known whether early detection of PML and discontinuation of RIABNI will mitigate the disease. The relationship between the risk of PML and the duration of treatment is unknown.

Skin

Severe skin reactions such as Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS), some with fatal outcome, have been reported. In case of such an event, with a suspected relationship to RIABNI, treatment should be permanently discontinued.

Use in Patients with RA who had no Prior Inadequate Response to TNF Antagonists

A favourable benefit-risk relationship has not been established in patients with RA with prior inadequate responses to non-biologic DMARDs, and in MTX-naïve patients. The use of RIABNI in patients with RA who have no prior inadequate response to one or more TNF antagonists is not recommended.

Retreatment in Patients with GPA and MPA

The safety and efficacy of retreatment with rituximab have not been established.

The efficacy and safety of rituximab for the treatment of autoimmune diseases other than rheumatoid arthritis and GPA/MPA has not been established.

7.1 Special Populations

7.1.1 Pregnant Women

IgG immunoglobulins are known to pass the placental barrier. Developmental toxicity studies performed in cynomolgus monkeys revealed no evidence of embryotoxicity in utero. Newborn offspring of maternal animals exposed to rituximab were noted to have depleted B-cell populations during the postnatal phase. B-cell levels in human neonates following maternal exposure to rituximab have not been studied in clinical trials. There are no adequate and well-controlled data from studies in pregnant women, however, transient B-cell depletion and lymphocytopenia have been reported in some infants born to mothers exposed to rituximab during pregnancy. For these reasons, RIABNI should not be administered to pregnant women unless the possible benefit outweighs the potential risk. Women of childbearing age should employ effective contraceptive methods during and for up to 12 months after treatment with RIABNI.

The potential risk of transmissible maternal infections either recently acquired or reactivated through the use of RIABNI should also be considered when prescribing RIABNI to pregnant women.

7.1.2 Breast-feeding

It is not known whether rituximab is excreted in human milk. Because human IgG is excreted in human milk and the potential for absorption and immunosuppression in the infant is unknown, women should be advised to discontinue nursing until circulating drug levels are no longer detectable (see **10 CLINICAL PHARMACOLOGY**).

7.1.3 Pediatrics

The safety and effectiveness of rituximab in pediatric patients have not been established.

Hypogammaglobulinemia has been observed in pediatric patients treated with rituximab, in some cases severe and requiring long-term immunoglobulin substitution therapy.

7.1.4 Geriatrics

No dose adjustment is required in geriatric patients (aged > 65 years). In diffuse large B-cell lymphoma clinical studies, no overall differences in effectiveness were observed between elderly and younger subjects. However, geriatric patients were more likely to experience cardiac adverse events, mostly supraventricular arrhythmias. Serious pulmonary adverse events were also more common among the elderly, including pneumonia and pneumonitis.

In low-grade or follicular lymphoma clinical studies, no overall differences in safety or effectiveness were observed between geriatric and younger subjects.

In the trial of previously untreated CLL patients, patients over the age of 65 had, in general, more Grade 3/4 AEs with increasing age, and more AEs were recorded in the R-FC arm compared with FC alone. Similar patterns were observed for SAEs (see **8 ADVERSE REACTIONS**). The effect of rituximab when added to FC seems to be most pronounced with younger age. Due to the small size of the subgroup of patients over the age of 70 (FC, n = 25; R-FC, n = 33), no meaningful conclusion can be drawn for the effect rituximab might have in this age category (see **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG**).

Safety findings were similar in the BO17072 trial in previously treated CLL patients. Grade 3/4 AEs and SAEs generally increased with age in both arms of the study and were more frequently reported in the R-FC arm than the FC arm. However, the incidence of Grade 3/4 AEs was the same in R-FC and FC-treated patients over the age of 70 years (see **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG**).

In RA clinical studies, adverse reactions, including incidence, severity and type of adverse reaction were similar between older and younger patients.

8 ADVERSE REACTIONS

The adverse drug reaction profiles reported in clinical studies that compared RIABNI to the reference biologic drug, Rituxan, were comparable. The description of adverse reactions in this section is based on clinical experience with the reference biologic drug.

8.1 Adverse Reaction Overview – Hemato-Oncology

Clinical trials have been conducted in patients with various malignancies and benign disorders in hematology treated with rituximab, predominantly in combination with chemotherapy. Across all hematologic indications, the most frequently observed serious adverse drug reactions were:

- bacterial infections, viral infections, bronchitis
- neutropenia, leucopenia, febrile neutropenia, thrombocytopenia
- infusion related reactions, angioedema

The majority of serious infusion-related reactions occurred during the first infusion of rituximab.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

EXPERIENCE FROM CLINICAL TRIALS IN HEMATO-ONCOLOGY

The frequencies of adverse drug reactions (ADRs) reported with rituximab alone or in combination with chemotherapy are summarised in the tables below and are based on data from clinical trials. These ADRs had either occurred in single-arm studies or had occurred with at least a 2% difference compared to the control-arm in at least one of the major randomized clinical trials. ADRs are added to the appropriate category in the tables below according to the highest incidence seen in any of the major clinical trials. Within each frequency grouping ADRs are listed in descending order of severity. Frequencies are defined as very common $\geq 1/10$, common $\geq 1/100$ to $< 1/10$ and uncommon $\geq 1/1,000$ to $< 1/100$.

Rituximab Monotherapy/Maintenance Therapy

The ADRs in Table 2 are based on data from single-arm studies including 356 patients with low-grade or follicular lymphoma treated with rituximab weekly as single-agent for the treatment or re-treatment of non-Hodgkin's lymphoma up to 4 weeks in most patients and from 25 patients who received doses other than 375 mg/m² for four doses and up to 500 mg/m² single dose in the Phase I setting. The table also contains ADRs based on data from 671 patients with follicular lymphoma who received rituximab as maintenance therapy for up to 2 years following response to initial induction with CHOP or R-CHOP, R-CVP or R-FCM (see **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG** section for further details). The ADRs were reported up to 12 months after treatment with monotherapy and up to 1 month after treatment with rituximab maintenance.

Table 2. Summary of ADRs Reported in Patients with Low-grade or Follicular Lymphoma Receiving Rituximab Monotherapy (N = 356) or Rituximab Maintenance Treatment (N = 166) in Clinical Trials

System Organ Class	Very Common ($\geq 10\%$)	Common ($\geq 1\%$ to $< 10\%$)	Uncommon ($\geq 0.1\%$ to $< 1\%$)
Infections and infestations	bacterial infections, viral infections	sepsis, *pneumonia, *febrile infection, *herpes zoster, *respiratory tract infection, fungal infections, infections of unknown etiology	
Blood and the lymphatic system disorders	neutropenia, leucopenia	anemia, thrombocytopenia	coagulation disorders, transient aplastic anemia, hemolytic anemia, lymphadenopathy
Immune system disorders	angioedema	hypersensitivity	
Metabolism and nutrition disorders		hyperglycemia, weight decrease, peripheral edema, face edema, increased LDH, hypocalcemia	

Table 2. Summary of ADRs Reported in Patients with Low-grade or Follicular Lymphoma Receiving Rituximab Monotherapy (N = 356) or Rituximab Maintenance Treatment (N = 166) in Clinical Trials

System Organ Class	Very Common (≥ 10%)	Common (≥ 1% to < 10%)	Uncommon (≥ 0.1% to < 1%)
Psychiatric disorders			depression, nervousness
Nervous system disorders		paresthesia, hypoesthesia, agitation, insomnia, vasodilatation, dizziness, anxiety	dysgeusia
Eye disorders		lacrimation disorder, conjunctivitis	
Ear and labyrinth disorders		tinnitus, ear pain	
Cardiac disorders		*myocardial infarction, arrhythmia, *atrial fibrillation, tachycardia, *cardiac disorder	*left ventricular failure, *supraventricular tachycardia, *ventricular tachycardia, *angina, *myocardial ischemia, bradycardia
Vascular disorders		hypertension, orthostatic hypotension, hypotension	
Respiratory, thoracic and mediastinal disorders		bronchospasm, respiratory disease, chest pain, dyspnea, cough, rhinitis	asthma, bronchiolitis obliterans, lung disorder, hypoxia
Gastrointestinal disorders	nausea	vomiting, diarrhea, abdominal pain, dysphagia, stomatitis, constipation, dyspepsia, anorexia, throat irritation	abdominal enlargement
Skin and subcutaneous tissue disorders	pruritus, rash	urticaria, *alopecia, sweating, night sweats	
Musculoskeletal, connective tissue and bone disorders		hypertonia, myalgia, arthralgia, back pain, neck pain, pain	
General disorders and administration site conditions	fever, chills, asthenia, headache	tumour pain, flushing, malaise, cold syndrome	infusion site pain
Investigations	decreased IgG levels		

For each term, the frequency count was based on reactions of all grades (from mild to severe), except for terms marked with "+" where the frequency count was based only on severe (≥ Grade 3 NCI common toxicity criteria) reactions. Only the highest frequency observed in either trial is reported.

Rituximab as Monotherapy

The adverse events listed below were considered by the investigator to be related or of unknown relationship to rituximab and were reported during or up to 12 months after treatment. Adverse events were graded according to the four scale National Cancer Institute (NCI) Common Toxicity Criteria.

Table 3. Summary of Adverse Events Reported in $\geq 1\%$ of 356 NHL Patients Receiving Rituximab Monotherapy in Clinical Trials

System Organ Class Adverse event	All grades		Grade 3 and 4	
	N	%	N	%
Any adverse event	324	91.0	63	17.7
Blood and lymphatic system				
Leukopenia	44	12.4	10	2.8
Neutropenia	40	11.2	15	4.2
Thrombocytopenia	34	9.6	6	1.7
Anemia	13	3.7	4	1.1
Body as a whole				
Fever	172	48.3	2	0.6
Chills	113	31.7	8	2.2
Asthenia	64	18.0	1	0.3
Headache	45	12.6	2	0.6
Throat irritation	27	7.6	-	-
Abdominal pain	25	7.0	2	0.6
Back pain	16	4.5	1	0.3
Flushing	15	4.2	-	-
Pain	15	4.2	-	-
Chest pain	8	2.2	-	-
Infection	7	2.0	2	0.6
Malaise	7	2.0	-	-
Tumour pain	6	1.7	-	-
Cold syndrome	5	1.4	-	-
Neck pain	4	1.1	-	-
Cardiovascular system				
Hypotension	35	9.8	3	0.8
Hypertension	16	4.5	1	0.3
Arrhythmia	5	1.4	2	0.6
Tachycardia	5	1.4	-	-
Hypotension orthostatic	4	1.1	-	-
Digestive system				
Nausea	61	17.1	1	0.3
Vomiting	24	6.7	1	0.3
Diarrhea	15	4.2	-	-

Table 3. Summary of Adverse Events Reported in $\geq 1\%$ of 356 NHL Patients Receiving Rituximab Monotherapy in Clinical Trials

System Organ Class Adverse event	All grades		Grade 3 and 4	
	N	%	N	%
Anorexia	10	2.8	-	-
Dyspepsia	10	2.8	-	-
Dysphagia	5	1.4	1	0.3
Stomatitis	5	1.4	-	-
Constipation	4	1.1	-	-
Metabolic and nutritional disorders				
Angioedema	38	10.7	1	0.3
Hyperglycemia	19	5.3	1	0.3
Peripheral edema	17	4.8	-	-
Hypocalcemia	8	2.2	-	-
Increased lactate-dehydrogenase	8	2.2	-	-
Face edema	4	1.1	-	-
Decreased weight	4	1.1	-	-
Musculoskeletal system				
Myalgia	29	8.1	1	0.3
Arthralgia	21	5.9	2	0.6
Hypertonia	5	1.4	-	-
Pain	4	1.1	1	0.3
Nervous system				
Dizziness	26	7.3	-	-
Paresthesia	9	2.5	-	-
Anxiety	8	2.2	-	-
Insomnia	8	2.2	-	-
Vasodilatation	6	1.7	-	-
Agitation	5	1.4	-	-
Hypesthesia	5	1.4	-	-
Respiratory system				
Bronchospasm	28	7.9	5	1.4
Rhinitis	26	7.3	1	0.3
Increased cough	18	5.1	1	0.3
Dyspnea	8	2.2	3	0.8
Pneumonia	7	2.0	1	0.3
Infection	6	1.7	1	0.3
Sinusitis	6	1.7	-	-
Pharyngitis	5	1.4	-	-
Bronchitis	4	1.1	-	-
Chest pain	4	1.1	-	-
Respiratory disease	4	1.1	-	-

Table 3. Summary of Adverse Events Reported in $\geq 1\%$ of 356 NHL Patients Receiving Rituximab Monotherapy in Clinical Trials

System Organ Class Adverse event	All grades		Grade 3 and 4	
	N	%	N	%
Skin and appendages				
Pruritus	44	12.4	1	0.3
Rash	40	11.2	1	0.3
Urticaria	26	7.3	3	0.8
Sweat	10	2.8	-	-
Night sweat	10	2.8	-	-
Herpes zoster	8	2.2	1	0.3
Herpes simplex	5	1.4	1	0.3
Special senses				
Lacrimation disorder	11	3.1	-	-
Conjunctivitis	5	1.4	-	-
Ear pain	4	1.1	-	-
Tinnitus	4	1.1	-	-

8.3 Less Common Clinical Trial Adverse Drug Reactions (< 1%)

The following adverse events were also reported: coagulation disorders, asthma, lung disorder, bronchiolitis obliterans, hypoxia, abdominal enlargement, pain at the infusion site, bradycardia, lymphadenopathy, nervousness, depression, dysgeusia.

Subpopulations

Elderly patients (≥ 65 years): The incidence of any adverse event and of Grade 3 and 4 adverse events was similar in elderly (N = 94) and younger (N = 237) patients (88.3% versus 92.0% for any adverse event and 16.0% versus 18.1% for Grade 3 and 4 adverse events).

Bulky disease: Patients with bulky disease (N = 39) had a higher incidence of Grade 3 and 4 adverse events than patients without bulky disease (N = 195; 25.6% versus 15.4%). The incidence of any adverse event was similar in these two groups (92.3% in bulky disease versus 89.2% in non-bulky disease).

Retreatment: The percentage of patients reporting any adverse event and Grade 3 and 4 adverse events upon re-treatment (N = 60) with further courses of rituximab was similar to the percentage of patients reporting any adverse event and Grade 3 and 4 adverse events upon initial exposure (N = 203; 95.0% versus 89.7% for any adverse event and 13.3% versus 14.8% for Grade 3 and 4 adverse events).

Rituximab Maintenance Treatment

Previously Untreated Follicular Non-Hodgkin's Lymphoma

In a study (MO18264) of patients with previously untreated Follicular Non-Hodgkin's Lymphoma (see **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG**), detailed safety data collection was limited to Grade ≥ 2 infections, Grade ≥ 3 adverse events, and serious adverse events (see Table 4).

Table 4. Summary of Adverse Events Reported in $\geq 1\%$ of Patients Receiving Rituximab Maintenance Therapy in MO18264

System Organ Class Adverse Event	Observation N = 508 n (%)	Rituximab N = 501 n (%)
All Body Systems	179 (35.2)	263 (52.5)
Infections and infestations	114 (22.4)	184 (36.7)
Bronchitis	24 (4.7)	47 (9.4)
Upper respiratory tract infection	11 (2.2)	26 (5.2)
Sinusitis	8 (1.6)	19 (3.8)
Infection	10 (2.0)	12 (2.4)
Nasopharyngitis	14 (2.8)	8 (1.6)
Urinary tract infection	8 (1.6)	13 (2.6)
Oral herpes	2 (0.4)	10 (2.0)
Rhinitis	2 (0.4)	10 (2.0)
Lung infection	4 (0.8)	7 (1.4)
Pharyngitis	4 (0.8)	7 (1.4)
Pneumonia	4 (0.8)	7 (1.4)
Respiratory tract infection	3 (0.8)	8 (1.6)
Viral infection	3 (0.6)	5 (1.0)
Ear infection	1 (0.2)	5 (1.0)
Gastroenteritis	1 (0.2)	5 (1.0)
Blood and lymphatic system disorders	7 (1.4)	26 (5.2)
Neutropenia	5 (1.0)	19 (3.8)
Leukopenia	1 (0.2)	8 (1.6)
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)	19 (3.7)	22 (4.4)
Basal cell carcinoma	4 (0.8)	5 (1.0)

Uncommon (< 1%) Adverse Events Reported in Clinical Trial MO18264 (not already listed in the Oncology Adverse Events Section)

Infections and infestations: escherichia urinary tract infection, herpes virus infection, cystitis, folliculitis, hemophilus infection, viral upper respiratory tract infection, skin infection, acute tonsillitis, catheter related infection, cellulitis, central line infection, paronychia, pyelonephritis, skin candida, staphylococcal infection, viral pharyngitis, abscess limb, appendicitis, ascariasis, broncopneumonia, campylobacter infection, campylobacter intestinal infection, cystitis escherichia, device related infection, endocarditis, fungal skin infection, gastric infection, gastrointestinal infection, helicobacter infection, herpes ophthalmic, impetigo, infective exacerbation of chronic obstructive airways disease, klebsiella infection, laryngitis, lower respiratory tract infection, lyme disease, meningitis, moraxella infection, mycobacterial infection, oral fungal infection, pertussis, postoperative abscess, postoperative wound infection, pulmonary tuberculosis, roseola, salmonellosis, serratia infection, skin bacterial infection, staphylococcal bacteremia, staphylococcal skin infection, streptococcal bacteremia, tinea cruris, tinea pedis, tracheitis, upper aerodigestive tract infection, vaginitis bacterial, vulvovaginal candidiasis, vulvovaginal mycotic infection

Neoplasms benign, malignant and unspecified (including cysts and polyps): colon cancer, Bowen's disease, breast cancer, dysplastic naevus syndrome, prostate cancer, acute myeloid leukaemia, adenocarcinoma, hypergammaglobulinemia benign monoclonal, lipoma, lung adenocarcinoma, stage unspecified meningioma, neoplasm prostate, neuroendocrine carcinoma of the skin, skin cancer, skin papilloma, squamous cell carcinoma of skin

Nervous system disorders: carpal tunnel syndrome, convulsion, transient ischemic attack, aphasia, facial palsy, Parkinson's disease, subarachnoid hemorrhage

Cardiac disorders: aortic valve disease, cardiac arrest, congestive cardiomyopathy, ventricular extrasystoles

Respiratory, thoracic and mediastinal disorders: oropharyngeal pain, dyspnea, sleep apnea syndrome, pulmonary hemorrhage, rhinorrhea

Gastrointestinal disorders: intestinal obstruction, abdominal hernia, inguinal hernia, umbilical hernia, colonic polyp, gastroesophagitis, jejunal perforation, parotid gland enlargement, sigmoiditis

Musculoskeletal and connective tissue disorders: arthralgia, intervertebral disc protrusion, crest syndrome

General Disorders and Administration Site Conditions: hyperthermia

Psychiatric disorders: depression, suicide attempt, anxiety disorder, panic attack

Eye disorders: conjunctivitis, glaucoma, maculopathy

Investigations: neutrophil count decreased, aspartate aminotransferase increased, gamma-glutamyltransferase increased

Vascular disorders: thrombophlebitis, vena cava thrombosis

Renal and urinary disorders: hydronephrosis

Table 5. Summary of Grade 3–5 AEs by Age Group (MSAP) in MO18264

Age Group (years)	Observation N = 508 n (%)	Rituximab N = 501 n (%)
< 65	n = 387	n = 379
Total patients with at least one Grade 3/4 AE	54 (13.9)	84 (22.2)
Total patients with at least one Grade 3/4 Infection & Infestations AE	2 (0.5)	16 (4.2)
Total patients with a Grade 5 AE	1 (0.2)	2 (0.5)
Total patients with a Grade 5 Infection & Infestations AE	-	-*
65-74 inclusive	n = 97	n = 99
Total patients with at least one Grade 3/4 AE	18 (18.6)	24 (24.2)
Total patients with at least one Grade 3/4 Infection & Infestations AE	2 (2.1)	4 (4.0)
Total patients with a Grade 5 AE	1 (1.0)	-
Total patients with a Grade 5 Infection & Infestations AE	-	-
≥ 75	n = 24	n = 23
Total patients with at least one Grade 3/4 AE	9 (37.5)	6 (26.1)
Total patients with at least one Grade 3/4 Infection & Infestations AE	1 (4.2)	2 (8.7)
Total patients with a Grade 5 AE	-	1 (4.3)
Total patients with a Grade 5 Infection & Infestations AE	-	-

MSAP: Maintenance Safety Analysis Population; Percentages are based on corresponding number (n)

*One patient died of fulminant hepatitis B (categorized as a hepatobiliary AE rather than an Infection & Infestation AE).

The results of rituximab maintenance treatment in patients older than 75 years of age should be interpreted with caution due to the small number of patients in this subgroup.

Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

The following data are from a phase III clinical trial where patients with relapsed or refractory follicular non-Hodgkin's lymphoma were randomized in a first phase to induction treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or rituximab plus CHOP (R-CHOP). Patients who responded to induction treatment with CHOP or R-CHOP were randomized in a second phase to receive no further treatment (observation) or maintenance treatment with rituximab.

In the induction phase of the trial, a total of 462 patients (228 on CHOP, 234 on R-CHOP) contributed to the safety evaluation of the two induction regimens.

Table 6. Induction Phase: Summary of NCIC-CTC Grade 3 and 4 Adverse Events Reported in $\geq 1\%$ of 462 Patients in Either Treatment Group (CHOP or R- CHOP)

System Organ Class Adverse Event	Incidence N (%)	
	CHOP 152 (67)	R-CHOP 185 (79)
Blood and lymphatic system disorders		
Neutropenia*	108 (47)	129 (55)
Leucopenia	106 (46)	111 (47)
Thrombocytopenia	18 (8)	17 (7)
Febrile neutropenia*	8 (4)	14 (6)
Hematotoxicity	12 (5)	9 (4)
Anemia	5 (2)	6 (3)
Lymphopenia	3 (1)	2 (< 1)
Cardiac disorders		
Cardiac disorder	6 (3)	2 (< 1)
Gastrointestinal disorders		
Nausea*	9 (4)	13 (6)
Vomiting	8 (4)	7 (3)
Diarrhea	5 (2)	6 (3)
Abdominal pain	6 (3)	4 (2)
Constipation*	1 (< 1)	7 (3)
Stomatitis*	1 (< 1)	4 (2)
General disorders and administration site conditions		
Asthenia	10 (4)	5 (2)
Pyrexia	6 (3)	7 (3)
Pain	1 (<1)	3 (1)
Immune system disorders		
Hypersensitivity*	-	10 (4)
Infections and infestations		
Neutropenic infection	18 (8)	15 (6)
Sepsis	5 (2)	3 (1)
Urinary tract infection	4 (2)	3 (1)
Pneumonia	-	3 (1)
Metabolic and nutrition disorders		
Hyperglycemia	5 (2)	4 (2)

Table 6. Induction Phase: Summary of NCIC-CTC Grade 3 and 4 Adverse Events Reported in $\geq 1\%$ of 462 Patients in Either Treatment Group (CHOP or R-CHOP)

System Organ Class Adverse Event	Incidence N (%)	
	CHOP	R-CHOP
	152 (67)	185 (79)
Musculoskeletal and connective tissue disorders		
Back pain*	1 (< 1)	4 (2)
Pain in extremity	3 (1)	-
Nervous system disorders		
Sensory disturbance	4 (2)	7 (3)
Respiratory, thoracic and mediastinal disorders		
Dyspnea	6 (3)	3 (1)
Skin and subcutaneous tissue disorders		
Alopecia*	15 (7)	30 (13)
Skin disorder*	2 (< 1)	4 (2)
Vascular disorders		
Deep vein thrombosis	3 (1)	2 (< 1)

*Adverse events that were reported at a higher incidence ($\geq 2\%$ difference) in the R-CHOP group compared to the CHOP group and, therefore, may be attributable to rituximab.

A total of 333 patients (167 observations, 166 rituximab) were included in the safety evaluation of the maintenance phase of the study. Maintenance treatment with rituximab consisted of a single infusion of rituximab at 375 mg/m² body surface area administered every 3 months for a maximum period of 2 years or until disease progression.

**Table 7. Maintenance Phase: Summary of NCIC-CTC Adverse Events
(Grades 1–4 and Grades 3-4) Reported in ≥ 1% of 333 Patients in Either Treatment Group
(Observation or Rituximab Maintenance)**

System Organ Class Adverse Event	Incidence			
	Observation N = 167		Rituximab N = 166	
	Grade 1-4 N (%)	Grade 3-4 N (%)	Grade 1-4 N (%)	Grade 3-4 N (%)
Total patients with at least one adverse event	138 (83)	41 (25)	151 (91)	64 (39)
Blood and lymphatic system disorders				
Leukopenia* #	37 (22)	4 (2)	50 (30)	9 (5)
Neutropenia* #	22 (13)	8 (5)	40 (24)	18 (11)
Thrombocytopenia	23 (14)	2 (1)	20 (12)	1 (< 1)
Hematotoxicity	4 (2)	4 (2)	2 (1)	2 (1)
Lymphopenia	2 (1)	-	2 (1)	-
Cardiac disorders				
Cardiac disorder #	9 (5)	4 (2)	10 (6)	6 (4)
Palpitations*	-	-	3 (2)	-
Angina pectoris	2 (1)	2 (1)	-	-
Arrhythmia	-	-	2 (1)	-
Ear and labyrinth disorders				
Hearing impaired	1 (< 1)	-	2 (1)	-
Eye disorders				
Conjunctivitis*	-	-	3 (2)	-
Gastrointestinal disorders				
Diarrhea *	14 (8)	2 (1)	17 (10)	2 (1)
Abdominal pain*	11 (7)	-	17 (10)	-
Nausea	14 (8)	-	14 (8)	-
Stomatitis*	2 (1)	-	14 (8)	-
Dyspepsia	6 (4)	-	8 (5)	-
Vomiting*	4 (2)	-	9 (5)	-
Constipation*	2 (1)	-	8 (5)	-
Abdominal pain upper	3 (2)	-	4 (2)	-
Abdominal distension	3 (2)	-	2 (1)	-
Dry mouth	3 (2)	-	2 (1)	-
Reflux esophagitis	3 (2)	-	-	-
Gastric ulcer	2 (1)	-	-	-
Gastrointestinal ulcer	-	-	2 (1)	-
Intestinal obstruction	-	-	2 (1)	2 (1)

Table 7. Maintenance Phase: Summary of NCIC-CTC Adverse Events (Grades 1–4 and Grades 3-4) Reported in ≥ 1% of 333 Patients in Either Treatment Group (Observation or Rituximab Maintenance)

System Organ Class Adverse Event	Incidence			
	Observation N = 167		Rituximab N = 166	
	Grade 1-4 N (%)	Grade 3-4 N (%)	Grade 1-4 N (%)	Grade 3-4 N (%)
General disorders and administration site conditions				
Asthenia*	43 (26)	4 (2)	50 (30)	1 (< 1)
Pyrexia*	6 (4)	1 (< 1)	12 (7)	2 (1)
Influenza like illness*	6 (4)	-	10 (6)	-
Pain*	2 (1)	-	7 (4)	-
Chest Pain	5 (3)	-	3 (2)	-
Edema due to cardiac disease	3 (2)	-	4 (2)	-
Edema peripheral	3 (2)	-	3 (2)	-
Chills*	-	-	5 (3)	-
Chest discomfort	1 (< 1)	-	2 (1)	-
Immune system disorders				
Hypersensitivity*	1 (< 1)	-	12 (7)	-
Infections and infestations				
Nasopharyngitis*	5 (3)	-	14 (8)	-
Upper respiratory tract infection*	4 (2)	-	13 (8)	-
Sinusitis*	2 (1)	-	10 (6)	-
Herpes zoster*	4 (2)	-	7 (4)	2 (1)
Bronchitis	6 (4)	-	4 (2)	-
Lower respiratory tract infection*	2 (1)	-	7 (4)	-
Urinary tract infection	4 (2)	-	5 (3)	-
Herpes simplex*	2 (1)	-	6 (4)	-
Influenza	3 (2)	-	5 (3)	-
Pharyngitis*	1 (< 1)	-	6 (4)	-
Pneumonia*	2 (1)	1 (< 1)	5 (3)	4 (2)
Respiratory tract infection*	-	-	7 (4)	3 (2)
Candidiasis	1 (< 1)	-	3 (2)	-
Gastroenteritis	2 (1)	-	2 (1)	-
Lung infection	1 (< 1)	-	3 (2)	-
Rhinitis	1 (< 1)	-	3 (2)	-
Cystitis	1 (< 1)	-	2 (1)	-
Diverticulitis	1 (< 1)	-	2 (1)	-
Ear infection	1 (< 1)	-	2 (1)	-
Eye infection*	-	-	3 (2)	-
Localized infection	1 (< 1)	-	2 (1)	-

**Table 7. Maintenance Phase: Summary of NCIC-CTC Adverse Events
(Grades 1–4 and Grades 3-4) Reported in ≥ 1% of 333 Patients in Either Treatment Group
(Observation or Rituximab Maintenance)**

System Organ Class Adverse Event	Incidence			
	Observation N = 167		Rituximab N = 166	
	Grade 1-4 N (%)	Grade 3-4 N (%)	Grade 1-4 N (%)	Grade 3-4 N (%)
Onychomycosis	1 (< 1)	-	2 (1)	-
Vaginal candidiasis	1 (< 1)	-	2 (1)	-
Viral infection*	-	-	3 (2)	-
Cellulitis	2 (1)	-	-	-
Febrile infection	-	-	2 (1)	2 (1)
Infection	2 (1)	-	-	-
Otitis externa	-	-	2 (1)	-
Investigations				
Weight decreased	6 (4)	-	8 (5)	-
Weight increased*	3 (2)	-	7 (4)	-
Blood lactate dehydrogenase increased	1 (< 1)	-	3 (2)	-
Blood alkaline phosphatase increased	-	-	2 (1)	-
Metabolism and nutrition disorders				
Anorexia	8 (5)	-	5 (3)	-
Hyperglycemia	3 (2)	-	2 (1)	-
Hypokalemia	2 (1)	-	1 (< 1)	-
Diabetes mellitus	2 (1)	-	-	-
Gout	-	-	2 (1)	-
Musculoskeletal and connective tissue disorders				
Arthralgia*	13 (8)	-	20 (12)	-
Myalgia*	12 (7)	-	17 (10)	-
Back pain	8 (5)	-	12 (7)	-
Pain in extremity*	2 (1)	-	11 (7)	-
Bone pain	5 (3)	-	7 (4)	-
Shoulder pain	2 (1)	-	5 (3)	-
Groin pain	2 (1)	-	4 (2)	-
Musculoskeletal pain	3 (2)	-	1 (< 1)	-
Neck pain	1 (< 1)	-	2 (1)	-
Flank pain	-	-	2 (1)	-
Muscle spasms	-	-	2 (1)	-
Muscular weakness	-	-	2 (1)	-

Table 7. Maintenance Phase: Summary of NCIC-CTC Adverse Events (Grades 1–4 and Grades 3-4) Reported in ≥ 1% of 333 Patients in Either Treatment Group (Observation or Rituximab Maintenance)

System Organ Class Adverse Event	Incidence			
	Observation N = 167		Rituximab N = 166	
	Grade 1-4 N (%)	Grade 3-4 N (%)	Grade 1-4 N (%)	Grade 3-4 N (%)
Neoplasms benign, malignant and unspecified (including cysts and polyps)				
Cancer pain	1 (< 1)	-	2 (1)	-
Nervous system disorders				
Sensory disturbance	40 (24)	2 (1)	38 (23)	3 (2)
Headache	8 (5)	-	9 (5)	-
Dizziness	6 (4)	-	3 (2)	-
Insomnia	5 (3)	-	4 (2)	-
Dysgeusia	2 (1)	-	1 (< 1)	-
Vertigo	1 (< 1)	-	2 (1)	-
Syncope	2 (1)	-	-	-
Psychiatric disorders				
Anxiety	6 (4)	-	6 (4)	-
Depression	4 (2)	-	4 (2)	-
Mood altered	1 (< 1)	-	2 (1)	-
Renal and urinary disorders				
Dysuria	3 (2)	-	4 (2)	-
Pollakisuria	1 (< 1)	-	4 (2)	-
Nephrolithiasis	2 (1)	-	1 (< 1)	-
Nocturia	1 (< 1)	-	2 (1)	-
Hematuria	-	-	2 (1)	-
Renal colic	-	-	2 (1)	-
Urinary incontinence	2 (1)	-	-	-
Reproductive system and breast disorders				
Amenorrhea	-	-	2 (1)	-
Testicular pain	2 (1)	-	-	-
Respiratory, thoracic and mediastinal disorders				
Cough*	15 (9)	-	22 (13)	2 (1)
Dyspnea	7 (4)	-	5 (3)	-
Dyspnea exertional	2 (1)	-	4 (2)	-
Rhinitis allergic	2 (1)	-	2 (1)	-
Nasal congestion	-	-	3 (2)	-

Table 7. Maintenance Phase: Summary of NCIC-CTC Adverse Events (Grades 1–4 and Grades 3-4) Reported in ≥ 1% of 333 Patients in Either Treatment Group (Observation or Rituximab Maintenance)

System Organ Class Adverse Event	Incidence			
	Observation N = 167		Rituximab N = 166	
	Grade 1-4 N (%)	Grade 3-4 N (%)	Grade 1-4 N (%)	Grade 3-4 N (%)
Pharyngolaryngeal pain	-	-	3 (2)	-
Lung disorder	-	-	2 (1)	-
Pleural effusion	2 (1)	-	-	-
Pleuritic pain	-	-	2 (1)	-
Skin and subcutaneous tissue disorders				
Alopecia	12 (7)	-	12 (7)	3 (2)
Rash	11 (7)	-	10 (6)	-
Hyperhidrosis	10 (6)	2 (1)	7 (4)	-
Night sweats	10 (6)	-	6 (4)	-
Pruritus	6 (4)	-	6 (4)	-
Skin disorder	4 (2)	-	3 (2)	-
Rash pruritic	3 (2)	-	3 (2)	-
Nail disorder	2 (1)	-	2 (1)	-
Dermatitis	1 (< 1)	-	2 (1)	-
Psoriasis	3 (2)	-	-	-
Rash erythematous	1 (< 1)	-	2 (1)	-
Periorbital edema	2 (1)	-	-	-
Vascular disorders				
Hot Flush*	3 (2)	-	7 (4)	-
Hemorrhage	3 (2)	-	3 (2)	-
Hypertension	3 (2)	2 (1)	3 (2)	3 (2)
Lymphedema	-	-	2 (1)	-

*Adverse events (Grades 1-4) that were reported at a higher incidence (≥ 2% difference) in the rituximab maintenance group compared to observation and, therefore, may be attributable to rituximab.

#Adverse events (Grades 3-4) that were reported at a higher incidence (≥ 2% difference) in the rituximab maintenance group compared to observation and, therefore, may be attributable to rituximab.

Rituximab in Combination with Chemotherapy in NHL and CLL

The ADRs listed in the table below are based on rituximab-arm data from controlled clinical trials that occurred in addition to those seen with monotherapy/maintenance therapy and/or at a higher frequency grouping: 202 patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP, and from 234 and 162 patients with follicular lymphoma treated with R-CHOP or R-CVP, respectively, and from 397 previously untreated CLL patients and 274 previously treated CLL patients, treated with in combination with fludarabine and cyclophosphamide (R-FC) (see **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG** for further details).

Table 8. Summary of Severe ADRs Reported in Patients Receiving R-CHOP in DLBCL(N = 202), R-CHOP in Follicular Lymphoma (N = 234) and R-CVP in Follicular Lymphoma (N = 162) and R-FC in Previously Untreated CLL (N = 397) or Previously Treated CLL (N = 274)

System Organ Class	Very Common (≥ 10%)	Common (≥ 1% to < 10%)
Infections and infestations	bronchitis	acute bronchitis sinusitis hepatitis B*
Blood and the lymphatic system disorders	neutropenia# febrile neutropenia thrombocytopenia	pancytopenia granulocytopenia
Skin and subcutaneous tissue disorders	alopecia	skin disorder
General disorders and administration site conditions		fatigue, shivering

*includes reactivation and primary infections; frequency based on R-FC regimen in previously treated CLL
Frequency count was based on only severe reactions defined in clinical trials as ≥ Grade 3 NCI common toxicity criteria

Only the highest frequency observed in any trial is reported

#prolonged and/or delayed onset neutropenia after completion of an R-FC course in previously untreated or relapsed/refractory CLL

Rituximab in Combination with CVP Chemotherapy

The following data are based on 321 patients from a randomized phase III clinical trial comparing rituximab plus CVP (R-CVP) to CVP alone (162 R-CVP, 159 CVP). Differences between the treatment groups with respect to the type and incidence of adverse event were mainly accounted for by typical adverse events associated with rituximab monotherapy.

Table 9. Summary of Adverse Events (all Intensities) Reported in ≥ 1% of 321 Patients in Either Treatment Group (CVP or R-CVP)

System Organ Class Adverse Event	Incidence	
	CVP N = 159 N (%)	R-CVP N = 162 N (%)
Blood and lymphatic system disorders		
Neutropenia	3 (1.9)	13 (8.0)
Anemia NOS	4 (2.5)	4 (2.5)
Leukopenia NOS	-	2 (1.2)
Lymphadenopathy	2 (1.3)	-
Cardiac disorders		
Palpitations	2 (1.3)	2 (1.2)
Tachycardia NOS	1 (0.6)	2 (1.2)
Ear and labyrinth disorders		
Ear pain	3 (1.9)	4 (2.5)
Tinnitus	1 (0.6)	2 (1.2)
Vertigo	2 (1.3)	-

Table 9. Summary of Adverse Events (all Intensities) Reported in ≥ 1% of 321 Patients in Either Treatment Group (CVP or R-CVP)

System Organ Class Adverse Event	Incidence	
	CVP N = 159 N (%)	R-CVP N = 162 N (%)
Eye disorders		
Vision blurred	4 (2.5)	5 (3.1)
Eye pain	1 (0.6)	4 (2.5)
Dry eye NOS	1 (0.6)	2 (1.2)
Eye irritation	2 (1.3)	1 (0.6)
Gastrointestinal disorders		
Nausea	56 (35.2)	55 (24.0)
Constipation	43 (27.0)	42 (25.9)
Abdominal pain NOS	21 (13.2)	23 (14.2)
Vomiting NOS	25 (15.7)	19 (11.7)
Dyspepsia	16 (10.1)	23 (14.2)
Diarrhea NOS	19 (11.9)	19 (11.7)
Abdominal pain upper	10 (6.3)	11 (6.8)
Stomatitis	11 (6.9)	7 (4.3)
Oral pain	3 (1.9)	9 (5.6)
Abdominal distension	3 (1.9)	4 (2.5)
Abdominal discomfort	2 (1.3)	4 (2.5)
Flatulence	2 (1.3)	4 (2.5)
Mouth ulceration	3 (1.9)	3 (1.9)
Ascites	3 (1.9)	1 (0.6)
Gastritis NOS	1 (0.6)	3 (1.9)
Abdominal pain lower	2 (1.3)	1 (0.6)
Aphthous stomatitis	1 (0.6)	2 (1.2)
Gastroesophageal reflux disease	1 (0.6)	2 (1.2)
Rectal hemorrhage	2 (1.3)	1 (0.6)
Toothache	2 (1.3)	1 (0.6)
Dysphagia	-	2 (1.2)
Hypoesthesia oral	-	2 (1.2)
Loose stools	2 (1.3)	-
Tongue ulceration	2 (1.3)	-
General disorders and administration site conditions		
Fatigue	39 (24.5)	38 (23.5)
Pyrexia	14 (8.8)	21 (13.0)
Asthenia	14 (8.8)	8 (4.9)
Lethargy	9 (5.7)	12 (7.4)

Table 9. Summary of Adverse Events (all Intensities) Reported in $\geq 1\%$ of 321 Patients in Either Treatment Group (CVP or R-CVP)

System Organ Class Adverse Event	Incidence	
	CVP N = 159 N (%)	R-CVP N = 162 N (%)
Influenza like illness	7 (4.4)	13 (8.0)
Rigors	3 (1.9)	16 (9.9)
Pain NOS	5 (3.1)	12 (7.4)
Chest pain	5 (3.1)	11 (6.8)
Chest tightness	2 (1.3)	11 (6.8)
Edema peripheral	8 (5.0)	5 (3.1)
Mucosal inflammation NOS	4 (2.5)	5 (3.1)
Axillary pain	4 (2.5)	-
Feeling hot	1 (0.6)	2 (1.2)
Malaise	1 (0.6)	2 (1.2)
Chest discomfort	-	2 (1.2)
Hyperpyrexia	-	2 (1.2)
Immune system disorders		
Hypersensitivity NOS	1 (0.6)	5 (3.1)
Seasonal allergy	1 (0.6)	2 (1.2)
Infections and infestations		
Nasopharyngitis	11 (6.9)	15 (9.3)
Upper respiratory tract infection NOS	9 (5.7)	4 (2.5)
Urinary tract infection NOS	6 (3.8)	6 (3.7)
Herpes Simplex	4 (2.5)	4 (2.5)
Pneumonia NOS	2 (1.3)	6 (3.7)
Lower respiratory tract infection NOS	1 (0.6)	6 (3.7)
Influenza	4 (2.5)	2 (1.2)
Pharyngitis	3 (1.9)	1 (0.6)
Viral infection NOS	-	4 (2.5)
Gastroenteritis viral NOS	1 (0.6)	2 (1.2)
Herpes zoster	2 (1.3)	1 (0.6)
Oral candidiasis	1 (0.6)	2 (1.2)
Tooth abscess	2 (1.3)	1 (0.6)
Infection NOS	-	2 (1.2)
Neutropenic sepsis	2 (1.3)	-
Respiratory tract infection NOS	-	2 (1.2)
Sinusitis NOS	2 (1.3)	-
Injury, poisoning and procedural complications		
Excoriation	3 (1.9)	1 (0.6)

Table 9. Summary of Adverse Events (all Intensities) Reported in ≥ 1% of 321 Patients in Either Treatment Group (CVP or R-CVP)

System Organ Class Adverse Event	Incidence	
	CVP N = 159 N (%)	R-CVP N = 162 N (%)
Joint sprain	2 (1.3)	1 (0.6)
Investigations		
Weight increased	2 (1.3)	6 (3.7)
Weight decreased	4 (2.5)	3 (1.9)
Blood glucose increased	2 (1.3)	-
Blood lactate dehydrogenase increased	2 (1.3)	-
Metabolism and nutrition disorders		
Anorexia	5 (3.1)	2 (1.2)
Appetite increased NOS	2 (1.3)	2 (1.2)
Hyperglycemia NOS	-	2 (1.2)
Musculoskeletal and connective tissue disorders		
Back pain	16 (10.1)	13 (8.0)
Arthralgia	11 (6.9)	14 (8.6)
Pain in extremity	9 (5.7)	10 (6.2)
Myalgia	7 (4.4)	9 (5.6)
Muscle cramp	3 (1.9)	10 (6.2)
Bone pain	5 (3.1)	5 (3.1)
Groin pain	5 (3.1)	2 (1.2)
Pain in jaw	3 (1.9)	4 (2.5)
Neck pain	6 (3.8)	-
Chest wall pain	2 (1.3)	3 (1.9)
Joint swelling	3 (1.9)	2 (1.2)
Buttock pain	2 (1.3)	-
Facial pain	-	2 (1.2)
Nervous system disorders		
Headache	30 (18.9)	29 (17.9)
Peripheral neuropathy NOS	25 (15.7)	30 (18.5)
Paresthesia	25 (15.7)	28 (17.3)
Hypoesthesia	11 (6.9)	14 (8.6)
Dizziness	13 (8.2)	9 (5.6)
Dysgeusia	8 (5.0)	11 (6.8)
Peripheral sensory neuropathy	5 (3.1)	1 (0.6)
Polyneuropathy NOS	3 (1.9)	2 (1.2)
Neuropathy NOS	2 (1.3)	2 (1.2)

Table 9. Summary of Adverse Events (all Intensities) Reported in ≥ 1% of 321 Patients in Either Treatment Group (CVP or R-CVP)

System Organ Class Adverse Event	Incidence	
	CVP N = 159 N (%)	R-CVP N = 162 N (%)
Parosmia	4 (2.5)	-
Dysphonia	2 (1.3)	1 (0.6)
Hyperesthesia	1 (0.6)	2 (1.2)
Paresthesia oral	-	3 (1.9)
Tremor	1 (0.6)	2 (1.2)
Burning sensation NOS	-	2 (1.2)
Sinus headache	2 (1.3)	-
Psychiatric disorders		
Insomnia	16 (10.1)	20 (12.3)
Depression	7 (4.4)	4 (2.5)
Anxiety	4 (2.5)	3 (1.9)
Mood alteration NOS	1 (0.6))	3 (1.9)
Sleep disorder NOS	1 (0.6)	2 (1.2)
Irritability	-	2 (1.2)
Renal and urinary disorders		
Dysuria	4 (2.5)	2 (1.2)
Pollakiuria	2 (1.3)	4 (2.5)
Micturition urgency	2 (1.3)	3 (1.9)
Cystitis NOS	2 (1.3)	2 (1.2)
Hematuria	-	2 (1.2)
Renal failure acute	-	2 (1.2)
Urinary retention	-	2 (1.2)
Reproductive system and breast disorders		
Breast pain	1 (0.6)	2 (1.2)
Vaginal hemorrhage	2 (1.3)	1 (0.6)
Amenorrhea NOS	-	2 (1.2)
Respiratory, thoracic, and mediastinal disorders		
Cough	8 (5.0)	25 (15.4)
Pharyngolaryngeal pain	15 (9.4)	17 (10.5)
Dyspnea	9 (5.7)	14 (8.6)
Bronchitis NOS	3 (1.9)	6 (3.7)
Nasal congestion	3 (1.9)	4 (2.5)
Throat irritation	-	6 (3.7)
Asthma NOS	3 (1.9)	1 (0.6)

Table 9. Summary of Adverse Events (all Intensities) Reported in ≥ 1% of 321 Patients in Either Treatment Group (CVP or R-CVP)

System Organ Class Adverse Event	Incidence	
	CVP N = 159 N (%)	R-CVP N = 162 N (%)
Dyspnea exertional	3 (1.9)	1 (0.6)
Pleural effusion	2 (1.3)	2 (1.2)
Rhinitis NOS	3 (1.9)	1 (0.6)
Throat tightness	-	4 (2.5)
Bronchospasm NOS	-	3 (1.9)
Hiccups	2 (1.3)	1 (0.6)
Hoarseness	2 (1.3)	1 (0.6)
Productive cough	1 (0.6)	2 (1.2)
Respiratory tract congestion	1 (0.6)	2 (1.2)
Wheezing	1 (0.6)	2 (1.2)
Sinus pain	2 (1.3)	-
Skin and subcutaneous tissue disorders		
Alopecia	21 (13.2)	22 (13.6)
Rash NOS	7 (4.4)	22 (13.6)
Pruritus	1 (0.6)	15 (9.3)
Night sweats	8 (5.0)	5 (3.1)
Sweating increased	5 (3.1)	6 (3.7)
Urticaria NOS	-	9 (5.6)
Erythema	-	5 (3.1)
Acne NOS	-	4 (2.5)
Dry Skin	1 (0.6)	3 (1.9)
Hypotrichosis	1 (0.6)	3 (1.9)
Rash generalized	2 (1.3)	2 (1.2)
Contusion	2 (1.3)	1 (0.6)
Psoriasis	2 (1.3)	1 (0.6)
Rash pruritic	1 (0.6)	2 (1.2)
Skin lesion NOS	-	3 (1.9)
Pain of skin	2 (1.3)	-
Vascular disorders		
Flushing	4 (2.5)	21 (13.0)
Hypertension NOS	3 (1.9)	8 (4.9)
Hypotension NOS	1 (0.6)	6 (3.7)
Lymphedema NOS	2 (1.3)	-
Phlebitis NOS	-	2 (1.2)

Rituximab in Combination with CHOP Chemotherapy

The following table shows all Grade 3 to 4 clinical adverse events, including Grade 2 infections, reported in $\geq 1\%$ of patients in either treatment group (CHOP and rituximab plus CHOP [R- CHOP]) in a randomized phase III clinical trial in the total safety population (n = 398). Adverse events were graded according to the four-scale National Cancer Institute of Canada (NCIC) Common Toxicity Criteria.

Table 10. Summary of Grade 3 and 4 Adverse Events (Including Grade 2 Infections) Reported in $\geq 1\%$ of 398 Patients in Either Treatment Group (CHOP or R- CHOP)

System Organ Class	Incidence	
	CHOP N = 196 N (%)	R-CHOP N = 202 N (%)
Any Grade 3 and 4 Adverse Event (including Grade 2 infections)	148 (75.5)	164 (81.2)
Blood and lymphatic system disorders		
Febrile neutropenia [#]	47 (24.0)	46 (22.8)
Neutropenia	10 (5.1)	11 (5.4)
Anemia	10 (5.1)	9 (4.5)
Pancytopenia	2 (1.0)	2 (1.0)
Thrombocytopenia	2 (1.0)	2 (1.0)
Cardiac disorders		
Cardiac failure	11 (5.6)	9 (4.5)
Atrial fibrillation*	1 (0.5)	5 (2.5)
Pulmonary edema	2 (1.0)	4 (2.0)
Tachycardia	1 (0.5)	3 (1.5)
Cardiomyopathy	3 (1.5)	-
Left ventricular dysfunction	2 (1.0)	-
Endocrine disorders		
Diabetes mellitus inadequate control	4 (2.0)	2 (1.0)
Gastrointestinal disorders		
Vomiting	13 (6.6)	8 (4.0)
Abdominal pain*	9 (4.6)	13 (6.4)
Constipation	8 (4.1)	6 (3.0)
Nausea	9 (4.6)	4 (2.0)
Diarrhea	5 (2.6)	5 (2.5)
Gastrointestinal disorder	3 (1.5)	2 (1.0)
Abdominal pain upper	2 (1.0)	-
Dysphagia	2 (1.0)	-
Gastritis	2 (1.0)	-
Ileus paralytic	2 (1.0)	-
Melena	2 (1.0)	-

Table 10. Summary of Grade 3 and 4 Adverse Events (Including Grade 2 Infections) Reported in ≥ 1% of 398 Patients in Either Treatment Group (CHOP or R- CHOP)

System Organ Class	Incidence	
	CHOP N = 196 N (%)	R-CHOP N = 202 N (%)
General disorders and administration site conditions		
Pyrexia	34 (17.3)	26 (12.9)
Fatigue	14 (7.1)	9 (4.5)
General physical health deterioration	10 (5.1)	10 (5.0)
Mucosal inflammation	5 (2.6)	8 (4.0)
Shivering*	2 (1.0)	7 (3.5)
Chest pain	4 (2.0)	4 (2.0)
Influenza-like illness	3 (1.5)	4 (2.0)
Fall	4 (2.0)	3 (1.5)
Malaise	4 (2.0)	2 (1.0)
Multi-organ failure	4 (2.0)	2 (1.0)
Asthenia	1 (0.5)	4 (2.0)
Edema lower limb	1 (0.5)	4 (2.0)
Edema	-	3 (1.5)
Ulcer	2 (1.0)	1 (0.5)
Hepatobiliary disorders		
Cholestasis	1 (0.5)	3 (1.5)
Infections and infestations		
Bronchitis*	16 (8.2)	24 (11.9)
Urinary tract infection	18 (9.2)	20 (9.9)
Pneumonia	15 (7.7)	11 (5.4)
Sepsis	7 (3.6)	4 (2.0)
Septic shock	7 (3.6)	4 (2.0)
Herpes zoster*	3 (1.5)	8 (4.0)
Implant infection	5 (2.6)	4 (2.0)
Staphylococcal septicemia	3 (1.5)	5 (2.5)
Superinfection lung	4 (2.0)	5 (2.5)
Acute bronchitis*	1 (0.5)	5 (2.5)
Lung infection	4 (2.0)	2 (1.0)
Sinusitis*	-	5 (2.5)
Herpes simplex	3 (1.5)	3 (1.5)
Tonsillitis	3 (1.5)	3 (1.5)
Infection	3 (1.5)	2 (1.0)
Nasopharyngitis	3 (1.5)	2 (1.0)
Cystitis	2 (1.0)	1 (0.5)
Erysipelas	2 (1.0)	1 (0.5)

Table 10. Summary of Grade 3 and 4 Adverse Events (Including Grade 2 Infections) Reported in ≥ 1% of 398 Patients in Either Treatment Group (CHOP or R- CHOP)

System Organ Class	Incidence	
	CHOP N = 196 N (%)	R-CHOP N = 202 N (%)
Gastroenteritis helicobacter	2 (1.0)	-
Septicemia escherichial	2 (1.0)	-
Tooth infection	2 (1.0)	-
Injury and poisoning		
Femoral neck fracture	2 (1.0)	2 (1.0)
Investigations		
Abnormal ejection fraction	4 (2.0)	4 (2.0)
Positive blood cultures	4 (2.0)	1 (0.5)
Metabolism and nutrition disorders		
Anorexia	5 (2.6)	4 (2.0)
Dehydration	2 (1.0)	-
Hyperglycemia	2 (1.0)	-
Musculoskeletal and connective tissue disorders		
Back pain*	2 (1.0)	5 (2.5)
Sciatica	2 (1.0)	2 (1.0)
Nervous system disorders		
Paresthesia	2 (1.0)	5 (2.5)
Dizziness (excluding vertigo)	3 (1.5)	2 (1.0)
Cerebrovascular accident	1 (0.5)	3 (1.5)
Polyneuropathy	2 (1.0)	2 (1.0)
Depressed level of consciousness	2 (1.0)	-
Psychiatric disorders		
Confusion	5 (2.6)	-
Depression	2 (1.0)	2 (1.0)
Renal and urinary disorders		
Renal colic	2 (1.0)	2 (1.0)
Urinary retention	2 (1.0)	1 (0.5)
Renal failure	2 (1.0)	-
Respiratory, thoracic and mediastinal disorders		
Dyspnea*	7 (3.6)	18 (8.9)
Cough	7 (3.6)	8 (4.0)
Rhinitis	5 (2.6)	2 (1.0)
Rhinorrhea	4 (2.0)	1 (0.5)

Table 10. Summary of Grade 3 and 4 Adverse Events (Including Grade 2 Infections) Reported in ≥ 1% of 398 Patients in Either Treatment Group (CHOP or R- CHOP)

System Organ Class	Incidence	
	CHOP N = 196 N (%)	R-CHOP N = 202 N (%)
Skin and subcutaneous tissue disorders		
Pruritis	3 (1.5)	3 (1.5)
Vascular disorders		
Venous thrombosis deep limb	6 (3.1)	6 (3.0)
Hypotension	3 (1.5)	5 (2.5)
Hypertension*	1 (0.5)	5 (2.5)
Pulmonary embolism	3 (1.5)	2 (1.0)
Venous thrombosis	1 (0.5)	4 (2.0)
Peripheral ischemia	2 (1.0)	-
Phlebitis	2 (1.0)	-

* Adverse events that were reported at a higher incidence (≥ 2% difference) in the R-CHOP group as compared to the CHOP group and, therefore, may be attributable to R-CHOP.

Febrile neutropenia as reported by investigators: Fever and neutropenia with or without documented infection (see below, subsection Infections).

The following terms have been reported as adverse events, however, were reported at a similar (< 2% difference between the groups) or lower incidence in the rituximab-arms compared to control arms: hematotoxicity, neutropenic infection, urinary tract infection, septic shock, superinfection lung, implant infection, septicemia staphylococcal, lung infection, rhinorrhea, pulmonary edema, cardiac failure, sensory disturbance, venous thrombosis, mucosal inflammation NOS, influenza-like illness, edema lower limb, abnormal ejection fraction, pyrexia, general physical health deterioration, fall, multi-organ failure, venous thrombosis deep limb, abnormal ejection fraction, positive blood culture, anorexia, diabetes mellitus inadequate control.

The safety profile for rituximab in combination with other chemotherapies (eg, MCP, CHVP- IFN) is comparable to the safety profile as described for the combination of rituximab and CVP, CHOP or FC in equivalent populations.

Rituximab in Combination with FC Chemotherapy

The following table shows all Grade 3 to 4 clinical adverse events and serious adverse events reported with a ≥ 2% difference in frequency between either treatment group (R-FC and FC) in ML17102 and BO17072. Grade 1 and 2 adverse events and Grade 4 lymphocytopenia were not captured in study ML17102. A total of 550 SAEs in 344 patients were reported across the two arms in the primary analysis of ML17102. Infections and infestations (15% in FC vs 18% in R-FC) and blood and lymphatic system disorders (11% in FC vs 17% in R-FC) were reported at higher frequencies, as expected, for the rituximab-containing arm. One case of tuberculosis was recorded as an adverse event in the R-FC arm. In the updated overall survival results (final analysis) of study ML17102 after a median of 66.4 months of observation (additional four years of follow-up data beyond that for the primary analysis), the safety profile of rituximab in combination with FC remained unchanged compared with that reported at the time of the primary analysis.

Table 11. Summary of Grade 3 & 4 Adverse Events and Serious Adverse Events that Occurred with a Difference in Incidence of $\geq 2\%$ Between Either the R-FC Arm or the FC Arm

System Organ Class	Incidence			
	ML17102 (previously untreated CLL ^{**})		BO17072 (previously treated CLL)	
	FC N = 396 N (%)	R-FC N = 397 N (%)	FC N = 272 N (%)	R-FC N = 274 N (%)
Any Grade 3 and 4 Adverse Event*				
Blood and lymphatic system disorders				
Neutropenia	75 (18.9)	119 (30.0)	108 (39.7)	116 (42.3)
Leukopenia	46 (11.6)	93 (23.4)	-	-
Thrombocytopenia	39 (9.8)	39 (9.8)	-	-
Febrile neutropenia	22 (5.6)	37 (9.3)	32 (11.8)	40 (14.6)
Anemia	26 (6.6)	16 (4.0)	-	-
Pancytopenia	5 (1.3)	13 (3.3)	-	-
Granulocytopenia			12 (4.4)	18 (6.6)
General disorders and administration site conditions				
Pyrexia	21 (5.3)	12 (3.0)	-	-
Infections and infestations				
Hepatitis B	-	-	-	6 (2.2)
Any Serious Adverse Event*				
Blood and lymphatic system disorders				
Febrile neutropenia	22 (5.6)	30 (7.6)	21 (7.7)	29 (10.6)
Anemia	-	-	11 (4.0)	3 (1.1)

* Grade 1 and 2 adverse events and Grade 4 lymphocytopenia were not captured in ML17102.

** Primary analysis: 20.7 months median observation time.

Table 12. Summary of Grade 3 or 4 Adverse Events and Deaths by Binet Stage in ML17102 (Primary Analysis: 20.7 Months Median Observation Time)

Binet Stage	FC	R-FC
Overall incidence	246 (62%)	304 (77%)
Binet Stage A		
N	20	18
Total patients with at least one AE (%)	14 (70%)	13 (72%)
Deaths (%)	3 (15%)	1 (6%)
Binet Stage B		
N	253	256
Total patients with at least one AE (%)	144 (57%)	189 (74%)
Deaths (%)	32 (13%)	13 (5%)
Binet Stage C		
N	122	123
Total patients with at least one AE (%)	87 (71%)	102 (83%)
Deaths (%)	12 (10%)	19 (15%)

In the subgroup analysis of Binet stage, in both arms of ML17102, the rate of Grade 3 or 4 AEs slightly increased from Binet stage B to Binet stage C. In the Binet stage A subgroup, there was no difference in the incidence of Grade 3 or 4 AEs between the FC and R-FC arms. In Binet stage B and C patients, the rates of Grade 3 or 4 AEs were higher in the R-FC arm compared to the FC arm. Similar patterns were observed for SAEs.

Table 13. Summary of Grade 3 or 4 Adverse Events and Fatal AEs by Binet Stage in BO17072

Binet Stage	FC	R-FC
Binet Stage A		
N	31	24
Total patients with at least Grade 3/4 AE (%)	20 (65%)	18 (75%)
Fatal AEs (%)	4 (13%)	4 (17%)
Binet Stage B		
N	157	164
Total patients with at least Grade 3/4 AE (%)	109 (69%)	127 (77%)
Fatal AEs (%)	12 (8%)	16 (10%)
Binet Stage C		
N	84	86
Total patients with at least Grade 3/4 AE (%)	71 (85%)	74 (86%)
Fatal AEs (%)	10 (12%)	16 (19%)

Table 14. Summary of Grade 3 or 4 Adverse Events and Deaths by Age in ML17102 (Primary Analysis: 20.7 Months Median Observation Time)

Age (years)	FC	R-FC
< 65		
N	280	275
Total patients with at least one AE (%)	168 (60%)	203 (74%)
Deaths (%)	31 (11%)	26 (9%)
≥ 65 - ≤ 70		
N	91	90
Total patients with at least one AE (%)	59 (65%)	72 (80%)
Deaths (%)	15 (16%)	6 (7%)
> 70		
N	25	32
Total patients with at least one AE (%)	19 (76%)	29 (91%)
Deaths (%)	1 (4%)	1 (3%)

In the subgroup analysis of age in ML17102, Grade 3 or 4 AEs tended to increase with increasing age > 65 years, especially for > 70 years and more AEs were recorded in the R-FC arm compared with FC alone. Similar patterns were observed for SAEs.

Table 15. Summary of Grade 3 or 4 Adverse Events and Fatal AEs by Age in BO17072

Age (years)	FC	R-FC
< 65		
N	159	154
Total patients with at least Grade 3/4 AE (%)	105 (66%)	109 (71%)
Fatal AEs (%)	12 (8%)	5 (3%)
≥ 65 - ≤ 70		
N	68	74
Total patients with at least Grade 3/4 AE (%)	53 (78%)	67 (91%)
Fatal AEs (%)	6 (9%)	19 (26%)
> 70		
N	45	46
Total patients with at least Grade 3/4 AE (%)	42 (93%)	43 (93%)
Fatal AEs (%)	8 (18%)	12 (26%)

Further Information on Selected, Serious Adverse Drug Reactions - Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Patients

Infusion-Related Reactions

Monotherapy – 4 weeks treatment

Hypotension, fever, chills, rigors, urticaria, bronchospasm, sensation of tongue or throat swelling (angioedema), nausea, fatigue, headache, pruritus, dyspnea, rhinitis, vomiting, flushing, and pain at disease sites have occurred in association with rituximab infusion as part of an infusion-related symptom complex. Such infusion-related symptoms occurred in the majority of patients during the first infusion with rituximab. The incidence of infusion-related symptoms decreased from 77% (7% Grade 3/4) with the first infusion to approximately 30% (2% Grade 3/4) with the fourth infusion and to 14% (no Grade 3/4 events) with the eighth infusion. Some features of tumor lysis syndrome have also been observed (see **7 WARNINGS AND PRECAUTIONS, Tumor Lysis Syndrome**).

Maintenance Treatment (NHL) up to 2 years

Non-serious signs and symptoms suggestive of an infusion-related reaction were reported in 41% of patients under general disorders (mainly asthenia, pyrexia, influenza-like illness, pain) and in 7% of patients for immune system disorders (hypersensitivity). Serious infusion-related reactions occurred in <1% of patients (see **7 WARNINGS AND PRECAUTIONS, Infusion-Related Events**).

Combination Therapy (R-CVP in NHL; R-CHOP in DLBCL, R-FC in CLL)

Severe infusion-related reactions occurred in up to 12% of all patients at the time of the first treatment cycle with rituximab in combination with chemotherapy. The incidence of severe infusion-related reactions decreased to less than 1% by the eighth cycle of therapy. The signs and symptoms were consistent with those observed during monotherapy (see **7 WARNINGS AND PRECAUTIONS**), but also included dyspepsia, rash, hypertension, tachycardia, features of tumour lysis syndrome. Additional reactions reported in isolated cases at the time of R-CHOP therapy were myocardial infarction, atrial fibrillation, pulmonary edema and acute reversible thrombocytopenia.

Infections

Monotherapy 4 weeks treatment

These were usually common, non-opportunistic and mild. Rituximab induced B-cell depletion in 70 to 80% of patients but was associated with decreased serum immunoglobulins in only a minority of patients. Infectious events, irrespective of causal assessment, occurred in 30.3% of 356 patients: 18.8% of patients had bacterial infections, 10.4% had viral infections, 1.4% had fungal infections, and 5.9% had infections of unknown etiology. Severe infectious events (grade 3 or 4), including sepsis occurred in 3.9% of patients; in 1.4% during the treatment period and in 2.5% during the follow up period.

Maintenance Treatment (NHL) up to 2 years

The proportion of patients with Grade 1 to 4 infections was 26% in the observation group and 47% in the rituximab group with severe (Grade 3/4) infections in 2% of patients on observation and 11% receiving rituximab maintenance treatment. Severe infections reported $\geq 1\%$ of patients in the rituximab arm were pneumonia (2%), respiratory tract infection (2%), febrile infection (1%), and herpes zoster (1%). In a large proportion of infections (all grades), the infectious agent was not specified or isolated, however, where an infectious agent was specified, the most frequently reported underlying agents were bacterial (observation 2%, rituximab 11%), viruses

(observation 8%, rituximab 11 %) and fungi (observation 3%, rituximab 4%). There was no cumulative toxicity in terms of infections reported over the 2-year maintenance period.

Data from a phase III clinical trial included two cases of fatal PML in NHL patients that occurred after disease progression and retreatment (see **7 WARNINGS AND PRECAUTIONS**).

Combination Therapy (R-CVP in NHL; R-CHOP in DLBCL, R-FC in CLL)

In the R-CVP study the overall proportion of patients with infections or infestations during treatment and for 28 days after trial treatment end was comparable between the treatment groups (33% R-CVP, 32% CVP). The most common infections were upper respiratory tract infections which were reported for 12.3% patients on R-CVP and 16.4% patients receiving CVP; most of these infections were nasopharyngitis. Serious infections were reported in 4.3% of the patients receiving R-CVP and 4.4% of the patients receiving CVP. No life-threatening infections were reported during this study.

In the R-CHOP study the overall incidence of Grade 2 to 4 infections was 45.5% in the R-CHOP group and 42.3% in the CHOP group. Grade 2 to 4 fungal infections were more frequent in the R-CHOP group (4.5% vs 2.6% in the CHOP group); this difference was due to a higher incidence of localized *Candida* infections during the treatment period. The incidence of Grade 2 to 4 herpes zoster, including ophthalmic herpes zoster, was higher in the R-CHOP group (4.5%) than in the CHOP group (1.5%), with 7 of a total of 9 cases in the R-CHOP group occurring during the treatment phase [20, 61]. The proportion of patients with Grade 2 to 4 infections and/or febrile neutropenia was 55.4% in the R-CHOP group and 51.5% in the CHOP group. Febrile neutropenia (ie, no report of concomitant documented infection) was reported only during the treatment period, in 20.8% in the R-CHOP group and 15.3% in the CHOP group.

In patients with CLL, the overall incidence of Grade 3 or 4 infections during treatment and for 28 days after the end of trial treatment was comparable between the treatment groups both in the previously untreated (18% R-FC, 17% FC) and in the previously treated setting (19% R-FC, 18% FC). The incidence of Grade 3 or 4 hepatitis B infection (reactivation and primary infection) was 2% R-FC vs. 0% FC.

Hematologic Events

Monotherapy 4 weeks

Hematologic adverse events occur in a minority of patients and are usually mild and reversible. Severe neutropenia was reported in 4.2% of patients, severe anemia was reported in 1.1% of patients and severe thrombocytopenia was reported in 1.7% of patients. A single occurrence of transient aplastic anemia (pure red cell aplasia) and two occurrences of hemolytic anemia following therapy with rituximab were reported.

Maintenance Treatment (NHL) up to 2 years

Leucopenia (all grades) occurred in 26% of patients on observation vs 32% of patients in the rituximab arm, and neutropenia was reported in 14% of patients on observation and in 25% of patients on rituximab. There was a higher incidence of Grade 3-4 leucopenia (observation 2%, rituximab 5%) and neutropenia (observation 5%, rituximab 11%) in the rituximab arm compared to the observation arm. The incidence of Grade 3 to 4 thrombocytopenia (observation 1%, rituximab < 1%) was low. In approximately half of the patients with available data on B- cell recovery after end of rituximab induction treatment, it took 12 months or more for their B- cell levels to return to normal values.

Combination Therapy (R-CVP in NHL; R-CHOP in DLBCL, R-FC in CLL)

Severe (Grade 3/4) Adverse Events Neutropenia: There was a higher incidence of Grade 3-4 neutropenia in the rituximab containing study arms compared to the chemotherapy arms. In the R-CVP study, the incidence of neutropenia was 24% in the R-CVP arm versus 14% in the CVP arm. These laboratory findings were reported as adverse events and resulted in medical intervention in 3.1% of patients on R-CVP and 0.6% of patients on CVP. The higher incidence of neutropenia in the R-CVP group was not associated with a higher incidence of infections and infestations. In the R-CHOP study, the incidence of severe neutropenia was 97% in the R-CHOP arm versus 88% in the CHOP arm. In previously untreated patients with CLL, Grade 3/4 neutropenia was reported as an adverse event in 30% of patients in the R-FC arm and in 19% of patients in the FC arm. In patients with previously treated CLL, the incidence of Grade 3/4 neutropenia adverse events was slightly higher in the R-FC arm (42% R-FC) compared to FC arm (40%).

Severe (Grade 3/4) Adverse Events Leucopenia: In the R-CHOP study, the incidence of severe leucopenia was 88% in the R-CHOP arm versus 79% in the CHOP arm. In previously untreated CLL, more patients receiving R-FC experienced Grade 3/4 adverse events of leucopenia (23%) compared with patients receiving FC (12%). In patients with previously treated CLL, the overall incidence of Grade 3/4 leucopenia adverse events was comparable between the treatment arms (4% R-FC, 3% FC).

Studies in previously untreated and relapsed refractory CLL have established that in some cases neutropenia was prolonged or with late onset following treatment in the rituximab plus FC group.

Severe (Grade 3/4) Adverse Events Anemia and Thrombocytopenia: No relevant difference between the treatment arms was observed with respect to Grade 3 and 4 anemia or thrombocytopenia. In the R-CVP study, the incidence of anemia was 0.6% in the R-CVP arm versus 1.9% in the CVP arm. The incidence of thrombocytopenia was 1.2% in the R-CVP arm versus 0% in the CVP arm. In the R-CHOP study, the incidence of anemia was 14% in the R-CHOP arm versus 19% in the CHOP arm. The incidence of thrombocytopenia was 15% in the R-CHOP arm versus 16% in the CHOP arm. The time to recovery from all hematological abnormalities was comparable in the two treatment groups. In the CLL first-line study, grade 3/4 anemia was reported by 4% of patients treated with R-FC compared to 7% of patients receiving FC, and Grade 3/4 thrombocytopenia was reported by 7% of patients in the R-FC group compared to 10% of patients in the FC group. In the previously treated CLL study, adverse events of Grade 3/4 anemia were reported in 12% of patients treated with R-FC compared to 13% of patients receiving FC and Grade 3/4 thrombocytopenia was reported by 11% of patients in the R-FC group compared to 9% of patients in the FC group.

Cardiovascular Events (see 7 WARNINGS AND PRECAUTIONS)

Monotherapy 4 weeks treatment

Cardiovascular events were reported in 18.8% of patients during the treatment period. The most frequently reported events were hypotension and hypertension. Two patients (0.6%) experienced grade 3 or 4 arrhythmia (including ventricular and supraventricular tachycardia) during an infusion with rituximab and one patient with a history of myocardial infarction experienced angina pectoris, evolving into myocardial infarction 4 days later.

Maintenance Treatment (NHL) up to 2 years

The incidence of Grade 3 to 4 cardiac disorders was comparable between the two treatment groups (5% in observation, 7% in rituximab). Cardiac events were reported as serious adverse event in < 1% of patients on observation and in 3% of patients on rituximab: atrial fibrillation (1%), myocardial infarction (1%), left ventricular failure (< 1%), myocardial ischemia (< 1%).

Combination Therapy (R-CVP in NHL; R-CHOP in DLBCL, R-FC in CLL)

In the R-CVP study the overall incidence of cardiac disorders in the safety population was low (4% R-CVP, 5% CVP), with no relevant differences between the treatment groups.

In the R-CHOP study the incidence of Grade 3 and 4 cardiac arrhythmias, predominantly supraventricular arrhythmias such as tachycardia and atrial flutter/fibrillation, was higher in the R-CHOP group (14 patients, 6.9%) as compared to the CHOP group (3 patients, 1.5%). All of these arrhythmias either occurred in the context of a rituximab infusion or were associated with predisposing conditions such as fever, infection, acute myocardial infarction or pre-existing respiratory and cardiovascular disease (see **7 WARNINGS AND PRECAUTIONS**). No difference between the R-CHOP and CHOP group was observed in the incidence of other Grade 3 and 4 cardiac events including heart failure, myocardial disease and manifestations of coronary artery disease.

In CLL, the overall incidence of Grade 3 or 4 cardiac disorders was low both in previously untreated patients (4% R-FC, 3% FC) and in previously treated patients (4% R-FC, 4% FC).

IgG Levels

Maintenance Treatment (NHL) up to 2 years

After induction treatment, median IgG levels were below the lower limit of normal (LLN) (< 7 g/L) in both the observation and the rituximab groups. In the observation group, the median IgG level subsequently increased to above the LLN, but remained constant during rituximab treatment. The proportion of patients with IgG levels below the LLN was about 60% in the rituximab group throughout the 2-year treatment period, while it decreased in the observation group (36% after 2 years).

Neurologic Events

Combination Therapy (R-CVP in NHL; R-CHOP in DLBCL, R-FC in CLL)

During the treatment period, (2% of patients) in the R-CHOP group, all with cardiovascular risk factors, experienced thromboembolic cerebrovascular accidents during the first treatment cycle. There was no difference between the treatment groups in the incidence of other thromboembolic events. In contrast, (1.5% of patients) had cerebrovascular events in the CHOP group, all of which occurred during the follow-up period.

In CLL, the overall incidence of Grade 3 or 4 nervous system disorders was low both in previously untreated patients (4% R-FC, 4% FC) and in previously treated patients (3% R-FC, 3% FC).

Pulmonary Events (see 7 WARNINGS AND PRECAUTIONS)

Three pulmonary events have been reported in temporal association with rituximab infusion as a single agent: acute, infusion-related bronchospasm, an acute pneumonitis presenting 1-4 weeks post infusion with rituximab, and bronchiolitis obliterans. The bronchiolitis obliterans was associated with progressive pulmonary symptoms and culminated in death several months following the last infusion with rituximab. The safety of resumption or continued administration of rituximab in patients with pneumonitis or bronchiolitis obliterans is unknown.

Malignancy

Combination Therapy (R-CVP in NHL; R-CHOP in DLBCL, R-FC in CLL)

In the CLL previously untreated study, the incidence of malignancy following exposure to rituximab was 4.5% compared to 3.8% in patients not exposed to rituximab.

Rituximab in Combination with FC Chemotherapy

The following table shows all serious clinical adverse events reported in $\geq 1\%$ of patients in either treatment group (R-FC and FC) in ML17102 and BO17072. In ML17102 Grade 1 and 2 adverse events and Grade 4 lymphocytopenia were not captured in the study.

Table 16. Summary of Serious Adverse Events that Occurred with an Incidence of $\geq 1\%$

System Organ Class	Incidence			
	ML17102# (previously untreated CLL ^{***})		BO17072 (previously treated CLL)	
	FC N = 396 N (%)	R-FC N = 397 N (%)	FC N = 272 N (%)	R-FC N = 274 N (%)
Blood and lymphatic system disorders*				
Febrile neutropenia	22 (6)	30 (8)	21 (8)	29 (11)
Anemia	9 (2)	6 (2)	11 (4)	3 (1)
Anemia hemolytic autoimmune	-	-	5 (2)	2 (<1)
Hemolytic anemia	-	-	3 (1)	2 (<1)
Leukopenia	3 (<1)	9 (2)	1 (<1)	3 (1)
Neutropenia	3 (<1)	8 (2)	7 (3)	8 (3)
Thrombocytopenia	5 (1)	6 (2)	-	-
Autoimmune thrombocytopenia	-	-	4 (1)	2 (<1)
Pancytopenia	3 (<1)	6 (2)	5** (2)	5 (2)
Febrile bone marrow aplasia	-	-	2 (<1)	3 (1)
Infections and infestations				
Pneumonia	20 (5)	18 (5)	18 (7)	15 (5)
Herpes zoster	6 (2)	8 (2)	3 (1)	1 (<1)
Sepsis	8 (2)	5 (1)	3 (1)	4 (1)
Bronchitis	5 (1)	5 (1)	2 (<1)	6 (2)
Infection	2 (<1)	5 (1)	-	-
Sinusitis	1 (<1)	4 (1)	-	-
Septic shock	-	-	2 (<1)	5 (2)
Neutropenic sepsis	-	-	4 (1)	2 (<1)
Hepatitis B	-	-	0	5 (2)
Respiratory tract infection	-	-	3 (1)	2 (<1)
<i>Pneumocystis jiroveci</i> pneumonia	-	-	3 (1)	1 (<1)

Table 16. Summary of Serious Adverse Events that Occurred with an Incidence of $\geq 1\%$

System Organ Class	Incidence			
	ML17102 [#] (previously untreated CLL ^{***})		BO17072 (previously treated CLL)	
	FC N = 396 N (%)	R-FC N = 397 N (%)	FC N = 272 N (%)	R-FC N = 274 N (%)
General disorders and administration site conditions				
Pyrexia	20 (5)	18 (5)	9 (3)	14 (5)
Cardiac disorders				
Angina pectoris	2 (<1)	5 (1)	-	-
Gastrointestinal disorders				
Diarrhea	2 (<1)	5 (1)	-	-
Vomiting	-	-	3 (1)	1 (<1)
Neoplasms, benign, malignant and unspecified (including cysts and polyps)				
Squamous cell carcinoma of skin	-	-	4 ^{**} (1)	1 (<1)
Tumour lysis syndrome	-	-	3 (1)	1 (<1)
Basal cell carcinoma	-	-	3 (1)	-

*Grade 4 lymphocytopenia was not captured in ML17102.

** Onset in one patient before starting study medication.

*** (Primary analysis: 20.7 months median observation time)

Grade 1 and 2 adverse events and Grade 4 lymphocytopenia were not captured in the study.

Combination Therapy

Elderly patients (≥ 65 years): The incidence of Grade 3/4 blood and lymphatic adverse events was higher in elderly patients (≥ 65 years of age) compared to younger patients, with previously untreated or previously treated CLL.

EXPERIENCE FROM CLINICAL TRIALS IN RHEUMATOID ARTHRITIS

The clinical efficacy of rituximab, given together with methotrexate was studied in three double-blind controlled clinical trials (one phase III trial and two phase II trials) in patients with rheumatoid arthritis. More than 1000 patients received at least one treatment course and were followed for periods ranging from 6 months to over 3 years; approximately 600 patients received two or more courses of treatment during the follow-up period.

Patients received 2 x 1000 mg of rituximab separated by an interval of two weeks; in addition to methotrexate (10-25 mg/week). Infusions of rituximab were administered after an IV infusion of 100 mg methylprednisolone; patients also received treatment with oral prednisolone for 15 days. Listed in Table 17 are ADRs that occurred with at least a 2% difference compared to the control arm and more frequently by patients who had received at least one infusion of rituximab than among patients that had received placebo in the phase III trial and the combined population included in phase II studies. In these studies, adverse reactions were more frequent in patients

treated with rituximab than in patients treated with placebo. Frequencies are defined as very common ($\geq 1/10$) and common ($\geq 1/100$ to $< 1/10$).

The most frequent ADRs considered due to receipt of 2 x 1000 mg rituximab in phase II and III studies were acute infusion reactions. Infusion reactions occurred in 15% of patients following the first infusion of rituximab and 5% in placebo patients. Infusion reactions decreased to 2% following the second infusion in both rituximab and placebo groups.

Table 17. Summary of Adverse Drug Reactions Occurring in Patients with Rheumatoid Arthritis Receiving Rituximab During Phase II and III Clinical Studies

	Pooled Phase II Study Population		Phase III Study Population	
	Very Common ($\geq 10\%$)	Common ($\geq 1\%$ to $< 10\%$)	Very Common ($\geq 10\%$)	Common ($\geq 1\%$ to $< 10\%$)
Acute infusion reactions*		hypertension, rash, pruritus, chills, pyrexia, rhinitis, throat irritation, tachycardia, oropharyngeal pain,		hypertension, nausea, rash, pyrexia, pruritus, urticaria, throat irritation, hot flush, hypotension
Gastrointestinal disorders		dyspepsia		dyspepsia
Infections and infestations	Any Infection	urinary tract infections	any infection, Upper respiratory tract infection	
Metabolism and nutritional disorders				hypercholesterolemia
Musculoskeletal disorders		arthralgia / musculoskeletal pain		arthralgia / musculoskeletal pain, osteoarthritis, bursitis
Nervous system disorders		Migraine		paresthesia, sciatica

This table include all events with an incidence difference of $\geq 2\%$ for rituximab compared to placebo

* Reactions occurring during or within 24 hours of infusion

Table 18. Adverse Reactions Occurring in at Least 1% of Patients and More Frequently in Rheumatoid Arthritis Patients Receiving Rituximab During Phase II and III Clinical Studies

System Organ Class	Pooled Phase II Study Population		Phase III Study Population	
	MTX + Placebo N = 189 n (%)	Rituximab + MTX N = 232 n (%)	MTX + Placebo N = 209 n (%)	Rituximab + MTX N = 308 n (%)
Acute infusion reactions*				
Hypertension	10 (5%)	22 (9%)	11 (5%)	21 (7%)
Nausea	14 (7%)	19 (8%)	5 (2%)	22 (7%)
Rash	6 (3%)	18 (8%)	9 (4%)	17 (6%)
Pyrexia	1 (<1%)	12 (5%)	7 (3%)	15 (5%)
Pruritus	1 (<1%)	14 (6%)	4 (2%)	12 (4%)

Table 18. Adverse Reactions Occurring in at Least 1% of Patients and More Frequently in Rheumatoid Arthritis Patients Receiving Rituximab During Phase II and III Clinical Studies

System Organ Class	Pooled Phase II Study Population		Phase III Study Population	
	MTX + Placebo N = 189 n (%)	Rituximab + MTX N = 232 n (%)	MTX + Placebo N = 209 n (%)	Rituximab + MTX N = 308 n (%)
Urticaria	0	2 (<1%)	3 (1%)	10 (3%)
Rhinitis	2 (1%)	6 (3%)	4 (2%)	8 (3%)
Throat irritation	0	5 (2%)	0	6 (2%)
Hot Flush	4 (2%)	2 (<1%)	0	6 (2%)
Hypotension	11 (6%)	10 (4%)	1 (<1%)	5 (2%)
Chills	3 (2%)	13 (6%)	6 (3%)	3 (<1%)
Gastrointestinal disorders				
Dyspepsia	3 (2%)	9 (4%)	0	7 (2%)
Abdominal pain upper	3 (2%)	7 (3%)	1 (<1%)	4 (1%)
General disorders				
Asthenia	0	3 (1%)	1 (<1%)	6 (2%)
Infections and infestations				
Any infection	56 (30%)	85 (37%)	78 (37%)	127 (41%)
Urinary tract infections	8 (4%)	14 (6%)	17 (8%)	15 (5%)
Upper respiratory tract	28 (15%)	31 (13%)	26 (12%)	48 (16%)
Lower respiratory tract	10 (5%)	9 (4%)	5 (2%)	8 (3%)
Infection/pneumonia				
Metabolism and nutritional disorders				
Hypercholesterolemia	1 (<1%)	3 (1%)	0	6 (2%)
Musculoskeletal disorders				
Arthralgia/musculoskeletal pain	8 (4%)	18 (7%)	6 (3%)	17 (7%)
Muscle spasms	0	1 (<1%)	2 (1%)	7 (2%)
Osteoarthritis	1 (<1%)	4 (2%)	0	6 (2%)
Nervous system				
Paresthesia	2 (1%)	4 (2%)	1 (<1%)	8 (3%)
Migraine	0	4 (2%)	2 (1%)	5 (2%)

* Reactions occurring within 24 hours of infusion

The following adverse events were reported at a frequency between 1% and 2% greater in the rituximab arms compared to the control arms: lower respiratory tract infections/pneumonia, abdominal pain upper, muscle spasms, asthenia, anxiety.

In addition to the events tabulated above, medically significant events reported rarely in the population treated with rituximab and considered potential reactions to treatment include the following:

General Disorders: Generalized edema

Immune system Disorders: Anaphylaxis, anaphylactoid reaction

Respiratory Disorders: Bronchospasm, wheezing, laryngeal edema

Skin and Subcutaneous Disorders: Angioneurotic edema, generalized pruritus.

The following serious adverse events were reported with an incidence rate of at least 1%:

Rheumatoid Arthritis and osteoarthritis (Pooled Phase II Study Population)

Rheumatoid Arthritis (Phase III Study Population).

Multiple Courses

Multiple courses of treatment are associated with a similar ADR profile to that observed following first exposure. The safety profile improved with subsequent courses due to a decrease in IRRs, RA exacerbation and infections, all of which were more frequent in the first 6 months of treatment.

In a study where all patients initially received rituximab followed by retreatment with either rituximab or placebo, the safety profile was similar to placebo. The proportion of patients who experienced any AEs, SAEs infections or serious infections was comparable between the placebo and rituximab retreatment arms.

Adverse Reactions Reported in RA Patients who had no Prior Inadequate Response to TNF Antagonists

Listed below are additional ADRs reported in Phase III placebo-controlled RA trials in either DMARD-IR or MTX Naive patients. These ADRs occurred with at least a 2% greater difference compared to control arm:

Very Common ($\geq 10\%$): headache

Common ($\geq 1\%$ to $< 10\%$) (listed in decreasing order of frequency): diarrhea, dizziness, bronchitis, sinusitis, gastroenteritis, fatigue, alopecia, mouth ulceration, gastro-esophageal reflux, peripheral edema, erythema, depression anxiety, tinea pedis.

Further Information on Selected Adverse Drug Reactions - Rheumatoid Arthritis

Please note that the information presented below includes the all exposure population of more than 3000 RA patients who have received at least one treatment course and were followed for periods ranging from 6 months to over 5 years with an overall exposure equivalent to 7198 patient years. The patient populations receiving rituximab differed between studies, ranging from early active RA patients who were methotrexate (MTX) naïve, through MTX inadequate responders (MTX-IR) to patients who had inadequate response to anti-TNF therapies (TNF-IR).

Infusion-related reactions

The most frequent ADRs following receipt of rituximab in clinical studies were infusion-related reactions. Among the 3095 patients treated with rituximab, 1077 (35%) experienced at least one IRR. The vast majority of IRRs were CTC Grade 1 or 2. In clinical studies, fewer than 1% (14/3095 patients) of patients with RA who received an infusion of rituximab at any dose

experienced a serious infusion-related reaction. There were no CTC Grade 4 IRRs and no deaths due to IRRs in the clinical studies. The proportion of CTC Grade 3 events and of IRRs leading to withdrawal decreased by course and were rare from course 3 onwards.

Signs and or symptoms suggesting an infusion-related reaction (nausea, pruritus, fever, urticaria/rash, chills, pyrexia, rigors, sneezing, angioneurotic edema, throat irritation, cough and bronchospasm, with or without associated hypotension or hypertension) were observed in 720/3095 (23%) patients with rheumatoid arthritis following first infusion of the first exposure to rituximab. Premedication with IV glucocorticoid significantly reduced the incidence and severity of these events (see **7 WARNINGS AND PRECAUTIONS, Rheumatoid Arthritis**).

In patients with moderate-to-severe active rheumatoid arthritis who did not experience a serious infusion-related reaction during or within 24 hours of their first infusion at the standard infusion regimen and received a 120-minute infusion of rituximab at the second infusion, the incidence of infusion-related reactions on Infusion 2 was 6.5% (95% CI [4.1%, 9.7%]). For the subsequent infusions (Infusion 3 and Infusion 4) in the second course of treatment with rituximab, the incidence of infusion-related reactions during or within 24 hours of the 120-minute infusion was 5.9% (95% CI [3.5%, 9.3%]) for Infusion 3 and 0.7% (95% CI [0.1%, 2.6%]) for Infusion 4, respectively (see **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG, Rheumatoid Arthritis**).

Infections

The overall rate of infection was approximately 97 per 100 patient years in patients treated with rituximab. The infections were predominately mild to moderate and consisted mostly of upper respiratory tract infections and urinary tract infections. In the all-exposure population the rate of serious infections, was approximately 4 per 100 patient years, some of which were fatal, including clostridium difficile colitis, pneumonia, progressive multifocal leukoencephalopathy (PML), neutropenic sepsis, septic shock and abdominal sepsis. In addition to the ADRs in Table 17, medically serious events reported also included pneumonia (including atypical pneumonia) at a frequency of 1.9%.

Malignancies

In RA clinical studies, the incidence of malignancy following exposure to rituximab is 0.8 per 100 patient years, which is within the range expected for an age- and gender- matched population. The rate of melanoma in RA clinical studies was 0.06 per 100 patient years (95% CI 0.02-0.14 per 100 patient years), which is similar to the rate expected for an age and gender matched population. This overall rate includes 3 patients of 431 in the Study 2 extension.

On the basis of limited experience with rituximab in rheumatoid arthritis patients, a possible risk for the development of solid tumours cannot be excluded at this time, although present data do not seem to suggest any increased risk.

EXPERIENCE FROM CLINICAL TRIALS IN GRANULOMATOSIS WITH POLYANGITIS (GPA, ALSO KNOWN AS WEGENER'S GRANULOMATOSIS) AND MICROSCOPIC POLYANGITIS (MPA)

In the GPA/MPA clinical study, 99 patients were treated with rituximab (375 mg/m², once weekly for 4 weeks) and glucocorticoids (see **17 CLINICAL TRIALS – REFERENCE BIOLOGIC DRUG**).

The adverse events listed in Table 19 occurred at an incidence of ≥ 1% in the rituximab-treated group.

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class Adverse event	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Infections and infestations	61 (61.6%)	46 (46.9%)
Upper respiratory tract infection	8 (8.1%)	13 (13.3%)
Nasopharyngitis	6 (6.1%)	4 (4.1%)
Pneumonia	4 (4.0%)	5 (5.1%)
Sinusitis	5 (5.1%)	4 (4.1%)
Urinary tract infection	5 (5.1%)	3 (3.1%)
Oral candidiasis	3 (3.0%)	4 (4.1%)
Bronchitis	4 (4.0%)	2 (2.0%)
Herpes zoster	5 (5.1%)	1 (1.0%)
Candidiasis	2 (2.0%)	3 (3.1%)
Fungal infection	3 (3.0%)	2 (2.0%)
Oral herpes	4 (4.0%)	1 (1.0%)
Respiratory tract infection	4 (4.0%)	0 (0.0%)
Herpes simplex	2 (2.0%)	1 (1.0%)
Vulvovaginal mycotic infection	3 (3.0%)	0 (0.0%)
Escherichia infection	2 (2.0%)	0 (0.0%)
Infection	1 (1.0%)	1 (1.0%)
Rhinitis	1 (1.0%)	1 (1.0%)
Viral upper respiratory tract infection	2 (2.0%)	0 (0.0%)
Bacteriuria	1 (1.0%)	0 (0.0%)
Body tinea	1 (1.0%)	0 (0.0%)
Cellulitis orbital	1 (1.0%)	0 (0.0%)
Conjunctivitis infective	1 (1.0%)	0 (0.0%)
Cystitis viral	1 (1.0%)	0 (0.0%)
Diverticulitis	1 (1.0%)	0 (0.0%)
Enterococcal sepsis	1 (1.0%)	0 (0.0%)
Escherichia sepsis	1 (1.0%)	0 (0.0%)
Folliculitis	1 (1.0%)	0 (0.0%)
Fungal skin infection	1 (1.0%)	0 (0.0%)
Gastroenteritis viral	1 (1.0%)	0 (0.0%)
Gastrointestinal infection	1 (1.0%)	0 (0.0%)
Influenza	1 (1.0%)	0 (0.0%)
Keratitis herpetic	1 (1.0%)	0 (0.0%)
Lower respiratory tract infection	1 (1.0%)	0 (0.0%)
Mycobacterium avium complex infection	1 (1.0%)	0 (0.0%)
Esophageal candidiasis	1 (1.0%)	0 (0.0%)
Osteomyelitis	1 (1.0%)	0 (0.0%)
Paronychia	1 (1.0%)	0 (0.0%)
Parotitis	1 (1.0%)	0 (0.0%)
Pharyngitis	1 (1.0%)	0 (0.0%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Adverse event		
Rash pustular	1 (1.0%)	0 (0.0%)
Respiratory tract infection viral	1 (1.0%)	0 (0.0%)
Sputum purulent	1 (1.0%)	0 (0.0%)
Vulvovaginal candidiasis	1 (1.0%)	0 (0.0%)
Gastrointestinal disorders	52 (52.5%)	45 (45.9%)
Nausea	18 (18.2%)	20 (20.4%)
Diarrhea	17 (17.2%)	12 (12.2%)
Vomiting	6 (6.1%)	9 (9.2%)
Dyspepsia	6 (6.1%)	5 (5.1%)
Abdominal pain	5 (5.1%)	3 (3.1%)
Gastroesophageal reflux disease	4 (4.0%)	4 (4.1%)
Constipation	5 (5.1%)	1 (1.0%)
Abdominal discomfort	3 (3.0%)	1 (1.0%)
Hematochezia	2 (2.0%)	1 (1.0%)
Mouth ulceration	1 (1.0%)	2 (2.0%)
Paresthesia oral	3 (3.0%)	0 (0.0%)
Stomatitis	1 (1.0%)	2 (2.0%)
Abdominal distension	2 (2.0%)	0 (0.0%)
Esophagitis	2 (2.0%)	0 (0.0%)
Abdominal pain upper	1 (1.0%)	0 (0.0%)
Anorectal discomfort	1 (1.0%)	0 (0.0%)
Colitis ischemic	1 (1.0%)	0 (0.0%)
Colitis microscopic	1 (1.0%)	0 (0.0%)
Dry mouth	1 (1.0%)	0 (0.0%)
Erosive esophagitis	1 (1.0%)	0 (0.0%)
Feces discoloured	1 (1.0%)	0 (0.0%)
Flatulence	1 (1.0%)	0 (0.0%)
Gastrointestinal pain	1 (1.0%)	0 (0.0%)
Gingivitis ulcerative	1 (1.0%)	0 (0.0%)
Hemorrhoids	1 (1.0%)	0 (0.0%)
Melena	1 (1.0%)	0 (0.0%)
Mouth hemorrhage	1 (1.0%)	0 (0.0%)
Esophageal achalasia	1 (1.0%)	0 (0.0%)
Esophageal pain	1 (1.0%)	0 (0.0%)
Oral pain	1 (1.0%)	0 (0.0%)
Sensitivity of teeth	1 (1.0%)	0 (0.0%)
Tongue atrophy	1 (1.0%)	0 (0.0%)
Toothache	1 (1.0%)	0 (0.0%)
Upper gastrointestinal hemorrhage	1 (1.0%)	0 (0.0%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class Adverse event	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Injury, poisoning, and procedural complications	13 (13.1%)	7 (7.1%)
Contusion	2 (2.0%)	1 (1.0%)
Back injury	1 (1.0%)	1 (1.0%)
Fall	2 (2.0%)	0 (0.0%)
Joint sprain	1 (1.0%)	1 (1.0%)
Limb injury	1 (1.0%)	1 (1.0%)
Accidental overdose	1 (1.0%)	0 (0.0%)
Ankle fracture	1 (1.0%)	0 (0.0%)
Corneal abrasion	1 (1.0%)	0 (0.0%)
Glaucoma traumatic	1 (1.0%)	0 (0.0%)
Joint injury	1 (1.0%)	0 (0.0%)
Muscle rupture	1 (1.0%)	0 (0.0%)
Muscle strain	1 (1.0%)	0 (0.0%)
Skin laceration	1 (1.0%)	0 (0.0%)
Tooth fracture	1 (1.0%)	0 (0.0%)
Nervous system disorders	39 (39.4%)	42 (42.9%)
Headache	17 (17.2%)	19 (19.4%)
Dizziness	9 (9.1%)	9 (9.2%)
Tremor	9 (9.1%)	6 (6.1%)
Hypoesthesia	6 (6.1%)	5 (5.1%)
Paresthesia	4 (4.0%)	6 (6.1%)
Dysgeusia	4 (4.0%)	4 (4.1%)
Syncope	2 (2.0%)	2 (2.0%)
Hypogeusia	2 (2.0%)	1 (1.0%)
Poor quality sleep	1 (1.0%)	2 (2.0%)
Psychomotor hyperactivity	1 (1.0%)	1 (1.0%)
Restless legs syndrome	1 (1.0%)	1 (1.0%)
Cervicobrachial syndrome	1 (1.0%)	0 (0.0%)
Hyporeflexia	1 (1.0%)	0 (0.0%)
Meningeal disorder	1 (1.0%)	0 (0.0%)
Meralgia paresthetica	1 (1.0%)	0 (0.0%)
Nervous system disorder	1 (1.0%)	0 (0.0%)
Presyncope	1 (1.0%)	0 (0.0%)
Musculoskeletal and connective tissue disorders	46 (46.5%)	39 (39.8%)
Muscle spasm	17 (17.2%)	15 (15.3%)
Arthralgia	13 (13.1%)	9 (9.2%)
Back pain	9 (9.1%)	4 (4.1%)
Muscular weakness	5 (5.1%)	4 (4.1%)
Pain in extremity	5 (5.1%)	3 (3.1%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class Adverse event	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Myalgia	3 (3.0%)	4 (4.1%)
Joint swelling	4 (4.0%)	1 (1.0%)
Bone pain	3 (3.0%)	0 (0.0%)
Flank pain	1 (1.0%)	2 (2.0%)
Musculoskeletal pain	3 (3.0%)	0 (0.0%)
Osteoarthritis	1 (1.0%)	2 (2.0%)
Plantar fasciitis	1 (1.0%)	1 (1.0%)
Arthritis	1 (1.0%)	0 (0.0%)
Bursitis	1 (1.0%)	0 (0.0%)
Fibromyalgia	1 (1.0%)	0 (0.0%)
Musculoskeletal stiffness	1 (1.0%)	0 (0.0%)
Myopathy	1 (1.0%)	0 (0.0%)
Neck pain	1 (1.0%)	0 (0.0%)
Nose deformity	1 (1.0%)	0 (0.0%)
Neoplasms benign, malignant, and unspecified (including cysts and polyps)	3 (3.0%)	4 (4.1%)
Lung neoplasm	1 (1.0%)	2 (2.0%)
Prostate cancer	1 (1.0%)	1 (1.0%)
Basal cell carcinoma	1 (1.0%)	0 (0.0%)
Blood and lymphatic system disorders	30 (30.3%)	43 (43.9%)
Anemia	16 (16.2%)	20 (20.4%)
Leukopenia	10 (10.1%)	26 (26.5%)
Thrombocytopenia	7 (7.1%)	3 (3.1%)
Neutropenia	1 (1.0%)	3 (3.1%)
Pancytopenia	1 (1.0%)	2 (2.0%)
Iron deficiency anemia	1 (1.0%)	0 (0.0%)
Neutrophilia	1 (1.0%)	0 (0.0%)
Cardiac disorders	11 (11.1%)	8 (8.2%)
Palpitations	2 (2.0%)	4 (4.1%)
Tachycardia	4 (4.0%)	1 (1.0%)
Atrial fibrillation	3 (3.0%)	0 (0.0%)
Supraventricular tachycardia	1 (1.0%)	1 (1.0%)
Aortic valve sclerosis	1 (1.0%)	0 (0.0%)
Ventricular tachycardia	1 (1.0%)	0 (0.0%)
Congenital, familial, and genetic disorders	1 (1.0%)	0 (0.0%)
Congenital cystic kidney disease	1 (1.0%)	0 (0.0%)
Ear and labyrinth disorders	8 (8.1%)	6 (6.1%)
Ear pain	1 (1.0%)	3 (3.1%)
Ear discomfort	1 (1.0%)	1 (1.0%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class Adverse event	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Tinnitus	2 (2.0%)	0 (0.0%)
Conductive deafness	1 (1.0%)	0 (0.0%)
Deafness unilateral	1 (1.0%)	0 (0.0%)
Mastoid disorder	1 (1.0%)	0 (0.0%)
Tympanic membrane scarring	1 (1.0%)	0 (0.0%)
Endocrine disorders	7 (7.1%)	13 (13.3%)
Cushingoid	5 (5.1%)	6 (6.1%)
Steroid withdrawal syndrome	2 (2.0%)	5 (5.1%)
Eye disorders	23 (23.2%)	20 (20.4%)
Vision blurred	3 (3.0%)	5 (5.1%)
Conjunctival hemorrhage	3 (3.0%)	3 (3.1%)
Conjunctivitis	3 (3.0%)	1 (1.0%)
Lacrimation increased	2 (2.0%)	2 (2.0%)
Ocular hyperemia	1 (1.0%)	3 (3.1%)
Dry eye	2 (2.0%)	1 (1.0%)
Eye pain	3 (3.0%)	0 (0.0%)
Glaucoma	2 (2.0%)	1 (1.0%)
Abnormal sensation in eye	2 (2.0%)	0 (0.0%)
Cataract	2 (2.0%)	0 (0.0%)
Conjunctival hyperemia	2 (2.0%)	0 (0.0%)
Diplopia	2 (2.0%)	0 (0.0%)
Episcleritis	1 (1.0%)	1 (1.0%)
Eye swelling	2 (2.0%)	0 (0.0%)
Myodesopsia	1 (1.0%)	1 (1.0%)
Visual acuity reduced	1 (1.0%)	1 (1.0%)
Cataract nuclear	1 (1.0%)	0 (0.0%)
Chalazion	1 (1.0%)	0 (0.0%)
Diabetic retinopathy	1 (1.0%)	0 (0.0%)
Eye discharge	1 (1.0%)	0 (0.0%)
Eyelid edema	1 (1.0%)	0 (0.0%)
Eyelid ptosis	1 (1.0%)	0 (0.0%)
Hypoesthesia eye	1 (1.0%)	0 (0.0%)
Keratitis	1 (1.0%)	0 (0.0%)
Optic nerve disorder	1 (1.0%)	0 (0.0%)
Periorbital disorder	1 (1.0%)	0 (0.0%)
Photopsia	1 (1.0%)	0 (0.0%)
Pupillary reflex impaired	1 (1.0%)	0 (0.0%)
Retinal detachment	1 (1.0%)	0 (0.0%)
Retinal hemorrhage	1 (1.0%)	0 (0.0%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class Adverse event	Rituximab (n = 99)	Cyclophosphamide (n = 98)
General disorders and administration site conditions	36 (36.4%)	49 (50.0%)
Peripheral edema	16 (16.2%)	6 (6.1%)
Fatigue	13 (13.1%)	21 (21.4%)
Pyrexia	8 (8.1%)	13 (13.3%)
Chills	5 (5.1%)	6 (6.1%)
Chest pain	3 (3.0%)	4 (4.1%)
Chest discomfort	2 (2.0%)	3 (3.1%)
Edema	1 (1.0%)	4 (4.1%)
Asthenia	1 (1.0%)	3 (3.1%)
Malaise	3 (3.0%)	1 (1.0%)
Pain	2 (2.0%)	2 (2.0%)
Influenza like illness	1 (1.0%)	1 (1.0%)
Irritability	1 (1.0%)	1 (1.0%)
Suprapubic pain	1 (1.0%)	1 (1.0%)
Infusion related reaction	1 (1.0%)	0 (0.0%)
Multi-organ failure	1 (1.0%)	0 (0.0%)
Swelling	1 (1.0%)	0 (0.0%)
Psychiatric disorders	22 (22.2%)	17 (17.3%)
Insomnia	14 (14.1%)	12 (12.2%)
Anxiety	1 (1.0%)	5 (5.1%)
Depression	2 (2.0%)	3 (3.1%)
Agitation	2 (2.0%)	2 (2.0%)
Restlessness	2 (2.0%)	1 (1.0%)
Nervousness	1 (1.0%)	1 (1.0%)
Depressed mood	1 (1.0%)	0 (0.0%)
Hypomania	1 (1.0%)	0 (0.0%)
Renal and urinary disorders	9 (9.1%)	18 (18.4%)
Hematuria	3 (3.0%)	5 (5.1%)
Renal failure	3 (3.0%)	2 (2.0%)
Acute Renal failure	1 (1.0%)	2 (2.0%)
Cystitis hemorrhagic	1 (1.0%)	1 (1.0%)
Urinary retention	2 (2.0%)	0 (0.0%)
Nephrolithiasis	1 (1.0%)	0 (0.0%)
Proteinuria	1 (1.0%)	0 (0.0%)
Pyuria	1 (1.0%)	0 (0.0%)
Renal impairment	1 (1.0%)	0 (0.0%)
Reproductive system and breast disorders	8 (8.1%)	3 (3.1%)
Irregular menstruation	1 (1.0%)	2 (2.0%)
Cervical dysplasia	2 (2.0%)	0 (0.0%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class Adverse event	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Benign prostatic hyperplasia	1 (1.0%)	0 (0.0%)
Erectile dysfunction	1 (1.0%)	0 (0.0%)
Metrorrhagia	1 (1.0%)	0 (0.0%)
Ovarian cyst	1 (1.0%)	0 (0.0%)
Vaginal hemorrhage	1 (1.0%)	0 (0.0%)
Investigations	38 (38.4%)	61 (62/2%)
Increased ALT	13 (13.1%)	15 (15.3%)
White blood cell count decreased	4 (4.0%)	19 (19.4%)
Hematocrit	7 (7.1%)	13 (13.3%)
Increased AST	5 (5.1%)	11 (11.2%)
Increased blood creatinine	7 (7.1%)	7 (7.1%)
Increased C-reactive protein	6 (6.1%)	8 (8.2%)
Increased weight	6 (6.1%)	6 (6.1%)
Decreased hemoglobin	5 (5.1%)	4 (4.1%)
Increased red blood cell sedimentation rate	2 (2.0%)	7 (7.1%)
Decreased platelet count	4 (4.0%)	2 (2.0%)
Increased blood urea	2 (2.0%)	1 (1.0%)
Abnormal breath sounds	1 (1.0%)	2 (2.0%)
Cardiac murmur	1 (1.0%)	2 (2.0%)
Increased INR	2 (2.0%)	1 (1.0%)
White blood cells urine positive	1 (1.0%)	2 (2.0%)
Increased band neutrophil count	1 (1.0%)	1 (1.0%)
Decreased blood albumin	1 (1.0%)	1 (1.0%)
Increased mean cell volume	1 (1.0%)	1 (1.0%)
Increased transaminases	1 (1.0%)	1 (1.0%)
Decreased weight	1 (1.0%)	1 (1.0%)
Decreased blood glucose	1 (1.0%)	0 (0.0%)
Increased blood lactate dehydrogenase	1 (1.0%)	0 (0.0%)
Decreased blood potassium	1 (1.0%)	0 (0.0%)
Decreased blood thyroid stimulating hormone	1 (1.0%)	0 (0.0%)
Increased blood thyroid stimulating hormone	1 (1.0%)	0 (0.0%)
Blood temperature fluctuation	1 (1.0%)	0 (0.0%)
Increased creatinine renal clearance	1 (1.0%)	0 (0.0%)
Increased heart rate	1 (1.0%)	0 (0.0%)
Decreased oxygen saturation	1 (1.0%)	0 (0.0%)
Increased reticulocyte count	1 (1.0%)	0 (0.0%)
Metabolism and nutrition disorders	23 (23.2%)	29 (29.6%)
Hyperglycemia	7 (7.1%)	9 (9.2%)
Hypokalemia	2 (2.0%)	6 (6.1%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Adverse event		
Hyperkalemia	5 (5.1%)	2 (2.0%)
Anorexia	3 (3.0%)	3 (3.1%)
Hyponatremia	1 (1.0%)	4 (4.1%)
Decreased appetite	1 (1.0%)	1 (2.0%)
Dehydration	1 (1.0%)	2 (2.0%)
Increased appetite	1 (1.0%)	2 (2.0%)
Hypercalcemia	1 (1.0%)	1 (1.0%)
Fluid retention	1 (1.0%)	0 (0.0%)
Hypocalcemia	1 (1.0%)	0 (0.0%)
Type 2 diabetes mellitus	1 (1.0%)	0 (0.0%)
Respiratory, thoracic, and mediastinal disorders	51 (51.5%)	43 (43.9%)
Cough	13 (13.1%)	11 (11.2%)
Dyspnea	10 (10.1%)	11 (11.2%)
Epistaxis	11 (11.1%)	6 (6.1%)
Oropharyngeal pain	4 (4.0%)	5 (5.1%)
Hemoptysis	2 (2.0%)	5 (5.1%)
Nasal congestion	4 (4.0%)	2 (2.0%)
Paranasal sinus hypersecretion	1 (1.0%)	5 (5.1%)
Laryngeal stenosis	2 (2.0%)	3 (3.1%)
Nasal disorder	2 (2.0%)	3 (3.1%)
Rhinorrhea	2 (2.0%)	3 (3.1%)
Pulmonary embolism	2 (2.0%)	2 (2.0%)
Throat irritation	3 (3.0%)	1 (1.0%)
Wheezing	3 (3.0%)	1 (1.0%)
Dysphonia	2 (2.0%)	1 (1.0%)
Pleuritic pain	2 (2.0%)	1 (1.0%)
Productive cough	2 (2.0%)	1 (1.0%)
Rales	3 (3.0%)	0 (0.0%)
Bronchospasm	1 (1.0%)	1 (1.0%)
Chronic obstructive pulmonary disease	1 (1.0%)	1 (1.0%)
Oropharyngeal discomfort	2 (2.0%)	0 (0.0%)
Sinus congestion	2 (2.0%)	0 (0.0%)
Wegener's granulomatosis	1 (1.0%)	1 (1.0%)
Asthma	1 (1.0%)	0 (0.0%)
Dry throat	1 (1.0%)	0 (0.0%)
Lung disorder	1 (1.0%)	0 (0.0%)
Lung infiltration	1 (1.0%)	0 (0.0%)
Nasal septum perforation	1 (1.0%)	0 (0.0%)
Pharyngeal erythema	1 (1.0%)	0 (0.0%)
Pleural effusion	1 (1.0%)	0 (0.0%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Adverse event		
Pulmonary hemorrhage	1 (1.0%)	0 (0.0%)
Pulmonary hypertension	1 (1.0%)	0 (0.0%)
Pulmonary pneumatocele	1 (1.0%)	0 (0.0%)
Rhinitis allergic	1 (1.0%)	0 (0.0%)
Stridor	1 (1.0%)	0 (0.0%)
Throat tightness	1 (1.0%)	0 (0.0%)
Vocal cord disorder	1 (1.0%)	0 (0.0%)
Vascular disorders	28 (28.3%)	18 (18.4%)
Hypertension	12 (12.1%)	5 (5.1%)
Deep vein thrombosis	3 (3.0%)	8 (8.2%)
Flushing	5 (5.1%)	4 (4.1%)
Hot flush	4 (4.0%)	2 (2.0%)
Hypotension	2 (2.0%)	1 (1.0%)
Orthostatic hypotension	1 (1.0%)	1 (1.0%)
Pallor	1 (1.0%)	1 (1.0%)
Arteriosclerosis	1 (1.0%)	0 (0.0%)
Extremity necrosis	1 (1.0%)	0 (0.0%)
Hypertensive emergency	1 (1.0%)	0 (0.0%)
Infarction	1 (1.0%)	0 (0.0%)
Phlebitis superficial	1 (1.0%)	0 (0.0%)
Raynaud's phenomenon	1 (1.0%)	0 (0.0%)
Immune system disorders	16 (10.1%)	10 (5.1%)
Infusion related reactions ^b	12 (12.1%)	11 (11.2%)
Drug hypersensitivity	1 (1.0%)	3 (3.1%)
Hypersensitivity	2 (2.0%)	0 (0.0%)
Seasonal allergy	2 (2.0%)	0 (0.0%)
Anti-neutrophil cytoplasmic antibody positive vasculitis	2 (2.0%)	0 (0.0%)
Skin and subcutaneous tissue disorders	44 (44.4%)	48 (49.0%)
Rash	10 (10.1%)	17 (17.3%)
Alopecia	9 (9.1%)	18 (18.4%)
Acne	7 (7.1%)	4 (4.1%)
Hyperhidrosis	2 (2.0%)	7 (7.1%)
Pruritus	3 (3.0%)	2 (2.0%)
Night sweats	2 (2.0%)	2 (2.0%)
Skin lesion	2 (2.0%)	2 (2.0%)
Purpura	2 (2.0%)	1 (1.0%)
Swelling face	1 (1.0%)	2 (2.0%)
Dermatitis acneiform	1 (1.0%)	1 (1.0%)
Erythema	2 (2.0%)	0 (0.0%)

Table 19. Adverse Events Occurring in at Least 1% of Rituximab-Treated GPA/MPA Patients in Clinical Study Up to Month 6*

System Organ Class Adverse event	Rituximab (n = 99)	Cyclophosphamide (n = 98)
Rash macular	1 (1.0%)	1 (1.0%)
Urticaria	2 (2.0%)	0 (0.0%)
Dermatitis	1 (1.0%)	0 (0.0%)
Drug eruption	1 (1.0%)	0 (0.0%)
Ecchymosis	1 (1.0%)	0 (0.0%)
Nail dystrophy	1 (1.0%)	0 (0.0%)
Rash follicular	1 (1.0%)	0 (0.0%)
Rash generalized	1 (1.0%)	0 (0.0%)
Rash maculo-papular	1 (1.0%)	0 (0.0%)
Rash popular	1 (1.0%)	0 (0.0%)
Skin burning sensation	1 (1.0%)	0 (0.0%)
Skin discolouration	1 (1.0%)	0 (0.0%)
Skin exfoliation	1 (1.0%)	0 (0.0%)
Skin nodule	1 (1.0%)	0 (0.0%)
Skin striae	1 (1.0%)	0 (0.0%)
Skin ulcer hemorrhage	1 (1.0%)	0 (0.0%)

*The study design allowed for crossover or treatment by best medical judgment, and 13 patients in each treatment group received a second therapy during the 6 month study period.

^a Most common infections in the rituximab group included upper respiratory tract infections, urinary tract infections, and herpes zoster.

^b Most common terms reported in the rituximab group included cytokine release syndrome, flushing, throat irritation, and tremor.

Further information on selected adverse drug reactions - GPA and MPA

Infusion-related reactions

Infusion related reactions (IRRs) in the GPA/MPA clinical study were defined as any adverse event occurring within 24 hours of an infusion and considered to be infusion-related by investigators in the safety population. Ninety-nine patients were treated with rituximab and 12% experienced at least one IRR. All IRRs were CTC Grade 1 or 2. The most common IRRs included cytokine release syndrome, flushing, throat irritation, and tremor. Rituximab was given in combination with intravenous glucocorticoids which may reduce the incidence and severity of these events.

Infections

In the RAVE study, 62% (61/99) of patients in the rituximab group experienced an infection of any type compared to 47% (46/98) of patients in the cyclophosphamide group by Month 6, infections were predominately mild to moderate and consisted mostly of upper respiratory tract infections, herpes zoster and urinary tract infections. The incidence of serious infections was 11% in the rituximab -treated patients and 10% in the cyclophosphamide treated patients. The most frequently reported serious infection in the rituximab group was pneumonia at a frequency of 4%.

Malignancies

In the RAVE study by Month 6, one malignancy was reported in each treatment arm. By the common close out date (the last patient's 18-month visit), 5 patients in the rituximab arm reported 6 malignancies and 2 patients in the cyclophosphamide arm reported 2 malignancies.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Rheumatoid Arthritis (RA) Patients

Hypogammaglobulinaemia (IgG or IgM below the lower limit of normal) has been observed in RA patients treated with rituximab. There was no increased rate in overall infections or serious infections after the development of low IgG or IgM.

Events of neutropenia associated with rituximab treatment, the majority of which were transient and mild or moderate in severity, were observed in clinical trials in RA patients after the first course of treatment. Neutropenia can occur several months after the administration of rituximab.

In placebo-controlled periods of clinical trials, 0.94% (13/1382) of rituximab treated patients and 0.27% (2/731) of placebo patients developed severe (Grade 3 or 4) neutropenia. In these studies, rates of severe neutropenia were 1.06 and 0.53/100 patient-years after the first treatment course, respectively, and 0.97 and 0.88/100 patient-years after multiple courses, respectively. Therefore, neutropenia can be considered an ADR for the first course only. Time to onset of neutropenia was variable. In clinical trials neutropenia was not associated with an observed increase in serious infection, and most patients continued to receive additional courses of rituximab after episodes of neutropenia.

Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) Patients

Hypogammaglobulinemia (IgA, IgG or IgM below the lower limit of normal) has been observed in GPA and MPA patients treated with rituximab. At 6 months, in the rituximab group, 27% (21/79), 58% (40/69) and 51% (35/69) of patients with normal immunoglobulin levels at baseline, had low IgA, IgG and IgM levels, respectively compared to 25% (17/67), 50% (30/60) and 46% (31/68) in the cyclophosphamide group. There was no increased rate in overall infections or serious infections in patients with low IgA, IgG or IgM.

In the active-controlled, randomized, double-blind, multicenter, non-inferiority study of rituximab in GPA and MPA, 24% (20/83) of patients in the rituximab group (single course) and 23% (20/87) of patients in the cyclophosphamide group developed CTC Grade 3 or greater neutropenia. Neutropenia was not associated with an observed increase in serious infection in rituximab-treated patients. The effect of multiple rituximab courses on the development of neutropenia in GPA and MPA patients has not been studied in clinical trials.

8.5 Post-Market Adverse Drug Reactions

Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) Patients

As part of the continuing post-marketing surveillance of the reference biologic drug, Rituxan[®] safety, the following have been observed in the RA setting and are also expected, if not already observed, in GPA/MPA patients:

Infections and infestations

Progressive multifocal leukoencephalopathy (PML) and reactivation of hepatitis B infection have been reported.

Body as a whole

Serum sickness-like reaction has been reported.

Skin and subcutaneous tissue disorders

Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome some with fatal outcome have been reported very rarely.

Blood and lymphatic system disorders

Neutropenic events, including severe late onset and persistent neutropenia, have been reported rarely in the post-marketing setting, some of which were associated with fatal infections.

Nervous system

Cases of posterior reversible encephalopathy syndrome (PRES) / reversible posterior leukoencephalopathy syndrome (RPLS) have been reported. Signs and symptoms included visual disturbance, headache, seizures and altered mental status, with or without associated hypertension. A diagnosis of PRES/RPLS requires confirmation by brain imaging. The reported cases had recognized risk factors for PRES/RPLS, including hypertension, immunosuppressive therapy and/or other concomitant therapies.

General disorders and administration site conditions

Severe infusion-related reactions with fatal outcome have been reported in the post-marketing setting (see **7 WARNINGS AND PRECAUTIONS**).

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Patients

The reporting frequencies in this section (rare, very rare) are based on estimated marketed exposures and largely data derived from spontaneous reports.

Additional cases of severe infusion-related reactions have been reported during post-marketing use of rituximab (see **7 WARNINGS AND PRECAUTIONS**). As part of the continuing post-marketing surveillance of the safety of rituximab, the following serious adverse reactions have been observed:

Blood and Lymphatic System

Neutropenia: Rarely, the onset of neutropenia has occurred more than four weeks after the last infusion of rituximab. Cases of infusion-related acute reversible thrombocytopenia have been reported.

In post-marketing studies of rituximab in patients with Waldenstrom's macroglobulinemia, transient increases in serum IgM levels have been observed following treatment initiation, which may be associated with hyperviscosity and related symptoms. The transient IgM increase usually returned to at least baseline level within 4 months from the administration/start of rituximab treatment.

Body as a Whole

Anaphylaxis; mucositis and serum sickness-like reactions have been reported rarely.

Cardiovascular System

Severe cardiac events, including congestive heart failure and myocardial infarction have been observed, mainly in patients with prior cardiac condition and/or cardiotoxic chemotherapy and mostly associated with infusion-related reactions. Vasculitis, predominantly cutaneous, such as leukocytoclastic vasculitis and fatal cardiac failure have been reported very rarely.

Infections and Infestations

Cases of HBV reactivation, occasionally with fulminant hepatitis, hepatic failure, and death has been reported in some patients with hematologic malignancies treated with rituximab. The majority of patients received rituximab in combination with chemotherapy (see **7 WARNINGS AND PRECAUTIONS**).

Other serious viral infections, either new, reactivation or exacerbation, some of which were fatal, have been reported with rituximab treatment. The majority of patients had received rituximab in combination with chemotherapy or as part of a hematopoietic stem cell transplant. Examples of these serious viral infections are infections caused by the herpes viruses (cytomegalovirus (CMV), Varicella zoster virus and Herpes simplex virus), JC virus (progressive multifocal leukoencephalopathy (PML) and Hepatitis C virus (see **7 WARNINGS AND PRECAUTIONS**).

Progression of Kaposi's sarcoma has been observed in rituximab-exposed patients with pre-existing Kaposi's sarcoma. These cases occurred in non-approved indications and the majority of patients were HIV positive.

Increase in fatal infections in HIV lymphoma has been reported very rarely when rituximab is used with chemotherapy.

Immune Phenomena

Paraneoplastic neuropathy, encephalomyelitis, polymyositis, have been rarely reported. Other possible rare adverse events include: optic neuritis, uveitis, vasculitis, serum sickness or a lupus-like syndrome, pleuritis and arthritis. Systemic vasculitis has been reported very rarely.

Nervous System

Cases of cranial neuropathy with or without peripheral neuropathy have been rarely reported. Signs and symptoms of cranial neuropathy, such as severe vision loss, hearing loss, loss of other senses and facial nerve palsy, occurred at various times up to several months after completion of rituximab therapy.

Cases of posterior reversible encephalopathy syndrome (PRES) / reversible posterior leukoencephalopathy syndrome (RPLS) have been reported. Signs and symptoms included visual disturbance, headache, seizures and altered mental status, with or without associated hypertension. A diagnosis of PRES/RPLS requires confirmation by brain imaging. The reported cases had recognized risk factors for PRES/RPLS, including the patients' underlying disease, hypertension, immunosuppressive therapy and/or chemotherapy.

Respiratory System

Respiratory failure/insufficiency and lung infiltration in the context of infusion-related reactions (see **7 WARNINGS AND PRECAUTIONS**). In addition to pulmonary events associated with infusions interstitial lung disease, some with fatal outcome, has been reported; pleural effusions, and pneumonia.

Skin and Appendages

Severe bullous skin reactions (including Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome) and pemphigus, some with fatal outcome, have been reported rarely.

Urogenital System

Renal insufficiency/failure.

9 DRUG INTERACTIONS

9.1 Serious Drug Interactions

No serious drug interactions at the time of authorization.

9.2 Drug Interactions Overview

There have been no formal drug interaction studies performed with rituximab. However, the existing data suggest that rituximab does not affect the pharmacokinetics of drugs which are used in combination with rituximab.

9.3 Drug-Behavioural Interactions

Drug-behavioural interactions have not been established.

9.4 Drug-Drug Interactions

There have been no formal drug interaction studies performed with rituximab. The tolerability of simultaneous or sequential combination of rituximab with chemotherapy other than CHOP and CVP or agents which are liable to cause depletion of normal B-cells is not well defined.

Renal failure requiring dialysis has been observed in patients treated with the combination of rituximab and cisplatin. If this combination is used, extreme caution should be exercised and renal function should be monitored closely.

Based on information from the limited number of previously treated CLL patients in study BO17072, co-administration with rituximab did not appear to have an effect on the pharmacokinetics of fludarabine or cyclophosphamide.

Co-administration with methotrexate had no effect on the pharmacokinetics of rituximab in rheumatoid arthritis patients.

Concomitant use with Biologic Agents and DMARDs other than Methotrexate in RA

Limited data are available on the safety of the use of biologic agents or DMARDs other than methotrexate in patients exhibiting peripheral B-cell depletion following treatment with rituximab. Patients should be closely observed for signs of infection if biologic agents and/or DMARDs are used concomitantly.

In the RA clinical trial program, 373 rituximab-treated patients received subsequent therapy with other DMARDs, of whom 240 received a biologic DMARD. In these patients the rate of serious infection while on rituximab (prior to receiving a biologic DMARD) was 6.1 per 100 patient years compared to 4.9 per 100 patient years following subsequent treatment with the biologic DMARD.

9.5 Drug-Food Interactions

There have been no formal drug-food interaction studies performed with rituximab.

9.6 Drug-Herb Interactions

There have been no formal drug-herb interaction studies performed with rituximab.

9.7 Drug-Laboratory Test Interactions

There have been no formal drug-laboratory interaction studies performed with rituximab.

10 CLINICAL PHARMACOLOGY

Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is also expressed on > 90% of B-cell non-Hodgkin's lymphomas (NHL) but is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation.

Type B lymphocytes are believed to play a central role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B-cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T cell activation, and/or pro-inflammatory cytokine production. Depletion of CD 20 surface antigen positive B-cells was associated with reduction of pro-inflammatory cytokines in rheumatoid synovial tissue.

10.1 Mechanism of Action

The Fab domain of rituximab binds to the CD20 antigen on B-lymphocytes and the Fc domain recruits immune effector functions to mediate B-cell lysis *in vitro*. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lymphoma line.

In patients with rheumatoid arthritis, the duration of peripheral B-cell depletion was variable. The majority of patients received further treatment prior to full B-cell repletion. Some patients had prolonged peripheral B-cell depletion lasting 2 years or more after their last dose of rituximab.

10.2 Pharmacodynamics

Normal Tissue Cross-reactivity

Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B-lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in non-lymphoid tissues examined.

10.3 Pharmacokinetics

Non-Hodgkin's Lymphoma (NHL)

In patients given single doses at 10, 50, 100, 250 or 500 mg/m² as an IV infusion, serum levels and the half-life of rituximab were proportional to dose. In 9 patients given 375 mg/m² as an IV infusion for four doses, the mean serum half-life was 59.8 hours (range 11.1 to 104.6 hours) after the first infusion and 174 hours (range 26 to 442 hours) after the fourth infusion. The wide range of half-

lives may reflect the variable tumour burden among patients and the changes in CD20 positive (normal and malignant) B-cell populations upon repeated administrations.

Rituximab at a dose of 375 mg/m² was administered as an IV infusion at weekly intervals for four doses to 166 patients. The peak and trough serum levels of rituximab were inversely correlated with baseline values for the number of circulating CD20 positive B-cells and measures of disease burden. Median steady-state serum levels were higher for responders compared to non-responders; however, no difference was found in the rate of elimination as measured by serum half-life. Serum levels were higher in patients with International Working Formulation (IWF) subtypes B, C, and D as compared to those with subtype A. Rituximab was detectable in the serum of patients three to six months after completion of treatment.

The pharmacokinetic profile of rituximab when administered as six infusions of 375 mg/m² in combination with six cycles of CHOP chemotherapy was similar to that seen with rituximab alone.

Administration of rituximab resulted in a rapid and sustained depletion of circulating and tissue-based B-cells. Lymph node biopsies performed 14 days after therapy showed a decrease in the percentage of B-cells in seven of eight patients who had received single doses of rituximab ≥ 100 mg/m². Among the 166 patients in the pivotal study, circulating B-cells (measured as CD19+ cells) were depleted within the first three doses with sustained depletion for up to 6 to 9 months post-treatment in 83% of patients. One of the responding patients (1%), failed to show significant depletion of CD19+ cells after the third infusion of rituximab as compared to 19% of the non-responding patients. B-cell recovery began at approximately six months following completion of treatment. Median B-cell levels returned to normal by twelve months following completion of treatment.

There were sustained and statistically significant reductions in both IgM and IgG serum levels observed from 5 through 11 months following rituximab administration. However, only 14% of patients had reductions in IgG and/or IgM serum levels, resulting in values below the normal range.

Peripheral B-cell counts declined to levels below normal following the first dose of rituximab. In patients treated for hematological malignancies, B-cell recovery began within 6 months of treatment and generally returning to normal levels within 12 months after completion of therapy, although in some patients this might take longer. In rheumatoid arthritis patients, immediate depletion of B-cells in the peripheral blood was observed following two infusions of 1000 mg of rituximab separated by a 14 day interval. Peripheral blood B-cell counts begin to increase from week 24 and evidence of repopulation is observed in the majority of patients by week 40, whether rituximab was administered as monotherapy or in combination with methotrexate.

Diffuse large B-cell non-Hodgkin's lymphoma (DLBCL)

Elimination and distribution have not been extensively studied in patients with diffuse large B-cell non-Hodgkin's lymphoma, but available data indicate that serum levels of rituximab in DLBCL patients are comparable to those in patients with low-grade or follicular NHL following treatment with similar doses.

Chronic Lymphocytic Leukemia (CLL)

No pharmacokinetic information in the untreated CLL population is available. Rituximab was administered as an IV infusion at a first-cycle dose of 375 mg/m² and increased to 500 mg/m² each cycle for 5 doses in combination with fludarabine and cyclophosphamide in the previously treated, low tumor burden CLL patients (absolute lymphocytes $< 25 \times 10^9$ cells/L). The mean (\pm SD) C_{max} and AUC_{0- τ} was 175 \pm 76 mcg/mL and 728 \pm 488 mcg·d/mL, respectively, after the first-cycle dose

(N = 21). The mean (\pm SD) C_{max} and $AUC_{0-\tau}$ was 408 ± 199 mcg/mL and $4,080 \pm 2,400$ mcg·d/mL, respectively, after the fifth 500 mg/m² infusion (N = 15).

Rheumatoid Arthritis

Following two intravenous infusions of rituximab at a dose of 1000 mg, two weeks apart, the mean terminal half-life was 20.8 days (range, 8.58 to 35.9 days), mean systemic clearance was 0.23 L/day (range, 0.091 to 0.67 L/day), and mean steady-state distribution volume was 4.6 L (range, 1.7 to 7.51 L). Population pharmacokinetic analysis of the same data gave similar mean values for systemic clearance and half-life, 0.26 L/day and 20.4 days, respectively. Population pharmacokinetic analysis revealed that BSA and gender were the most significant covariates to explain inter individual variability in pharmacokinetic parameters. After adjusting for BSA, male subjects had a larger volume of distribution and a faster clearance than female subjects. The gender-related pharmacokinetic differences are not considered to be clinically relevant and dose adjustment is not required.

The pharmacokinetics of rituximab were assessed following two IV doses of 500 mg and 1000 mg on Days 1 and 15 in four studies (WA17047, WA17045, WA17044, U3384G). In all these studies, rituximab pharmacokinetics were dose proportional over the limited dose range studied.

Table 20. Mean PK Parameters for Rituximab

	C_{first} (mcg/mL)	C_{second} (mcg/mL)	$t_{1/2}$ (days)
2 × 0.5 g in Course 1			
WA17047	171 ± 54 (32)	198 ± 58 (29)	14.83 ± 5.78 (39)
WA17045	157 ± 45.9 (29)	183 ± 54.7 (30)	15.65 ± 5.12 (33)
WA17044	164 ± 41 (25)	193 ± 61 (32)	16.38 ± 6.06 (37)
2 × 0.5 g in Course 2			
WA17047	170 ± 38 (22)	ND	ND
WA17045	ND	ND	ND
WA17044	175 ± 41 (24)	207 ± 69 (33)	19.37 ± 5.97 (31)
2 × 1 g in Course 1			
WA17047	341 ± 84 (25)	404 ± 102 (25)	16.89 ± 5.36 (32)
WA17045	318 ± 85.8 (27)	381 ± 98.3 (26)	18.50 ± 5.82 (31)
WA17044	312 ± 103 (33)	365 ± 126 (34)	17.95 ± 6.21 (35)
U3384G	298 ± 91.2 (30.6)	355 ± 112 (31.4)	21.2 ± 8.2 (38.7)
2 × 1 g in Course 2			
WA17047	370 ± 101 (27)	ND	ND
WA17045	ND	ND	ND
WA17044	348 ± 89 (26)	386 ± 132 (34)	21.82 ± 6.39 (29)
U3384G	317 ± 107 (33.8)	377 ± 120 (31.8)	20.9 ± 5.77 (27.6)

C_{first} = post-infusion concentration after first infusion; C_{second} = post-infusion concentration after second infusion
Values are mean \pm SD (CV%); ND = not determined

The PK parameters in the anti-TNF inadequate responder population, following the same dosage regimen (2 × 1000 mg, iv, 2 weeks apart), were similar with a mean maximum serum concentration of 369 mcg/mL and a mean terminal half-life of 19.2 days.

Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

In GPA/MPA patients, peripheral blood CD19 B-cells depleted to less than 10 cells/ μ l following the first two infusions of rituximab and remained at that level in most patients through month 6.

Rituximab mean clearance and volume of distribution were 0.313 L/day (range, 0.116 to 0.726 L/day) and 4.50 L (range, 2.25 to 7.39 L) respectively.

Special Populations and Conditions

Pediatrics

Age had no effect on the pharmacokinetics of rituximab.

Geriatrics

Age had no effect on the pharmacokinetics of rituximab.

Gender

Gender had no effect on the pharmacokinetics of rituximab.

Hepatic Insufficiency

No pharmacokinetic data are available in patients with hepatic impairment.

Renal Insufficiency

No pharmacokinetic data are available in patients with renal impairment.

11 STORAGE, STABILITY AND DISPOSAL

Unopened vial

Store RIABNI vials refrigerated at 2°C to 8°C. Protect from light. Do not freeze or shake.

Diluted medicinal product

- 0.9% Sodium Chloride solution

Aseptically prepared infusion solution of RIABNI in 0.9% sodium chloride solution is physically and chemically stable for 30 days at 2°C to 8°C plus an additional 24 hours at \leq 30°C.

- 5% Dextrose solution

Aseptically prepared infusion solution of RIABNI in 5% dextrose solution is physically and chemically stable for 24 hours at 2°C to 8°C plus an additional 24 hours at room temperature.

As RIABNI for infusion does not contain any antimicrobial preservative, diluted solutions in 0.9% sodium chloride should be stored refrigerated (2°C to 8°C) for up to 7 days, and diluted solutions in 5% dextrose should be stored refrigerated (2°C to 8°C) for up to 24 hours.

Administration should take place as per standard practices after the aseptic preparation of intravenous admixtures.

Incompatibilities

No incompatibilities between RIABNI and polyethylene or polypropylene or polyvinylchloride bags have been observed.

12 SPECIAL HANDLING INSTRUCTIONS

The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater, and disposal through household waste should be avoided. Use established 'collection systems' if available in your location.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance


Proper name: rituximab

Chemical name: anti-CD20 monoclonal antibody

Molecular formula and molecular mass:

Heavy chain - $C_{2197}H_{3389}N_{577}O_{676}S_{16}$, Light chain - $C_{1016}H_{1577}N_{273}O_{328}S_6$, approximately 145 kDa

Structural formula: Each heavy chain contains 451 amino acids with 4 intrachain disulfide bonds. Each light chain contains 213 amino acids with 2 intrachain disulfide bonds. Each heavy chain contains an N-linked glycan at a consensus glycosylation site on asparagine 301.



Heavy chains are shown in blue and light chains are shown in orange.

V_H is the variable domain of the heavy chain.

C_H1, C_H2, and C_H3 are the constant domains of the heavy chain.

V_L is the variable domain of the light chain.

C_L is the constant domain of the light chain.

Product Characteristics

Physicochemical properties: RIABNI (rituximab) is a genetically engineered chimeric mouse/human monoclonal antibody of the immunoglobulin G1 (IgG1) subclass consisting of 2 heavy chains and 2 light chains of the kappa subclass. The antibody is produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity chromatography and ion exchange, including specific viral inactivation and removal procedures.

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

Clinical studies conducted to support similarity between RIABNI and the reference biologic drug included:

- A randomized, double-blind study to compare pharmacokinetics and pharmacodynamics, efficacy and safety of RIABNI with Rituxan and MabThera in patients with moderate to severe rheumatoid arthritis on a background of methotrexate and with an inadequate response or intolerance to one or more TNF antagonist therapies.
- A randomized, double-blind study evaluating the efficacy, safety, and immunogenicity of RIABNI compared with Rituxan in patients with low tumor burden follicular B-cell non-Hodgkin's lymphoma.

A summary of the designs and subject demographics of the clinical studies is presented in Table 21.

Table 21. Trial Design and Study Demographics – Comparative studies between RIABNI and reference rituximab

Study	Trial Design	Test Product(s); Dosage Regimen; Route of Administration	Study Subjects (n)	Mean age (Range)	Sex (n)
20130108 PK	Phase 1/3 randomized, multicenter, double-blind, active-controlled, 3-arm, multiple-dose study in adult patients with moderate to severe Rheumatoid Arthritis	1000mg IV infusion of RIABNI, Rituxan ^a , or MabThera, on days 1 and 15 (dose 1) and weeks 24 and 26 (dose 2)	Randomized: 311 RIABNI: 104 Rituxan: 103 MabThera: 104	Total: 55.9 (22-79) RIABNI: 54.6 (22-79) Rituxan: 56.4 (27-77) MabThera: 56.8 (24-79)	Male: 47 Female: 264
2013019 Efficacy and Safety	Phase 3 randomized, multicenter, double-blind, active-controlled, 2-arm, multiple-dose study in adult patients with histologically confirmed grade 1, 2, or 3a follicular B cell NHL and low tumor burden	375-mg/m ² IV infusion of RIABNI or Rituxan, weekly for 4 weeks followed by dosing at weeks 12 and 20	Randomized: 256 RIABNI: 128 Rituxan: 128	Total: 57.9 (24-84) RIABNI: 57.6 (24-79) Rituxan: 58.2 (25-84)	Male: 126 Female: 130

Rituxan = rituximab sourced from the United States; MabThera = rituximab sourced from the European Union; IV = intravenous; PK = pharmacokinetic; RA = Rheumatoid Arthritis; NHL = Non-Hodgkin's Lymphoma.

^aSubjects initially randomized to receive Rituxan transitioned to receive RIABNI at a dose of 1000 mg × 2 IV infusions administered 2 weeks apart on week 24 and week 26 as the second dose to assess any potential impact on such transition on safety or immunogenicity.

14.2 Study Results

Efficacy

Study 20130109 (Non-Hodgkin's Lymphoma)

The comparative clinical efficacy and safety study (Study 20130109) was designed to rule out any clinically meaningful differences between RIABNI and Rituxan with respect to efficacy. The study was a randomized, double-blind, active-controlled, 2-arm study in adult subjects with grade 1, 2, or 3a CD20+ follicular B-cell NHL and low tumour burden.

The primary endpoint was the overall response rate (ORR) by week 28 and was compared between the two groups based on the risk difference (RD). Results of the primary analysis of ORR by week 28, based on data from the central, independent, blinded assessments of disease are provided in Table 22. The point estimate of the RD of ORR between treatment groups (RIABNI - Rituxan) was 7.7% (95% CI: -3.2, 18.6). The 95% confidence limits were contained within the prespecified noninferiority margin of -15% and nonsuperiority margin of +35.5%. These results demonstrate comparable efficacy between RIABNI and Rituxan.

Table 22. Summary of Overall Response Rate by Week 28 in Study 20130109 - Primary Efficacy Analysis Based on Independent Central Assessment of Disease (Modified Full Analysis Set)

Statistic	RIABNI (N = 123)	Rituxan (N = 124)
ORR ^a [n (%)]	96 (78.0)	87 (70.2)
95% CI of ORR (%)	(70.7, 85.4)	(62.1, 78.2)
RD (RIABNI - Rituxan) ^b (%)		7.7
2-sided 95% CI		(-3.2, 18.6)

Rituxan = rituximab sourced from the United States; Modified Full Analysis Set = includes all randomized subjects with evidence of disease at baseline per the tumor assessment from the central, independent, blinded assessments

^a ORR is defined as the percentage of subjects with a best overall response of CR, PR, or CRu, defined per IWG-NHL criteria.

^b Point estimate and CIs were estimated using a generalized linear model adjusted for the randomization stratification factors geographic region and age group.

14.3 Comparative Bioavailability Studies

Pharmacokinetics

Comparative Pharmacokinetic Study 20130108 (Rheumatoid Arthritis)

When comparing the pharmacokinetic parameters of RIABNI to Rituxan (US), RIABNI to MabThera, and Rituxan (US) to MabThera, the 90% confidence intervals (CIs) of the ratios of the geometric means for AUC_T were fully contained within the pre-defined bounds of 80% to 125%. The ratios of the geometric means for C_{max} were also contained within the pre-defined bounds of 80% to 125%. Therefore, pharmacokinetic similarity was confirmed between RIABNI and Rituxan.

The statistical assessments of the pharmacokinetic parameters for RIABNI and Rituxan are shown in Table 23.

**Table 23. Summary of Statistical Assessment of RIABNI and Rituxan
(Study 20130108; Pharmacokinetic Parameter Population)**

Parameter	Geometric LS Mean [n] Arithmetic Mean (CV %)		Ratio of Geometric LS Means %	90% CI
	RIABNI	Rituxan		
AUC _T (mcg•hr/mL)	146369 [99] 153698 (34.3)	155240 [96] 163498 (33.7)	96.0	0.8950, 1.0303
AUC _{inf} (mcg•hr/mL)	149398 [94] 157772 (36.2)	158529 [94] 167533 (34.9)	95.7	0.8870, 1.0323
C _{max} (mcg/mL)	361 [96] 371 (23.5)	372 [93] 384 (24.7)	98.4	0.9356, 1.0348
T _{max} (hour) Median [n] (Min – Max)	3.57 [96] (2.17 – 49.58)	4.12 [93] (0.00 – 10.83)		
T _½ (hour) Mean [n] (SD)	355.30 [96] (108.57)	355.42 [96] (110.81)		

Rituxan = rituximab sourced from the United States; AUC_T – area under the conc time curve from time zero to the last measurable conc and it the analysis of data from AUC_{0-12wk}; AUC_{inf} = area under the serum drug concentration-time curve from time 0 to infinity; CI = confidence interval; C_{max} = maximum observed serum concentration; LS = least squares; max = maximum; min = minimum; n = number of non-missing observations; SD = standard deviation; T_{max} = time at which the maximum observed serum concentration was observed; T_½ = terminal elimination half-life

14.4 Immunogenicity

Comparing the incidences of antibodies between studies or between products may be misleading due to differences in the types, sensitivities and/or specificities of the assays employed.

Study 20130108 (Rheumatoid Arthritis)

In Study 20130108, all 311 (100%) subjects in the safety analysis set had at least 1 on-study ADA result. A total of 7 (6.7%) subjects in the RIABNI treatment group, 10 (9.6%) subjects in the MabThera treatment group, and 6 (5.8%) subjects in the Rituxan treatment group tested positive for pre-existing binding ADA at baseline; 2 (1.9%), 2 (1.9%), and 3 (2.9%) subjects, respectively, tested positive for pre-existing neutralizing ADA at baseline.

Postbaseline, from day 1 until the first infusion of the second dose, 13 (13.4%) subjects in the RIABNI treatment group, 10 (10.6%) subjects in the MabThera treatment group, and 19 (19.6%) subjects in the Rituxan treatment group tested positive for the development of binding ADAs. Postbaseline, from day 1 through week 48/EOS, 14 (14.4%) subjects in the RIABNI treatment group and 13 (13.8%) subjects in the MabThera treatment group tested positive for the development of binding ADA. Postbaseline, 8 (8.2%) subjects in the RIABNI treatment group and 4 (4.3%) subjects in the MabThera treatment group tested positive for the development of neutralizing ADAs.

Study 20130109 (Non-Hodgkin's Lymphoma)

In Study 20130109, all 254 (100%) subjects in the safety analysis set had at least 1 on-study ADA result. One (0.8%) subject in the RIABNI treatment group and 3 (2.4%) subjects in the Rituxan treatment group tested positive for pre-existing binding ADAs at or before baseline; no subjects tested positive for pre-existing neutralizing ADAs at baseline. Postbaseline, from day 1 through week 28/EOS, three (2.4%) subjects in the RIABNI treatment group and one (0.8%) subject in the Rituxan treatment group tested positive for the development of binding ADAs. Postbaseline, 1 (0.8%) subject in the RIABNI treatment group and 1 (0.8%) subject in the Rituxan treatment group tested positive for the development of neutralizing ADAs.

14.5 Clinical Trials - Reference Biologic Drug

*The median time of all clinical time-to event endpoints (eg, progression free survival – PFS or overall survival – OS) was calculated by applying the Kaplan-Meier method (see table of trial results below).

NON-HODGKIN'S LYMPHOMA

Table 24. Follicular Non-Hodgkin's Lymphoma, Monotherapy

Trial design	Dosage	Number of study subjects	Mean age (Range)	Gender	Results			
					Complete Response (CR)	Partial Response (PR)	Overall Response Rate	95% CI (ORR)
Multicenter, open-label, single arm, phase III trial	Rituximab injection 375 mg/m ² given as an IV infusion weekly for 4 doses	N = 166	58 (22-79)	Male: 105 (63%) Female: 61 (37%)	10/166 (6%)	70/166 (42%)	80/166 (48%)	41-56%

Follicular Non-Hodgkin's Lymphoma, Monotherapy

A multicenter, open-label, single-arm study was conducted in 166 patients with relapsed or refractory low-grade or follicular B-cell NHL who received 375 mg/m² of rituximab injection given as an IV infusion weekly for four doses. Patients with tumour masses > 10 cm or with > 5,000 lymphocytes/mcL in the peripheral blood were excluded from the study. The results are presented in Table 24. The overall response rate (ORR) was 48% (80/166) with a 6% (10/166) complete response (CR) and a 42% (70/166) partial response (PR) rate. Disease-related signs and symptoms (including B-symptoms) were present in 23% (39/166) of patients at study entry and resolved in 64% (25/39) of those patients. The median time to onset of response was 50 days and the median duration of response is projected to be 10 to 12 months.

In a multivariate analysis, the ORR was higher in patients with IWF B, C, and D histologic subtypes as compared to IWF A subtype (58% vs. 12%), higher in patients whose largest lesion was < 5 cm vs. > 7 cm in greatest diameter (53% vs. 38%), and higher in patients with chemosensitive relapse as compared to chemoresistant (defined as duration of response < 3 months) relapse (53% vs. 36%). ORR in patients previously treated with autologous bone marrow transplant was 78% (18/23). The following factors were not associated with a lower response rate: age ≥ 60 years, extra-nodal disease, prior anthracycline therapy, and bone marrow involvement.

In a second multicenter, multiple-dose study, 37 patients with relapsed or refractory B-cell NHL received 375 mg/m² of rituximab injection as an IV infusion once weekly for four doses. The ORR was 46% with a median duration of response of 8.6 months (range 2.6 to 26.2+). Single doses of up to 500 mg/m² were well-tolerated in a phase I, dose escalation study.

Twenty one patients who have responded to rituximab initially have been treated again with rituximab. Response rate seems to be comparable in these retreated patients. Twenty patients have received two courses and one patient has received three courses of rituximab as 4-weekly infusions of 375 mg/m² per infusion. The percentage of patients reporting adverse events upon retreatment was similar to that reported following the first course, although the incidence of specific adverse events differed (see **8 ADVERSE REACTIONS**). All patients had obtained an objective clinical response (CR or PR) to the first course of rituximab; upon retreatment, 6 of 12 patients evaluable for response obtained a complete or partial remission.

In another study with twenty-nine patients with relapsed or refractory, bulky (single lesion of > 10 cm in diameter), low grade NHL received 375 mg/m² of rituximab as four weekly infusions. The overall incidence of adverse events and the incidence of Grade 3 and 4 adverse events was higher in patients with bulky disease than in patients with non-bulky disease (see **8 ADVERSE REACTIONS**). Ten of 21 patients evaluable for response have obtained a complete or partial remission.

Table 25. Follicular Non-Hodgkin's Lymphoma, Initial Treatment in Combination with CVP

Trial design	Dosage	Number of study subjects	Mean age (Range)	Gender	Results (42 months median observation time)		
					Kaplan-Meier Estimate of Median Time to Event (Months) ^{3*}		
					CVP	R-CVP	log-rank p-value (treatment effect) ⁴
Open-label, Randomized, phase III trial	CVP ¹	N = 159	53.9 (29-80)	Male: 85 (53.5%) Female: 74 (46.5%)			
	R-CVP ²	N = 162	52.6 (27-79)	Male: 88 (54.3%) Female: 74 (45.7%)	Median observation time (months)	41.3	42.1
					Time to treatment failure	6.6	27.0 < 0.0001 (66%)
					Time to disease progression or death	14.5	33.6 < 0.0001 (58%)
					Overall survival	NR	NR 0.0700 (38%)
					Overall tumour response (CR, CRu, PR) ⁵	57%	81% < 0.0001 ⁶ (3.2) ⁷
					Duration of response	13.5	37.7 < 0.0001 (65%)
					Disease-free survival	20.5	44.8 0.0005 (71%)
					Time to new lymphoma treatment or death	12.3	46.3 < 0.0001 (63%)

¹CVP = cyclophosphamide (750 mg/m² i.v. on day 1), vincristine (1.4 mg/m² i.v. Up to a maximum of 2 mg on day 1), prednisolone (40 mg/m² p.o. on days 1-5).

²R-CVP = rituximab (375 mg/m² i.v., every 3 weeks, on day 1 of the treatment cycle for 8 cycles) plus CVP chemotherapy.

³According to investigator's assessment, all data stratified by center.

⁴Treatment effect: for event-free parameters, estimates were calculated by risk reduction; for tumour response, odds ratio was used. NR: not reached since the Kaplan-Meier estimates of event-free rates were above 50% during the entire observation period of the study.

⁵Overall response rate is calculated from the tumour response as assessed at the end of trial treatment.

⁶Chi-square test

⁷Odds ratio

Abbreviations: CR, complete response; CRu, complete response unconfirmed; PR, partial response; NR, not reached.

Follicular Non-Hodgkin's Lymphoma, Initial Treatment in Combination with CVP

In an open-label randomized trial, a total of 322 previously untreated low-grade or follicular B-cell NHL patients were randomized to receive either CVP chemotherapy (cyclophosphamide 750 mg/m², vincristine 1.4 mg/m² up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m²/day on days 1-5) every 3 weeks for 8 cycles or rituximab 375 mg/m² in combination with CVP (R-CVP). Rituximab was administered on the first day of each treatment cycle. The results are presented in Table 25. A total of 321 patients (162 R-CVP, 159 CVP) received therapy and were analyzed for efficacy. At the time of the analysis, the median observation time was 42 months. R-CVP led to a significant benefit over CVP for the primary endpoint, time to treatment failure (27 months vs. 6.6 months, $p < 0.0001$, log-rank test). The risk of experiencing a treatment failure event was reduced by 66% (95% CI: 55% - 74%) with R-CVP compared with CVP alone, using a Cox regression analysis. The Kaplan-Meier estimated event free rate at 36 months was 44% in the R-CVP group compared with 11% in the CVP group. The proportion of patients with a tumour response (CR, CRu, PR) was significantly higher ($p < 0.0001$ Chi-Square test) in the R-CVP group (81%) than the CVP group (57%). The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group ($p < 0.0001$, log-rank test). Amongst responding patients, Cox regression analysis showed that the risk of relapse was reduced by 65% (95% CI: 51% - 75%) in the R-CVP group compared to the CVP group.

The time to institution of new lymphoma treatment or death was significantly longer in the R-CVP group (not estimable), compared to the CVP group (12.3 months) ($p < 0.0001$, log-rank test). Treatment with R-CVP significantly prolonged the time to disease progression compared to CVP, 31.9 months and 14.5 months, respectively. At 36 months, 49% in the R-CVP group had not progressed, relapsed or died compared to 20% of patients receiving CVP.

A subsequent analysis of the primary and all secondary parameters, carried out with a median observation time of approximately 42 months, confirmed the benefit of R-CVP over CVP.

The rate of cause-specific deaths (death due to lymphoma) was significantly lower in the R-CVP arm when compared to the CVP arm ($p = 0.02$ with stratification by center, log-rank test; 3-year event-free rate 93% for R-CVP versus 85% for CVP).

Treatment with R-CVP compared with CVP resulted in a consistent and positive treatment effect in the following subgroups: BNLI criteria, age, extra-nodal sites, bone marrow involvement, elevated LDH, elevated β_2 microglobulin, International Prognostic Index, B symptoms, bulky disease, nodal disease, and Follicular Lymphoma Prognostic Index.

Follicular Non-Hodgkin's Lymphoma, Maintenance Therapy (previously untreated and relapsed refractory patients)

Previously Untreated Advanced High-Tumour Burden Follicular Non-Hodgkin's Lymphoma

In a prospective open-label, international, multicenter, randomized phase III trial (MO18264) 1193 patients with previously untreated advanced follicular lymphoma received induction therapy (phase one). During this phase, patients with advanced follicular lymphoma were evaluated for response to different rituximab plus chemotherapy induction regimens: R-CHOP ($n = 881$), R-CVP ($n = 268$) or R-FCM ($n = 44$), according to the investigators' choice. The benefit-risk profile of induction therapy with R-FCM could not be determined due to the small number of patients treated with this chemotherapy regimen. Patients who responded to induction treatment (ie, achieved a confirmed or unconfirmed complete response [CR/CRu] or partial response [PR] at the end of induction), see Table 26, were randomized in the second phase to receive either rituximab maintenance therapy or no further treatment (observation). All randomized

patients were treated or observed for two years or until disease progression, whichever occurred first.

Table 26. Summary of Demographics and Characteristics

	R-CHOP N = 881	R-CVP N = 268	R-FCM N = 44
Sex			
Male	463 (53%)	134 (51%)	22 (50%)
Female	418 (47%)	131 (49%)	22 (50%)
Age			
≤ 40	96 (11%)	34 (13%)	7 (16%)
40 – 50	194 (22%)	42 (16%)	16 (36%)
50 – 60	286 (32%)	83 (31%)	12 (27%)
60 – 70	221 (25%)	68 (25%)	6 (14%)
> 70	84 (10%)	41 (15%)	3 (7%)
Mean	55.4	57.0	51.3
SD	11.47	12.66	10.87
Min – Max	22 – 80	22 - 87	29 – 74
Height (cm)			
Mean	168.46	169.00	164.70
SD	9.56	10.07	9.54
Min – Max	141.0 – 197.0	140.0 – 191.0	147.0 - 185
Weight (kg)			
Mean	73.27	76.00	73.50
SD	15.02	15.73	18.92
Min – Max	35.00 – 143.00	43.00 – 146.00	34.00 – 130.00

A total of 1078 patients responded to induction therapy, 35.5% had complete response, 28.3% had unconfirmed complete response and 26.5% had partial response. The table below provides responses for the R-CHOP and R-CVP regimens.

Table 27. Response at End of Induction Phase*

	R-CHOP (N = 881)	R-CVP (N = 268)
Responders	818 (92.8%)	227 (84.7%)
CR	326 (37.0%)	77 (28.7%)
Cru	267 (30.3%)	65 (24.3%)
PR	225 (25.5%)	85 (31.7%)
Non-Responders¹	63 (7.2%)	41 (15.3%)


*patients treated with R-FCM were not included in the table as the benefit/risk profile of this induction chemotherapy regimen could not be determined due to the small number of patients

¹ non-responders including stable disease, progressive disease, not evaluated and missing (ie, no response assessment)

Following induction therapy, 1018 were randomized to rituximab maintenance therapy (n = 505) or observation (n = 513). The number of patients 65 years of age or older that were included within the maintenance therapy or observation arm were 123 and 124 respectively. The two treatment groups were well-balanced with regards to baseline characteristics and disease status. Rituximab was administered on Day 1 of each cycle of chemotherapy. Rituximab maintenance treatment consisted of a single infusion of rituximab at 375 mg/m² body surface area given every 2 months until disease progression or for a maximum of 12 infusions (2 years).

After a median observation time of 25 months from randomization, maintenance therapy with rituximab resulted in an improvement in the primary endpoint of progression-free survival (PFS) based on independent review assessment (stratified log-rank *p*-value < 0.0001; stratified by induction treatment and response to induction treatment), refer to Figure 1.

Figure 1. Kaplan–Meier Plot of Independent Review Assessed PFS



Rituximab maintenance treatment provided benefit in PFS in all subgroups tested: gender (male, female), age (< 60 years, ≥ 60 years), FLIPI score (1, 2 or 3), induction therapy (R-CHOP, R-CVP) and regardless of the quality of response to induction treatment (CR or PR). The results of rituximab maintenance treatment in patients older than 75 years of age should be interpreted with caution due to the small number of patients in this subgroup.

The difference in overall survival between the two treatment arms was not conclusive. A longer follow-up is required to obtain mature overall survival results.

Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

Table 28. Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma, Maintenance Therapy

Induction Phase: Overview of Efficacy Results for CHOP vs R-CHOP																																													
Trial design	Dosage	Number of study subjects	Mean age (Range)	Gender	Results (50 months median observation time)																																								
Prospective, open label, international, multi-centre, phase III trial	³ CHOP	N = 231	54.1 (27-78)	Male: 118 (51%)	<table border="1"> <thead> <tr> <th></th> <th>CHOP</th> <th>R-CHOP</th> <th>RR¹</th> <th>p-value (log-rank)</th> </tr> </thead> <tbody> <tr> <td>Primary Efficacy</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>ORR²</td> <td>74%</td> <td>87%</td> <td>N/A</td> <td>0.0003</td> </tr> <tr> <td>CR²</td> <td>16%</td> <td>29%</td> <td>N/A</td> <td>0.0005</td> </tr> <tr> <td>PR²</td> <td>58%</td> <td>58%</td> <td>N/A</td> <td>0.9449</td> </tr> <tr> <td>Second Efficacy</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>OS (median)</td> <td>NR</td> <td>NR</td> <td>31%</td> <td>0.0267</td> </tr> <tr> <td>PFS (median)</td> <td>20.8 mo</td> <td>32.2 mo</td> <td>36%</td> <td>< 0.0001</td> </tr> </tbody> </table>		CHOP	R-CHOP	RR ¹	p-value (log-rank)	Primary Efficacy					ORR ²	74%	87%	N/A	0.0003	CR ²	16%	29%	N/A	0.0005	PR ²	58%	58%	N/A	0.9449	Second Efficacy					OS (median)	NR	NR	31%	0.0267	PFS (median)	20.8 mo	32.2 mo	36%	< 0.0001
						CHOP	R-CHOP	RR ¹	p-value (log-rank)																																				
				Primary Efficacy																																									
	ORR ²	74%	87%	N/A	0.0003																																								
	CR ²	16%	29%	N/A	0.0005																																								
	PR ²	58%	58%	N/A	0.9449																																								
Second Efficacy																																													
OS (median)	NR	NR	31%	0.0267																																									
PFS (median)	20.8 mo	32.2 mo	36%	< 0.0001																																									
⁴ R-CHOP	N = 234	54.1 (26-80)	Male: 107 (46%)																																										
			Female: 113 (49%)																																										
			Female: 127 (54%)																																										

¹ Estimates were calculated by hazard ratios.

² Last tumour response as assessed by the investigator. The "primary" statistical test for "response" was the trend test of CR versus PR versus non-response (p < 0.0001).

³ CHOP = cyclophosphamide (750 mg/m² i.v., day 1), doxorubicin (50 mg/m² i.v., day 1), vincristine (1.4 mg/m² i.v., (max. 2 mg) day and prednisone (100 mg orally, days 1-5, every 21 days for 6 cycles).

⁴ R-CHOP = rituximab (375 mg/m² i.v. Infusion, on day 1 of each cycle for 6 cycles) plus CHOP chemotherapy.

Abbreviations: RR = risk reduction; N/A = not available; NR = not reached; mo = months; ORR = overall response rate; CR = complete response; PR = partial response; OS = overall survival; PFS = progression free survival.

Maintenance Phase: Overview of Efficacy Results Rituximab vs Observation (47.2 months median observation time)				
Demographics	Observation		rituximab	
Mean age (range)	54.6 (27-80)		53.3 (29-76)	
Gender	Male: 83 (50%); Female: 84 (50%)		Male: 78 (47%); Female: 89 (53%)	
Efficacy Analyses	Progression-Free Survival		Overall Survival	
	Observation (N = 167)	rituximab (N = 167)	Observation (N = 167)	rituximab (N = 167)
Patients with event	124 (74.3 %)	95 (56.9 %)	52 (31.1 %)	37 (22.2 %)
Patients without events ¹	43 (25.7 %)	72 (43.1 %)	115 (68.9 %)	130 (77.8 %)
Time to event (days)				
Median ^{2*}	476.0	1304.0	NR	NR
95% CI for Median ^{2*}	[375 ; 632]	[1072 ; 1605 -]	[- ; -]	[- ; -]
25% and 75%-ile	203 ; 1623	432 ; -	1287 ; -	1885 - ; -
Range ³	20 to 2407	19 to 2429	127 to 2671	50 to 2688
p-value (Log-Rank Test)	<0.0001		0.0229	
Hazard Ratio	0.49		0.61	
95% CI	[0.37 ; 0.64]		[0.40 ; 0.94]	
p-value (Wald Test)	< 0.0001		0.0243	

Month 12				
Patients remaining at risk	97	131	155	161
Event free rate	0.59	0.78	0.93	0.96
95% CI for rate	[0.51 ; 0.66]	[0.72 ; 0.85]	[0.90 ; 0.97]	[0.94 ; 0.99]
Exploratory Analysis	Time to New Lymphoma Treatment or Death		Disease-Free Survival⁴	
	Observation (N = 167)	rituximab (N = 167)	Observation (N = 48)	rituximab (N = 49)
Patients with event	112 (67.1 %)	90 (53.9 %)	36 (75.0 %)	27 (55.1 %)
Patients without events¹	55 (32.9 %)	77 (46.1 %)	12 (25.0 %)	22 (44.9 %)
Time to event (days)				
Median ^{2*}	659.0	1547.0	515.0	1591.0
95% CI for Median ^{2*}	[568 ; 814]	[1143 ; 1750]	[450 ; 751]	[1120 ; -]
25% and 75%-ile	326; 2062 -	573 ; -	331 ; 1408	564 ; -
Range ³	36 to 2407	27 to 2364	78 to 2144	76 to 2221
<i>p</i> -value (Log-Rank Test)	0.0003		0.0014	
Hazard Ratio	0.60		0.44	
95% CI	[0.46; 0.80]		[0.26 ; 0.74]	
<i>p</i> -value (Wald Test)	0.0004		0.0018	
Month 12				
Patients remaining at risk	120	137	35	40
Event free rate	0.72	0.82	0.75	0.82
95% CI for rate	[0.66 ; 0.79]	[0.76 ; 0.88]	[0.62 ; 0.87]	[0.71 ; 0.92]

¹Censored

²Kaplan-Meier estimates

³Including censored observations

⁴Only applicable to patients achieving a CR.

⁵rituximab (375 mg/m² i.v., once every 3 months, until disease progression or for a maximum period of 24 months).

Abbreviations: NR, not reached

Follicular Non-Hodgkin's Lymphoma, Maintenance Therapy

In a prospective, open-label, international, multi-centre, phase III trial, 465 patients with relapsed/refractory follicular NHL were randomized in a first step to induction therapy with either CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone; n = 231) or rituximab plus CHOP (R-CHOP, N = 234). The two treatment groups were well-balanced with regard to baseline characteristics and disease status. The results are presented in Table 28. A total of 334 patients achieving a complete or partial remission following induction therapy were randomized in a second step to maintenance therapy with rituximab (n = 167) or observation (n = 167). Maintenance treatment with rituximab consisted of a single infusion of rituximab at 375 mg/m² body surface area given every 3 months until disease progression or for a maximum period of two years.

The final efficacy analysis included all patients randomized to both parts of the study. After a median observation time of 50 months for patients randomized to the induction phase, R-CHOP significantly improved the outcome of patients with relapsed or refractory follicular NHL when compared to CHOP.

For patients randomized to the maintenance phase of the trial, the median observation time was 47.2 months from maintenance randomization. Maintenance treatment with rituximab led to a clinically relevant and statistically significant improvement in the primary endpoint, PFS, (time from maintenance randomization to relapse, disease progression or death) when compared to observation alone ($p < 0.0001$ log-rank test). The median PFS was 42.9 months (range: 0.6 to 80.1 months) in the rituximab maintenance arm compared to 15.7 months (range: 0.6 to 79.4 months) in the observation arm. Using a cox regression analysis, the risk of experiencing progressive disease or death was reduced by 51% with maintenance treatment with rituximab when compared to observation (95% CI; 36% - 63%). Kaplan-Meier estimated progression-free rates at 12 months were 78% in the rituximab maintenance group vs 59% in the observation group. An analysis of overall survival suggested a benefit of maintenance treatment with rituximab over observation ($p = 0.0229$ log-rank test). The significance level for this analysis was set at 0.001.

The median time to new anti-lymphoma treatment was significantly longer with rituximab maintenance treatment than with observation (50.9 months (range 0.9 to 77.9 months) vs. 21.7 months (range 1.2 to 79.4 months), $p = 0.0003$ log-rank test). The risk of starting a new treatment was reduced by 40% (95% CI; 20% - 54%).

Table 29. Patients Starting New Lymphoma Treatment (NLT) / Reporting Disease Progression (PD)

	Observation (n = 167)	Rituximab (n = 167)
Total Patients reporting NLT (n)	85 (100%)	56 (100%)
No PD reported before initiation of NLT	-	2 (3.6%)
PD reported before initiation of NLT	85 (100%)	54 (96.4%)
PD reported <u>during</u> maintenance/observation phase		
PD > 3 months before NLT	27 (31.8%)	12 (21.4%)
PD ≤ 3 months before NLT	54 (63.5%)	30 (53.6%)
PD reported <u>after</u> maintenance/observation phase (follow-up)		
PD > 3 months before NLT	1 (1.2%)	4 (7.2%)
PD ≤ 3 months before NLT	3 (3.5%)	8 (14.3%)

In patients achieving a CR/CRu (complete response unconfirmed) as best response during induction treatment, maintenance treatment with rituximab significantly prolonged the median disease-free survival (DFS) compared to the observation group (52.3 (range 2.5 to 73.2 months) vs 16.9 months (range 2.6 to 70.7 months), $p = 0.0014$) log-rank test. The risk of relapse in complete responders was reduced by 56 % (95% CI; 26% - 74%).

The benefit of maintenance treatment with rituximab was confirmed in all subgroups analysed, regardless of induction regimen (CHOP or R-CHOP) or quality of response to induction treatment (CR or PR) (refer to Overview of Clinical Trials). Maintenance treatment with rituximab significantly prolonged median PFS in patients responding to CHOP induction therapy (median PFS 36.9 months (range 0.7 to 80.1 months) vs 11.6 months (range 0.7 to 67.5 months), $p < 0.0001$). The risk of experiencing progressive disease or death was reduced by 64% with maintenance treatment with rituximab when compared to observation (95% CI; 46% - 75%).

Maintenance treatment with rituximab also prolonged median PFS in patients responding to R-CHOP induction (median PFS 51.6 months (range 0.6 to 77.9 months) vs 23.1 months (range 1.4 to 79.4 months), $p = 0.0273$). The risk of experiencing progressive disease or death was reduced by 35% with maintenance treatment with rituximab when compared to observation (95% CI; 4% - 55%). Since subgroup analysis based on induction therapy was not pre-specified in the protocol, the results should be interpreted with caution.

Maintenance treatment with rituximab provided consistent benefit in all subgroups tested [gender (male, female), age (≤ 60 years, > 60 years), stage (III, IV), WHO performance status (0 versus 1 or 2), B symptoms (absent, present), bone marrow involvement (no versus yes), IPI (0-2 versus 3-5), FLIPI score (0-1, versus 2 versus 3-5), number of extra-nodal sites (0-1 versus > 1), number of nodal sites (< 5 versus ≥ 5), number of previous regimens (1 versus 2), best response to prior therapy (CR/PR versus NC/PD), hemoglobin (< 12 g/dL versus ≥ 12 g/dL), β_2 -microglobulin (< 3 mg/L versus ≥ 3 mg/L), LDH (elevated, not elevated) except for the small subgroup of patients with bulky disease.

Table 30. Diffuse Large B-cell Non-Hodgkin's Lymphoma

Trial Design	Dosage	Number of study subjects	Mean age (Range)	Gender	Results (24 months median follow-up)				
					24 month survival rate	CHOP	R-CHOP	Risk ratio	p-value (log-rank)
Randomized open-label phase III trial	¹ CHOP	N = 197	68.9 (60–80)	Male: 107 (54%) Female: 90 (46%)	Event-free survival ³	37.3%	57%	0.58	0.0001
	² R-CHOP	N = 202	69.5 (59–80)	Male: 92 (46%) Female: 110 (54%)	Overall survival ³	57.3%	70.2%	0.63	0.0072

¹ CHOP = cyclophosphamide (750 mg/m² i.v.), doxorubicin (50 mg/ m² i.v.), vincristine (1.4 mg/ m² up to a maximum of 2 mg on Day 1), prednisone (40 mg/ m²/day on days 1-5, every 3 weeks for 8 cycles).

² R-CHOP = rituximab (375 mg/ m² i.v., every 3 weeks, on day 1 of the treatment cycle for 8 cycles) plus CHOP chemotherapy.

³ Kaplan-Meier estimate.

Diffuse Large B-cell Non-Hodgkin's Lymphoma

In a randomized, open-label trial, a total of 399 previously untreated elderly patients (age 60 to 80 years) with diffuse large B-cell lymphoma received standard CHOP chemotherapy (cyclophosphamide 750 mg/m², doxorubicin 50 mg/ m², vincristine 1.4 mg/ m² up to a maximum of 2 mg on day 1, and prednisone 40 mg/m²/day on days 1-5) every 3 weeks for eight cycles, or rituximab 375 mg/ m² plus CHOP (R-CHOP). Rituximab was administered on the first day of the treatment cycle. In a planned interim analysis, a total of 328 patients (159 CHOP, 169 R-CHOP) were analyzed for efficacy. After a median follow up of approximately 12 months, R-CHOP led to a highly statistically significant increase in event-free survival compared to CHOP ($p = 0.0002$), where events were death, relapse or progression of lymphoma, or institution of a new anti-lymphoma treatment; R-CHOP treatment reduced the risk of an event by 48%. Lower rates of disease progression during treatment and of relapse after complete response accounted for this difference. Overall survival was statistically significantly prolonged in the R-CHOP group compared to CHOP ($p = 0.0055$), with a 49% reduction in the risk of death. R-CHOP treatment was also associated with a

statistically significant benefit, compared to CHOP, for complete response rate at the end of treatment (71% vs 59%; $p = 0.0176$), progression-free survival ($p = 0.0001$), and disease-free survival ($p = 0.0048$). The risk of disease progression was reduced by 54% and the risk of relapse after complete response by 51%. R-CHOP treatment benefited both low-risk and high-risk patients (age-adjusted International Prognostic Index score 0-1 and 2-3, respectively): the risk of an event was reduced by 69% in the low-risk group and 36% in the high-risk group.

An updated efficacy analysis including the total study population of 399 patients (197 CHOP, 202 R-CHOP), with a median follow-up of 24 months, presented in Table 30, confirmed that R-CHOP significantly prolongs both event-free survival ($p = 0.0001$) and overall survival ($p = 0.0072$). R-CHOP treatment reduced the risk of an event by 42% and the risk of death by 37%. Kaplan Meier estimates of event-free survival at 24 months were 57.0% in the R-CHOP arm compared to 37.3% in the CHOP arm and of overall survival were 70.2% in the R-CHOP arm compared to 57.3% in the CHOP arm.

CHRONIC LYMPHOCYTIC LEUKEMIA

(previously untreated and previously treated patients):

In two open-label randomized phase 3 trials, a total of 817 previously untreated patients and 552 previously treated patients with CLL were randomized to receive either FC chemotherapy (fludarabine 25 mg/m², cyclophosphamide 250 mg/m², days 1-3) every 4 weeks for 6 cycles or rituximab in combination with FC (R-FC). Rituximab was administered at a dosage of 375 mg/m² during the first cycle one day prior to chemotherapy and at a dosage of 500 mg/m² on day 1 of each subsequent treatment cycle.

A total of 810 previously untreated patients (primary analysis: 403 R-FC, 407 FC; updated OS (final) analysis: 408 R-FC, 409 FC) and 552 previously treated patients (276 R-FC, 276 FC) were analyzed for efficacy.

Previously Untreated CLL

Table 31. Study ML17102 Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) Overview of Efficacy Results for Rituximab Plus FC vs. FC alone

Efficacy Parameter	Primary Analysis ^a		Final Analysis ^b	
	Analyses at the time of primary PFS analysis (20.7 months median observation time)		Analyses at the time of final OS analysis (66.4 months median observation time)	
	FC N = 407	R-FC N = 403	FC N = 409	R-FC N = 408
Progression-free Survival				
Median time to event (months)	32.2	39.8	32.8	56.0
<i>p</i> -value (log-rank test)	$p < 0.0001$		$p < 0.0001$	
adjusted HR [95% CI], <i>p</i> -value (Wald test)	0.56 [0.43;0.72], $p < 0.0001$		0.57 [0.48;0.67], $p < 0.0001$	
Overall Survival				
Median time to event (months)	NR	NR	85.8	NR
<i>p</i> -value (log-rank test)	$p = 0.0427$		$p = 0.0010$	
adjusted HR [95% CI], <i>p</i> -value (Wald test)	0.64 [0.41;1.00], $p = 0.0487$		0.68 [0.54;0.86], $p = 0.0015$	

Table 31. Study ML17102 Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) Overview of Efficacy Results for Rituximab Plus FC vs. FC alone

Efficacy Parameter	Primary Analysis ^a		Final Analysis ^b	
	Analyses at the time of primary PFS analysis (20.7 months median observation time)		Analyses at the time of final OS analysis (66.4 months median observation time)	
	FC N = 407	R-FC N = 403	FC N = 409	R-FC N = 408
Event-free Survival				
Median time to event (months)	31.1	39.8	31.2	54.7
<i>p</i> -value (log-rank test)	p < 0.0001		p < 0.0001	
adjusted HR [95% CI], <i>p</i> -value (Wald test)	0.55 [0.43;0.70], p < 0.0001		0.57 [0.48;0.67], p < 0.0001	
End of Treatment Response Rate^c				
Responders (CR + PR/nPR)	72.7%	86.1%	72.4%	85.8%
Patients with				
complete response (CR)	17.2%	36.0%	16.9%	36.0%
partial response (PR/nPR)	55.5%	50.1%	55.5%	49.8%
stable disease (SD)	7.6%	4.7%	7.6%	4.7%
progressive disease (PD)	7.6%	3.5%	7.8%	3.7%
missing	12.0%	5.7%	12.2%	5.9%
Disease-free Survival^d				
Median time to event (months)	NR	NR	48.9	60.9
<i>p</i> -value (log-rank test)	p = 0.7882		p = 0.0523	
adjusted HR [95% CI], <i>p</i> -value (Wald test)	0.93 [0.44;1.96], p = 0.8566		0.73 [0.52;1.02], p = 0.0689	
Duration of Response^e				
Median time to event (months)	34.7	40.2	36.2	56.4
<i>p</i> -value (log-rank test)	p = 0.0040		p < 0.0001	
adjusted HR [95% CI], <i>p</i> -value (Wald test)	0.61 [0.43;0.85], p = 0.0036		0.58 [0.48;0.71], p < 0.0001	
Time to New Treatment				
Median time to event (months)	NR	NR	47.8	68.4
<i>p</i> -value (log-rank test)	p = 0.0052		p < 0.0001	
adjusted HR [95% CI], <i>p</i> -value (Wald test)	0.65 [0.47;0.90], p = 0.0082		0.59 [0.49;0.72], p < 0.0001	

NR: not reached; nPR: nodular partial response. Hazard ratios are from non-stratified (adjusted) analyses. 1 month = 30.4375 days.

^a Clinical cut-off July 04, 2007. Informed consent forms for seven patients (2 FC, 5 R-FC) were missing at the time of the primary analysis; hence, these patients were excluded from the analysis. Informed consent forms were later collected from those seven patients, and their data were added to the database ahead of the first updated analysis of efficacy.

^b Last patient visit October 31, 2011.

^c The response for one patient with PR at the time of the primary and updated analyses has changed to missing (and hence non responder) at the time of this final analysis.

^d Based on patients with confirmed CR (including late responders).

^e Based on patients with confirmed response (CR, PR, nPR).

**Table 32. Summary of Progression-Free Survival According to Binet Stage (ITT)
Primary Analysis (20.7 Months Median Observation Time)**

	FC N = 407	R-FC N = 403
Binet Stage A		
N	22	18
Progression Free Survival – Median (months)	31.6	Not Reached
Log Rank <i>p</i> -value	0.0099	
Hazard Ratio (95% CI)	0.13 (0.03; 0.61)	
<i>p</i> -value (Wald test, not adjusted)	0.0093	
Binet Stage B		
N	257	259
Progression Free Survival – Median (months)	32.3	43.3
Log Rank <i>p</i> -value	< 0.0001	
Hazard Ratio (95% CI)	0.45 (0.32; 0.63)	
<i>p</i> -value (Wald test, not adjusted)	< 0.0001	
Binet Stage C		
N	126	125
Progression Free Survival – Median (months)	33.4	38.0
Log Rank <i>p</i> -value	0.4671	
Hazard Ratio (95% CI)	0.88 (0.58; 1.33)	
<i>p</i> -value (Wald test, not adjusted)	0.5406	

**Table 33. Summary of Progression-Free Survival According to Age (ITT)
Primary Analysis (20.7 Months Median Observation Time)**

	FC N = 407	R-FC N = 403
Age <65		
N	288	279
Progression Free Survival – Median (months)	31.7	43.3
Log Rank <i>p</i> -value	< 0.0001	
Hazard Ratio (95% CI)	0.54 (0.40; 0.72)	
<i>p</i> -value (Wald test, not adjusted)	< 0.0001	
Age ≥ 65 - ≤ 70		
N	94	91
Progression Free Survival – Median (months)	27.4	39.9
Log Rank <i>p</i> -value	0.0037	
Hazard Ratio (95% CI)	0.45 (0.26; 0.78)	
<i>p</i> -value (Wald test, not adjusted)	0.0046	

**Table 33. Summary of Progression-Free Survival According to Age (ITT)
Primary Analysis (20.7 Months Median Observation Time)**

	FC N = 407	R-FC N = 403
Age > 70		
N	25	33
Progression Free Survival – Median (months)	Not Reached	38.0
Log Rank <i>p</i> -value	0.3787	
Hazard Ratio (95% CI)	1.61 (0.55; 4.74)	
<i>p</i> -value (Wald test, not adjusted)	0.3832	

In the primary analysis of the study in previously untreated patients (see Table 31) the median PFS, calculated by applying the Kaplan-Meier method, was 39.8 months in the R-FC group and 32.2 months in the FC group ($p < 0.0001$, log-rank test). The primary analysis that led to the stopping of the study based on crossing the statistical boundary for PFS, showed an improvement of R-FC over FC for the secondary endpoint overall survival ($p = 0.0427$). In updated overall survival results (final analysis) after a median of 64.4 months of observation, overall survival was significantly prolonged in the R-FC group compared with the FC group ($p = 0.0010$, log-rank test; adjusted HR 0.68 (95% CI [0.54, 0.86], $p = 0.0015$, Wald test). Although based on small numbers of patients, hazard ratios were greater than 1 (with wide confidence intervals) for the > 70 and ≥ 75 year age subgroups, and in the subgroup of patients who were diagnosed 6 to < 12 months before entering the study. Due to the exploratory nature of subgroup analyses, these results need to be interpreted with caution. The benefit in terms of PFS was consistently observed in most patient subgroups analyzed according to disease risk at baseline, although it was not statistically significant in patients with Stage C disease or for patients > 70 years (Table 32 and Table 33).

Study ML17102 was initially open to all symptomatic patients in need of treatment, regardless of stage. From amendment #1 onwards, however, new patients in the lowest risk group (Binet A) were excluded from the study. A total of 40 patients (22 FC arm, 18 R-FC arm) had been enrolled at that time, which represents 5% of the overall intent-to-treat (ITT) population. Within the Binet A patients, patients who received R-FC had a better outcome compared to those who received FC. If Binet A patients were to be excluded from the ITT analysis of ML17102, the overall results of the remaining Binet B and C patients would be slightly lower to the current overall results, but, due to the small numbers, would not change any of the overall results and conclusions of the study.

In all subgroups analyzed according to Binet stage, the median PFS in the primary analysis was increased or not yet reached in Binet A for R-FC and the risk of disease progression or death [(Hazard Ratio (HR))] was decreased by the addition of rituximab to FC when compared to FC alone, although not statistically significantly decreased in patients with stage C disease. The effect was most pronounced in the group of patients with stage A disease, and least in patients in stage C disease.

The effect of rituximab when added to FC seems to be most pronounced with younger age. Due to the small size of the subgroup of patients over the age of 70 (FC N = 25, R-FC N = 33), no meaningful conclusion can be drawn for the effect rituximab might have in this age category.

180/403 (45%) of patients in the R-FC arm received Colony Stimulating Factors vs. 95/407 (23%) in the FC arm. A comparison with regards to the primary endpoint, PFS, yields a result favoring the R-FC arm: HR = 0.59, 95% CI [0.43;0,81]. This outcome is similar to the overall study results. As is also true for the overall population, and as expected, in the subgroups more AEs were found in the R-FC arm compared to FC regardless if G-CSF was given or not.

Previously Treated CLL

**Table 34. Treatment of Previously Treated⁶ Chronic Lymphocytic Leukemia (CLL)
Overview of Efficacy Results for Rituximab plus FC vs. FC Alone**

Trial design	Dosage	Number of study subjects	Mean age (Range)	Gender	Efficacy Results (25.3 months mean observation time)								
					Analysis	Investigator-Assessed Results ^{3*}				IRC Results ^{3*}			
						FC	R-FC	Log rank <i>p</i> -value	Hazard Ratio	FC	R-FC	Log rank <i>p</i> -value	Hazard Ratio
Randomized open-label, phase III trial	FC ¹	N = 276	61.3 (35-81)	Male: 181 (66%) Female: 95 (34%)	Progression-free Survival (PFS) (months)	20.6 (18.1; 24.0) ⁵	30.6 (26.0; 38.1) ⁵	0.0002	0.65 (0.51; 0.82) ⁵	21.7 (18.3; 24.1) ⁵	26.7 (22.0; 31.1) ⁵	0.0218	0.76 (0.60; 0.96) ⁵
					PFS with censoring of new CLL treatment ⁷ (months)	22.5 (18.3; 29.0) ⁵	31.5 (26.2; 42.2) ⁵	0.0012	0.69 (0.53; 0.86) ⁵	22.6 (18.8; 25.2) ⁵	28.0 (22.9; 32.3) ⁵	0.0439	0.78 (0.61; 0.99) ⁵
	R-FC ²	N = 276	62.1 (35-83)	Male: 187 (68%) Female: 89 (32%)	Overall Survival (months)	51.9 (46.3; ...) ⁵	NR (51.0; ...) ⁵		0.83 (0.59; 1.17) ⁵				
					Response rate ⁴ (CR, nPR, PR)	58.0% (51.9; 63.9%) ⁵	69.9% (64.1; 75.3%) ⁵		NA	48.6% (42.5; 54.6%) ⁵	60.5% (54.5; 66.3%) ⁵		NA

¹FC = (fludarabine 25 mg/m², cyclophosphamide 250 mg/m², days 1-3) every 28 days for 6 cycles

²R-FC = Rituximab (375 mg/m² during the first cycle one day prior to chemotherapy and at a dosage of 500 mg/m² on day 1 of each subsequent treatment cycle with FC chemotherapy.

³Kaplan-Meier estimate.

⁴Response rate is based on the Best Overall Response

⁵95% CI

⁶Previous treatment included one of the following chemotherapy regimens: single agent chlorambucil +/- prednisone/ prednisolone, single agent fludarabine (or other nucleoside analogue), or alkylator containing combination therapy (e.g. CHOP/CVP)

⁷These results are based on a sensitivity analysis with censoring of new CLL treatment before documented disease progression

NR: not reached. NA: not applicable.

Table 35. Summary of Progression-Free Survival According to Age (ITT) as Assessed by IRC*

Age Subgroup	N	HR (95% CI)	FC		R-FC	
			Patients (N)	Median PFS (months)	Patients (N)	Median PFS (months)
<65	317	0.61 [0.44; 0.84]	162	22.5	155	30.2
≥ 65 to ≤ 70	142	0.94 [0.60; 1.47]	68	23.3	74	26.1
> 70	93	1.10 [0.63; 1.91]	46	18.8	47	15.5

* These results are based on exploratory analyses

Table 36. Summary of Progression-Free Survival According to Binet Stage (ITT) as Assessed by IRC*

Binet Stage	N	HR (95% CI)	FC		R-FC	
			Patients (N)	Media PFS (months)	Patients (N)	Median PFS (months)
Binet A	55	0.68 [0.29;1.57]	31	22.8	24	51.0
Binet B	326	0.79 [0.58;1.09]	160	24.6	166	30.2
Binet C	171	0.70 [0.47;1.03]	85	15.8	86	21.3

* These results are based on exploratory analyses

In the previously treated CLL study (see Table 34), the investigator-assessed median progression-free survival (primary endpoint) was 30.6 months in the R-FC group and 20.6 months in the FC group ($p = 0.0002$, log-rank test). The risk of having a PFS event (progression or death, whichever occurred first) was statistically significantly decreased by 35% (HR = 0.65; 95% CI: [0.51, 0.82]; $p = 0.0002$, Wald test) for patients in the R-FC arm compared to the FC arm (see Table 34). Forty-four percent of the patients in the FC arm, and 60% of those in the R-FC arm, were progression-free at two years using Kaplan-Meier estimates.

Based on Independent Review Committee (IRC) assessments, the median PFS was 21.7 months in the FC arm and 26.7 months in the R-FC arm ($p = 0.0218$, non-stratified Log-Rank test). The addition of rituximab to FC reduced the risk of disease progression or death by 24% (HR = 0.76; 95% CI [0.60, 0.96]; $p = 0.0222$, Wald test) compared to FC alone. Forty-three percent of patients in the FC arm and 54% of patients in the R-FC arm were progression-free at 2 years using Kaplan-Meier estimates. Please see Table 35 and Table 36 for a summary of progression-free survival according to Age and Binet stage respectively, as assessed by IRC. These results are based on exploratory analyses.

In this open-label randomized trial, the discordance between investigators' efficacy results and IRC's assessments were due to differences in assessing disease status (progression or not) and in determining the time of progression. The discordance observed reflects the subjectivity of PFS assessment in open-labeled trials. The results should be interpreted cautiously.

OS benefit has not been demonstrated and follow-up is needed to draw meaningful conclusions about the treatment effect of R-FC compared to FC in terms of OS.

RHEUMATOID ARTHRITIS

The efficacy and safety of rituximab in alleviating the symptoms and signs of rheumatoid arthritis was demonstrated in three randomized, controlled, double-blind, multicenter studies.

Study 1 was a double blind comparative study which included 517 patients that had experienced an inadequate response or intolerance to one or more TNF inhibitor therapies. Eligible patients had severe active rheumatoid arthritis, diagnosed according to the criteria of the American College of Rheumatology (ACR). The primary endpoint was the percent of patients who achieved an ACR20 response at week 24. Patients received two 1000 mg IV infusions of rituximab, each following an IV infusion of 100 mg methylprednisone and separated by an interval of 15 days. Patients were also pre-medicated with acetaminophen and diphenhydramine before each infusion of rituximab. All patients received concomitant oral methotrexate (10 – 25 mg/week) and 60 mg oral prednisone on days 2-7 and 30 mg on days 8-14 following the first infusion. Patients were followed beyond week 24 for long term endpoints, including radiographic assessment. During this time patients could receive further courses of rituximab (2 x 1000 mg + MTX) under an open label extension study protocol (see **Radiographic Response**). Retreatment frequency was determined by clinical evaluation, but no sooner than 16 weeks after the preceding course of rituximab.

Study 2 was a randomized, double-blind, double-dummy, controlled, 3 x 3 multifactorial study which compared two different dose levels of rituximab given with or without one of two per infusional corticosteroid regimens in combination with weekly methotrexate in patients with active rheumatoid arthritis which had not responded to treatment with 1 but no more than 5 other Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Study 3 was a double-blind, double-dummy, controlled study evaluating rituximab monotherapy, and rituximab in combination with either cyclophosphamide or methotrexate in patients with active rheumatoid arthritis which had not responded to one or more prior DMARDs.

The comparator group in all three studies was weekly methotrexate (10-25 mg weekly).

Disease Activity Outcomes

In all three studies, rituximab 2 x 1000 mg significantly increased the proportion of patients achieving at least a 20% improvement in ACR score compared with patients treated with methotrexate alone (Table 37). The treatment effect was similar in patients independent of rheumatoid factor status, age, gender, body surface area, race, number of prior treatments or disease status.

ACR20 response rates at week 24 in RF negative patients were significantly higher in patients receiving rituximab + MTX (40%) compared to those receiving placebo + MTX (12%, $p = 0.0009$), although lower than among rheumatoid factor positive patients (54%). In HACA positive patients, a total of 61/96 patients (63.4%) achieved at least an ACR20 response following their first treatment course. Mean change from original baseline DAS in HACA positive patients and HACA negative patients are -2.36 and -2.23 respectively.

The proportion of rituximab patients achieving an ACR20 response at week 24 in the US and non-US (including Canada) were 44% vs 61% respectively. ACR20 response in placebo patients was 18% in both regions. Treatment effect in favor of rituximab was statistically significant for both regions ($p < 0.001$).

Table 37. Cross-Study Comparison of ACR Responses at Week 24 (ITT Population)

ACR Response	Placebo + MTX	Rituximab + MTX
Study 1	N = 201	N = 298
ACR20	36 (18%)	153 (51%) ¹
ACR50	11 (5%)	80 (27%) ¹
ACR70	3 (1%)	37 (12%) ¹
Study 2	N = 143	N = 185
ACR20	45 (31%)	96 (52%) ²
ACR50	19 (13%)	61 (33%) ²
ACR70	6 (4%)	28 (15%) ²
Study 3	N = 40	N = 40
ACR20	15 (38%)	28 (70%) ³
ACR50	5 (13%)	17 (43%) ³
ACR70	2 (5%)	9 (23%) ³

¹p ≤ 0.0001; ²p ≤ 0.001; ³p < 0.05

In study 3, the ACR20 response in patients treated with rituximab alone was 65% compared with 38% on methotrexate alone (p = 0.025).

Clinically and statistically significant improvement was also noted on all individual components of the ACR response (tender and swollen joint counts, patient and physician global assessment, disability index scores (Health Assessment Questionnaire - HAQ), pain assessment and C- reactive protein (CRP - mg/dL).

Table 38. Components of ACR Response in Study 1

Rituximab + MTX (N = 122)	Study 1 [RF (+) and RF (-) Patients]					
	Placebo + MTX (N = 201)			rituximab + MTX (N = 298)		
	Wk 0 (SD) range	Wk 24 (SD) range	% mean change (SD) range	Wk 0 (SD) range	Wk 24 (SD) range	% mean change (SD) range
Tender Joint Count (68)	32.9 (15.61) 1:68	30.2 (18.99) 0:68	7.2 (144.58) -100:1733.3	33.9 (15.23) 3:68	19.5* (18.53) 0:68	-41.8 (52.39) -100:264.7
Swollen Joint Count (66)	22.9 (12.71) 8:64	20.3 (13.44) 0:63	-5.6 (59.19) -100:387.5	23.4 (11.87) 4:66	13.0* (12.70) 0:64	-43.0 (52.65) -100:366.7
Physician Global Assessment ^a	6.7 (1.629) 1.8:10	6.1 (2.573) 0.2:10	-4.2 (47.23) -97.1:183.3	6.9 (1.597) 1.2:9.8	4.0* (2.573) 0:10	-40.8 (39.31) -100:100
Patient Global Assessment ^b	7.0 (2.006) 0.9:10	6.4 (2.521) 0.3:10	-3.1 (44.01) -95.9:240	6.9 (2.106) 0.1:10	4.3** (2.752) 0.0:10	-25.4 (117.90) -100:1300
Pain ^a	6.5 (2.132) 0.6:10	6.2 (2.561) 0.1:10	2.8 (55.61) -98.4:347.4	6.4 (2.228) 0.2:10	4.1** (2.711) 0.0:10	-23.8 (131.59) -100:2050
Disability Index (HAQ) ^b	1.9 (0.54) 0.5:3.0	1.8 (0.64) 0.0:3.0	-2.0 (30.46) -100:183.3	1.9 (0.58) 0.1:3.0	1.4* (0.74) 0.0:3.0	-24.3 (34.92) -100:100
CRP (mg/dL)	3.8 (4.07) 0.2:22.7	3.7 (4.12) 0.2:23.9	80.0 (452.94) -98.2:4800	3.7 (3.83) 0.2:23.7	1.7* (2.45) 0.2:22.2	-36.3 (80.3) -99.1:550

^a Visual Analogue Scale: 0 = best, 10 = worst

^b Disability Index of the Health Assessment Questionnaire: 0 = best; 3 = worst

* p<0.0001, **p<0.005 Rituximab + MTX minus Placebo + MTX stratified for rheumatoid factor, region and baseline ACR
Negative % change from baseline value indicates an improvement.

Patients treated with rituximab had a significantly greater reduction in disease activity score (DAS28) than patients treated with methotrexate alone. A good to moderate European League against Rheumatism (EULAR) response was achieved by significantly more patients treated with rituximab compared to patients treated with methotrexate alone (Table 39).

Treatment with rituximab + MTX (2 x 1 g) over multiple courses resulted in sustained improvements in the clinical signs and symptoms of RA and physical function for patients who remained on treatment.

In a study, using treatment to DAS28-ESR remission, where all patients initially received rituximab followed by retreatment with either rituximab or placebo, patients who received rituximab retreatment had improved efficacy compared with placebo-retreated subjects at Week 48 relative to baseline, as measured by ACR20 response (53.5% vs. 44.6%; p = 0.0195).

Table 39. Cross-Study Comparison of DAS and EULAR Responses at Week 24 (ITT Population)

	Placebo + MTX	rituximab + MTX 2 × 1 g
Study 1	(N = 201)	(N = 298)
Change in DAS28 [Mean (SD)]	-0.4 (1.2)	-1.9 (1.6)*
EULAR Response		
None	78%	35%
Moderate	20%	50%*
Good	2%	15%
Study 2	(N = 143)	(N = 185)
Change in DAS28 (SD)	-0.8 (1.4)	-2.0 (1.6)
EULAR Response		
None	61%	37%
Moderate	35%	40%
Good	4%	23%
Study 3	(N = 40)	(N = 40)
Change in DAS [Mean (SD)]	-1.3 (1.2)	-2.6 (1.3)
EULAR Response		
None	50%	18%
Moderate	45%	63%
Good	5%	20%

*p-value < 0.0001. p-values not calculated for studies 2 and 3.

Radiographic Response

In study 1 (WA17042) joint damage was assessed radiographically and expressed as changes in Genant-modified Total Sharp Score (TSS) and its components, the erosion score (ES) and the joint space narrowing (JSN) score. Rituximab + MTX slowed the progression of joint damage compared to placebo + MTX after 1 year as shown in Table 40.

Table 40. Mean Radiographic Change from Baseline to 104 Weeks

Parameter	Inadequate Response to TNF Antagonists			95% CI
	rituximab 2 × 1000 mg + MTX ^b	Placebo + MTX ^c	Treatment Difference (Placebo – rituximab)	
<u>Change during First Year</u>				
TSS	0.66	1.77	1.11	(0.48, 1.76)
ES	0.44	1.19	0.75	(0.31, 1.19)
JSN Score	0.22	0.58	0.36	(0.10, 0.62)
<u>Change during Second Year^a</u>				
TSS	0.48	1.04	---	---
ES	0.28	0.62	---	---
JSN Score	0.20	0.42	---	---

^a Based on radiographic scoring following 104 weeks of observation

^b Patients receiving up to 2 years of treatment with rituximab + MTX

^c Patients receiving Placebo + MTX. Patients receiving Placebo + MTX could have received retreatment with rituximab + MTX from Week 16 onward.

In RA Study 1 and its open-label extension, 70% of patients initially randomized to rituximab + MTX and 72% of patients initially randomized to placebo + MTX were evaluated radiographically at Year 2. As shown in Table 40, progression of joint damage in rituximab + MTX patients was further reduced in the second year of treatment.

Following 2 years of treatment with rituximab + MTX, 57% of patients had no progression of joint damage, defined as a change in TSS of zero or less compared to baseline. During the first year, 60% of rituximab + MTX treated patients had no progression from baseline to Week 56 compared to 46% of placebo + MTX treated patients. In their second year of treatment with rituximab + MTX, more patients had no progression from Week 56 to Week 104 than in the first year (68% vs. 60%). Additionally, 87% of the rituximab + MTX treated patients who had no progression in the first year also had no progression in the second year.

Physical Function and Quality of Life Outcomes

Rituximab-treated patients reported an improvement in all patient-reported outcomes (Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and Short Form Health Survey (SF-36) questionnaires, (Table 41 and Table 42). Significant reductions in disability index (HAQ-DI), fatigue (FACIT-F), and improvement in both the physical and mental health domains of the SF-36 were observed in patients treated with rituximab compared to patients treated with methotrexate alone.

Table 41. Short Form Health Survey (SF-36): Mean and Categorical Change from Baseline to Week 24

	Study 1	
	Placebo + MTX N = 197 [#]	Rituximab + MTX N = 294 [#]
Mental Health		
Mean change (SD)	1.3 (9.4)	4.7 (11.8)
<i>p</i> -value*		0.0002
Range	-28:46	-24:60
Improved	40 (20%)	111 (38%)
Unchanged	128 (65%)	144 (49%)
Worsened	29 (15%)	39 (13%)
<i>p</i> -value*		0.0015
Physical Health		
Mean change (SD)	0.9 (5.7)	5.8 (8.5)
<i>p</i> -value*		< 0.0001
Range	-24:23	-29:31
Improved	25 (13%)	141 (48%)
Unchanged	158 (80%)	136 (46%)
Worsened	14 (7%)	17 (6%)
<i>p</i> -value*		< 0.0001

*No test was performed on study 2 data

Mental Health Change Category: Change > 6.33 = improved, -6.33<= Change < 6.33 = unchanged, Change < -6.33 = worsened Physical Health Change Category: Change > 5.42 = improved, -5.42<= Change < 5.42 = unchanged, Change < -5.42 = worsened

[#] Results based on Last Observation Carried Forward (LOCF). Number of patients that completed the survey at week 24 are 116 and 262 in the placebo and rituximab arm respectively.

Table 42. HAQ Responses at Week 24 in Study 1

Week 24 response: Change from baseline	Placebo + MTX ¹ N = 201 [#] mean (SD)	Rituximab + MTX ¹ N = 298 [#] mean (SD)	<i>p</i> -value
HAQ ²	-0.1 (0.5) -2.0:1.4 (range)	-0.4 (0.6) -2.5:1.3 (range)	< 0.0001

¹ MTX(Methotrexate); ²Health assessment questionnaire (HAQ)


[#] Results based on LOCF. Number of patients that completed the survey at week 24 are 120 and 273 in the placebo and rituximab arm respectively.

At week 24, in all three studies, the proportion of rituximab treated patients showing a clinically relevant improvement in HAQ-DI (defined as an individual total score decrease of > 0.25) was higher than among patients receiving methotrexate alone.

Laboratory Evaluations

In protocols WA17042, WA16291 and WA17043 rheumatoid factor (RF) positive patients, marked decreases were observed in rheumatoid factor concentrations following treatment with rituximab (range 45-64%, Figure 2).

Figure 2. Percentage Change in Total RF Concentration Over Time in Study 1 (ITT Population, RF-Positive Patients)



Plasma total immunoglobulin concentrations, total lymphocytes counts, and white cells generally remained within normal limits following treatment with rituximab, with the exception of a transient drop in white cells counts over the first four weeks following therapy. Titers of IgG antigen specific antibody to mumps, rubella, varicella, tetanus toxoid, influenza and streptococcus pneumococci remained stable over 24 weeks following exposure to rituximab in rheumatoid arthritis patients.

Effects of rituximab on a variety of biomarkers were evaluated in patients enrolled into Study 3 (WA16291). This substudy evaluated the impact of a single treatment course of rituximab on levels of biochemical markers, including markers of inflammation [Interleukin 6, C Reactive protein, Serum amyloid type A protein, Protein S100 isotypes A8 and A9], autoantibody (RF and anti-cyclic citrullinated peptide immunoglobulin) production and bone turnover [osteocalcin and procollagen 1 N terminal peptide (P1NP)]. Rituximab treatment, whether as monotherapy or in combination with methotrexate or cyclophosphamide reduced the levels of inflammatory markers significantly, relative to methotrexate alone, over the first 24 weeks of follow-up. Levels of markers of bone turnover, osteocalcin and P1NP, increased significantly in the rituximab groups compared to methotrexate alone.

120-minute infusion rate study (ML25641) in RA patients

In Study ML25641, a total of 351 patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to at least one TNF inhibitor and had no prior rituximab experience (N = 306) or had received one or two prior rituximab courses (N = 45) were evaluated in an open-label, multi-center, single-arm trial for the safety of 120-minute rituximab infusions. Patients with previous serious infusion-related reaction to any prior biologic therapy, including rituximab, or with clinically significant cardiovascular disease, were excluded from the study.

Eligible patients received 2 courses of rituximab treatment with 2 infusions of 1000 mg plus MTX treatment per course. The first course was administered on Day 1 (Infusion 1) and Day 15 (Infusion 2) and the second course six-months later on Day 168 (Infusion 3) and Day 182 (Infusion 4). Infusion 1 was administered over a 4.25-hour period. Infusion 2, 3, and 4 were administered over 120 minutes. Any patient experiencing a serious infusion-related reaction (IRR) with any infusion was withdrawn from the study. The main outcome measure was the incidence of infusion-related reactions during or within 24 hours after the 120-minute infusion at Infusion 2.

The incidence of infusion-related reactions (IRRs) at Infusion 2 was 6.5% (95% CI [4.1%-9.7%]) and was consistent with the rate observed historically. For Infusion 2, the incidence of Grade 3 - 4 IRRs was 0.6% (95% CI [0.1%, 2.1%]) and there were no serious IRRs observed. For Infusion 3 and Infusion 4, the incidence of IRRs was 5.9% (95% CI [3.5%-9.3%]) and 0.7% (95% CI [0.1%-2.6%]), respectively. Data observed for Infusion 3 and 4 demonstrates a low incidence of IRRs, similar to the rate observed historically; no Grade 3 - 4 or serious IRRs were observed. Acute infusion-related reactions requiring dose modification (stopping, slowing, or interruption of the infusion) occurred in 12% and 3.9% of patients receiving Infusion 1 at standard infusion regimen and Infusion 2 at 120-minute faster infusion, respectively (see **8 ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions**).

GRANULOMATOSIS WITH POLYANGITIS (GPA, ALSO KNOWN AS WEGENER'S GRANULOMATOSIS) AND MICROSCOPIC POLYANGITIS (MPA)

The efficacy and safety of rituximab in patients with severely active Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) was demonstrated in an active controlled, randomized, double-blind, multicentre non-inferiority study.

A total of 197 patients with severely, active GPA/MPA were enrolled and treated. Patients were 15 years of age or older, diagnosed with severely, active Granulomatosis with Polyangiitis, also known as Wegener's Granulomatosis (75% of patients) or Microscopic Polyangiitis (MPA) (24% of patients) according to the Chapel Hill Consensus conference criteria (1% of patients had unknown GPA/MPA type). Of the 99 rituximab treated patients participating in the phase III study, 3% were less than 18 years of age, 61% were between 18-64 years of age and 36% of patients were aged 65 years or older. Refer to Table 43 below for a summary of patient demographics and baseline disease characteristics.

Patients were randomized in a 1:1 ratio to receive either oral cyclophosphamide daily (2 mg/kg/day) for 3-6 months, followed by azathioprine or rituximab (375 mg/m²) once weekly for 4 weeks. Patients in both arms received 1000 mg of pulse intravenous (IV) methylprednisolone (or another equivalent-dose glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1 mg/kg/day, not exceeding 80 mg/day). Prednisone tapering was to be completed by 6 months from the start of study treatment.

Table 43. Baseline Demographic and Disease Characteristics in RAVE

	Rituximab n = 99	Cyclophosphamide n = 98	All Patients n = 197
Age at screening (years)			
Mean (SD)	54.0 (16.76)	51.5 (14.07)	52.8 (15.49)
Range (min – max)	16-92	15-80	15-92
Sex (%)			
Male	46.5	54.1	50.3
Female	53.5	45.9	49.7
Primary Race (%)			
White	91.9	94.9	93.4
Black or African American	3.0	3.1	3.0
Asian	1.0	0.0	0.5
Other	4.0	2.0	3.0
Ethnicity (%)			
Not Hispanic or Latino	91.9	94.9	93.4
Hispanic or Latino	6.1	3.1	4.6
Unknown	2.0	2.0	2.0
ANCA-associated vasculitis type (%)			
Wegener's granulomatosis	73.7	75.5	74.6
Microscopic polyangiitis	24.2	24.5	24.4
Indeterminate	1.0	0	0.5
Missing	1.0	0	0.5
Newly diagnosed at enrollment (%)			
48.5	48.5	49.0	48.7
BVAS/WG score, mean (SD) ^a	8.1 (2.82)	8.0 (3.41)	8.0 (3.12)
Creatinine clearance, mean (SD) (mL/min)	76.5 (46.27)	91.4 (49.24)	83.9 (48.23)
Creatinine clearance, median (mL/min)	67.61	87.47	73.81
Organ involvement (%)^b			
Renal			
65.7	65.7	66.3	66.0
Hematuria	28.3	28.6	28.4
Red blood cell casts	37.4	35.7	36.5
Rise in creatinine > 30% or fall in creatinine clearance > 25%	34.3	36.7	35.5
Pulmonary			
52.5	52.5	54.1	53.3
Alveolar hemorrhage	27.3	23.5	25.4
Endobronchial involvement	4.0	9.2	6.6
Nodules or cavities	18.2	27.6	22.8
Other lung infiltrate	25.3	21.4	23.4
Pleurisy	8.1	9.2	8.6
Respiratory failure	2.0	0	1.0

ANCA =anti-neutrophil cytoplasmic antibody; BVAS/WG =Birmingham Vasculitis Activity Score for Wegener’s granulomatosis; c-ANCA =cytoplasmic ANCA; MPO =myeloperoxidase; p-ANCA =perinuclear ANCA; PR3 =proteinase 3.

^a Scores for new/worse disease range from 0 to 67 (a higher score means more active disease). N = 77 for Rituximab arm and n = 67 for cyclophosphamide arm.

^b Tabulation includes new/worse disease and not persistent.

Complete Remission

The primary outcome measure was achievement of complete remission at 6 months defined as a Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG) of 0, and off glucocorticoid therapy. The prespecified non-inferiority margin for the treatment difference was 20%. The study demonstrated non-inferiority of rituximab to cyclophosphamide for complete remission at 6 months (Table 44).

Table 44. Percentage of Patients Who Achieved Complete Remission at 6 Months (Intent to Treat Population)

	Rituximab (n = 99)	Cyclophosphamide (n = 98)	Treatment Difference (Rituximab – Cyclophosphamide)
Rate	63.6%	53.1%	10.6%
95.1% ^b CI	(54.1%, 73.2%)	(43.1%, 63.0%)	(-3.2%, 24.3%) ^a

CI = confidence interval.

^a Non-inferiority was demonstrated since the lower bound (-3.2%) was higher than the pre-determined non-inferiority margin (-20%)

^b The 95.1% confidence level reflects an additional 0.001 alpha to account for an interim efficacy analysis.

Retreatment with Rituximab

The safety and efficacy of subsequent courses of rituximab in patients with GPA and MPA have not been determined (see **7 WARNINGS AND PRECAUTIONS** and **4 DOSAGE AND ADMINISTRATION**).

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

Immunohistology Studies with Human Tissues

The tissue reactivity of the chimeric mouse/human antibody rituximab was evaluated using a panel of 32 different human tissues fixed with acetone. The antibody was biotinylated to avoid background staining. No loss of immunoreactivity, as determined by FACS (fluorescence activated cell sorter) analysis using antigen-positive cells, was observed following biotinylation.

Biotinylated rituximab exhibited a highly restricted pattern of tissue reactivity, binding to antigen was found only on a subset of cells of lymphoid origin. Immunoreactivity was noted in the white pulp of the spleen, the lymphoid follicles of the tonsil, and in some, but not all, of the B lymphocytes present in the lymph node. Also, lymphoid cells present in other organs, eg, large and small intestines and stomach, were immunoreactive with rituximab.

All simple epithelial cells, as well as the stratified epithelia and squamous epithelia of different organs, were found to be unreactive. Similarly, no reactivity was seen with neuroectodermal cells, including those in the brain, spinal cord and peripheral nerves. Mesenchymal elements, such as skeletal and smooth muscle cells, fibroblasts, endothelial cells, and polymorphonuclear inflammatory cells were found to be negative.

***In Vitro* Testing for Cross-Reactivity with Human Tissues: rituximab Lot 0111**

The human tissue specificity of biotinylated rituximab antibody Lot 0111 was evaluated using immunoperoxidase staining of formalin-fixed, normal adult human tissues obtained at autopsy. Biotinylated rituximab was used to avoid background reactivity caused by use of anti-human secondary reagents. CD20-positive (SB) and CD20-negative (HSB) human cell lines were used as controls, as was an irrelevant biotinylated mouse/human chimeric antibody termed S-004. The molar ratio of biotin-to-protein was approximately 10:1 for both antibodies; no loss of immunoreactivity was observed by flow cytometry using CD20-positive SB-cells and the biotinylated rituximab antibody. Positive reactivity with staining intensity of 2+ to 3+ was observed with >90% of the CD20-positive control (SB) cells. No reactivity was observed with the CD20-negative cell line HSB.

The CD20 antigen exhibited a highly restricted pattern of distribution in the normal human tissues analyzed, and was mostly found on a subset of cells of lymphoid origin. Immunoreactivity was observed in the bone marrow, lymph node, peripheral blood B-cells, white pulp of the spleen and in the lymphoid follicles of the tonsil. Some lymphoid nodules in other organ tissues; eg, esophagus, kidney, small intestine, pancreas and stomach were also reactive.

All simple epithelial cells, and stratified epithelia and squamous epithelia of different organs were unreactive except for two specimens of large intestine with staining patterns of focal to diffuse. Reactivity was not seen in most neuroectodermal cells, including those of the brain and peripheral nerves; weak reactivity was observed in 30% of microglial cells present in 1 of 3 spinal cord specimens. Mesenchymal elements such as skeletal and smooth muscle cells, fibroblasts, and endothelial cells were unreactive.

Plasma Sample Analysis from Lot 0111 of Rituximab

Rituximab was evaluated in cynomolgus monkeys in a high-dose pathology/toxicology study designed to evaluate the safety of rituximab antibody Lot 0111 produced in suspension culture. Additionally, plasma samples from monkeys infused with this lot of rituximab antibody were analyzed for rituximab antibody levels as well as for the presence of anti-rituximab antibody: monkey anti-murine (MAMA) and monkey anti-rituximab (MACA). Groups 1 and 2, consisting of two animals each, received only vehicle; Groups 3 and 4, consisting of 6 animals each divided equally by sex, received rituximab (20 mg/kg). Groups 1 and 3 were dosed for four consecutive weeks; Groups 2 and 4 were dosed for eight consecutive weeks. Preliminary results from Groups 1 and 3 are available.

Plasma clearance study results indicate that high rituximab plasma levels (186 - 303 mcg/mL) were achieved in all treated monkeys 24 hours after the first and second infusions. Plasma antibody levels achieved 24 hours after the third and fourth antibody injections were similar to those detected after the first two injections in three Group 3 monkeys. Further, concentrations persisted at significant levels for two weeks after the last infusion in these animals. In the other three Group 3 animals, rituximab levels were markedly reduced at both the 24 hours and seven day time points after the third and fourth infusions; results correlated with the production of a MAMA response.

As seen in previous monkey studies, marked B-cell depletion occurred in all animals after each of the four infusions of rituximab antibody. However, the level of B-cell depletion was more marked in three of the six monkeys on day 36.

Three of the six Group 3 monkeys produced anti-rituximab antibodies that were detected two weeks after the last antibody injection. Results are confirmed by the rapid recovery of B lymphocytes in the peripheral blood of the three animals at time points that correlate with the appearance of the potentially neutralizing anti-chimeric antibody responses. None of the other Group 3 monkeys showed an anti-rituximab immune response greater than 0.2 mcg/mL on day 36. Results indicate that certain monkeys with competent immune systems may respond to multiple antibody exposures by producing significant amounts of neutralizing antibodies that alter the efficacy (depleting capability) of the antibody.

16.1 Comparative Non-Clinical Pharmacology and Toxicology

16.1.1 Comparative Non-Clinical Pharmacodynamics

In Vitro/In Vivo Studies

A comprehensive functional similarity assessment was designed and performed to demonstrate similarity between RIABNI, Rituxan and MabThera by evaluating the biological activity and immunochemical properties using in vitro binding and cell-based pharmacological assays as well as NHL xenograft models.

In vitro assays included CDC, ADCC and ADCP activities, CD20 binding, and apoptosis. Binding to Fc gamma receptors (Fc γ RIa/Fc γ RIIa/Fc γ RIIb/Fc γ RIIIa[F/V type]/Fc γ RIIIb), neonatal fragment crystallizable receptor (FcRn), and complement component (C1q) were also evaluated. Additional in vitro characterization studies included comparison of antibody internalization and trogocytosis. An in vivo pharmacology study in a mouse NHL xenograft tumour model was also conducted to compare tumour growth inhibition.

The results from both the in vitro and in vivo assays together demonstrate the functional similarity between RIABNI, Rituxan and MabThera.

16.1.2 Comparative Toxicology

A 4-week repeat-dose toxicology study with intravenous administration of RIABNI and Rituxan (20 mg/kg, IV, once weekly for 4 weeks; n = 3 per sex per group) was performed in male and female cynomolgus monkeys. Comparable toxicological profiles were observed for monkeys treated with RIABNI or Rituxan. Results were consistent with those previously reported for rituximab. Overall, the toxicokinetic profiles were comparable between RIABNI and Rituxan, and no unexpected toxicities were identified for RIABNI.

17 SUPPORTING PRODUCT MONOGRAPHS

Rituxan[®], Intravenous Infusion, 10 mg / mL, submission control 228891, Product Monograph, Hoffmann-La Roche Ltd., Oct 10, 2019

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

^{Pr}**RIABNI**[™] *pronounced ree AB nee*

rituximab for injection

Non-Hodgkin's Lymphoma & Chronic Lymphocytic Leukemia

Read this carefully before you start taking **RIABNI** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **RIABNI**.

RIABNI is a biosimilar biologic drug (biosimilar) to the reference biologic drug RITUXAN[®]. A biosimilar is authorized based on its similarity to a reference biologic drug that was already authorized for sale.

Serious Warnings and Precautions

- Some side effects associated with RIABNI are severe and may be life-threatening. This drug should only be used by health professionals experienced in treating cancer in a facility where sudden and life-threatening reactions can be immediately treated.
- Fatal allergic reactions and tumour lysis syndrome (TLS) causing fatal kidney damage have occurred.
- Repeat and sometimes fatal attacks of hepatitis have occurred. Recurrence of hepatitis B virus infection has occurred in patients who show evidence of the virus in a blood test. It is advised that all patients be tested for hepatitis B virus infection before starting treatment with RIABNI.
- Serious, including fatal infections can occur during or following treatment with RIABNI. A rare brain infection called JC virus causing progressive multifocal leukoencephalopathy (PML) and death has been reported in patients with non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). It is hard to predict who will get PML, but it is more common in people with weakened immune systems.
- Serious infusion reactions can happen during your infusion or within 24 hours after your infusion of RIABNI.
- Severe skin reactions such as Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) have been reported very rarely. Some cases have resulted in death.
- Serious and potentially fatal cardiovascular events have been reported rarely following treatment with rituximab.

What is RIABNI used for?

RIABNI (also known as rituximab) is a cancer medicine that is used to stop cancer cell growth and ideally cause the death of cancer cells. It is a cancer medicine that must be prescribed by a doctor.

It is used to treat patients with certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

What is non-Hodgkin's lymphoma?

Non-Hodgkin's lymphoma is a cancer of the lymph cells (lymphocytes), which are found in the blood and in the lymph nodes. Lymph nodes are located in the head and neck area, under the arms, in the groin and throughout the chest and abdomen. Lymphocytes are a type of white blood cell. There are two types: B lymphocytes and T lymphocytes. B lymphocytes produce antibodies or proteins that help our immune system to fight foreign substances which enter the body. All B-cells have a marker on their surface. This marker is called CD20.

What is chronic lymphocytic leukemia?

Chronic lymphocytic leukemia is a cancer of the bone marrow (spongy tissue inside bones where blood cells are made). It affects lymph cells (lymphocytes) which are a type of white blood cell. There are two types: B lymphocytes and T lymphocytes. B lymphocytes produce antibodies or proteins that help our immune system to fight foreign substances which enter the body. All B-cells have a marker on their surface. This marker is called CD20.

How does RIABNI work?

Our bodies have a natural defence system against cancer cells. When cancer cells appear, our bodies respond by making special proteins called antibodies. Researchers studied this response and learned how to create antibodies outside the body that help with cancer treatment. These are called monoclonal antibodies.

Monoclonal antibodies are now made to target tumours in an effort to control the growth of cancer.

RIABNI belongs to a family of medicine called monoclonal antibodies. It is an antibody that targets the CD-20 B-cell lymphocyte to stop its activity. RIABNI attaches to the CD20 marker that is located on the B-cell. When in place, it works to stop the growth of the cancer cells and may destroy them.

RIABNI is most active in patients whose lymphomas are of the B-cell type.

What are the ingredients in RIABNI?

Medicinal ingredients: rituximab

Non-medicinal ingredients: hydrochloric acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection.

RIABNI comes in the following dosage forms:

Liquid concentrate for intravenous (IV) administration.

Who should take RIABNI?

RIABNI is given alone for patients with low-grade CD20 antigen positive B-cell non-Hodgkin's lymphoma, who have not received prior treatment or who are no longer responding to their current anti-cancer treatment or where the lymphoma has returned despite previous anti-cancer treatment.

Depending on the type of lymphoma, RIABNI may also be given in combination with chemotherapy regimens called CHOP or CVP. CHOP stands for the following drugs: cyclophosphamide, doxorubicin, vincristine and prednisone while CVP stands for cyclophosphamide, vincristine and prednisolone.

RIABNI may also be used as a continuous (maintenance) treatment for patients who have responded to initial therapy.

RIABNI may also be used to treat patients with moderate or severe [stage B or C] B-cell chronic lymphocytic leukemia. In the CLL trial RIABNI was used with 2 other chemotherapy drugs FC [which stands for fludarabine and cyclophosphamide].

Do not use RIABNI if:

If you are allergic to rituximab or proteins of similar mouse or human origin or any other ingredient in RIABNI or if you have ever had a rare infection of the brain called progressive multifocal leukoencephalopathy (PML) you should not take RIABNI.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take RIABNI. Talk about any health conditions or problems you may have, including if you:

- ever had a bad reaction to rituximab or any of the non-medicinal ingredients.
- are allergic to other medications, food or dyes
- have a history of heart attack or stroke
- are taking any other medicines (including those not prescribed by the doctor). If you are taking medication to reduce blood pressure. If you are planning to be immunized with a vaccine during or after the completion of your RIABNI therapy
- have a pre-existing lung disease as you may have a greater chance of breathing difficulties during your RIABNI treatment infusion
- have a history of hepatitis B, current hepatitis B infection, or tuberculosis infection
- are pregnant or plan on becoming pregnant or are breast-feeding a child

Other warnings you should know about:

- Rituximab has not been studied in pregnant or breast-feeding women. If you are pregnant, could become pregnant or are breast-feeding, be sure to discuss with your doctor whether RIABNI is right for you. Women should avoid pregnancy and use effective birth control methods during treatment with RIABNI and for one year after treatment.
- RIABNI is an infusion (“drip”) which is given intravenously (into your veins). Very commonly patients being given RIABNI have some side effects while the infusion is being given. Most patients are also given medication such as acetaminophen [TYLENOL®], antihistamines, and steroids for allergic reactions [such as prednisone] before the infusion to prevent these reactions. If you notice any trouble breathing, feel hot or shivery, have hives or an itchy rash, tell the person giving you the infusion immediately.
- These side effects are more common with the first infusions of RIABNI. If you develop any of these symptoms, the infusion will be slowed down or stopped for a while. Once these symptoms go away, or improve, the infusion can be continued.
- If you have ever had heart disease [eg, angina (heart pain), arrhythmia (palpitations/irregular heart beat), or heart failure] or breathing problems, your doctor will take special care of you during therapy with RIABNI.
- One patient with CLL who had a tuberculosis infection had repeat and severe attacks when treated with rituximab. Tell the doctor if you think you had tuberculosis; you will be carefully checked for signs of tuberculosis infection.

- In some cases, patients who have had hepatitis B might have a repeat attack of hepatitis. Tell the doctor if you think you have had hepatitis in the past.
- Infection with hepatitis B virus causes inflammation of the liver which may show as mild fever, feeling of sickness, fatigue, loss of appetite, joint and/or abdominal pain and yellowing of whites of the eyes, skin and tongue. If you experience any of these symptoms immediately contact your doctor. If you show evidence of hepatitis B virus infection you may be referred to a liver disease expert for ongoing monitoring and management.
- RIABNI is not to be used in patients with active hepatitis B viral disease. Tell your doctor if you think you have hepatitis B.
- Live viral vaccines should not be given with RIABNI. Your doctor will check if you should have any vaccines before or after you receive RIABNI.
- Cases of Progressive Multifocal Leukoencephalopathy (PML) have been reported during use of rituximab in NHL and CLL. PML is a condition that causes nerve damage within the brain. Tell your doctor immediately if you have memory loss, trouble thinking, and difficulty with walking, clumsiness, falls or weakness on one side of the body, changes in mood or loss of vision. Your doctor will check if you need to see a neurologist.
- Cases of Tumour Lysis Syndrome [TLS] have been reported during the use of rituximab. TLS is a condition that causes sudden kidney failure and abnormal heart rhythms due to changes in blood chemistry, which may be fatal. Tell your doctor immediately if you have palpitations/irregular heartbeats; vomiting; fatigue/weakness; difficulty concentrating/trouble thinking; swelling, numbness or tingling in hands, face or feet; back pain; muscle cramps; fainting or trouble breathing. Some patients with TLS in its early stages have no symptoms, and your doctor will be performing blood tests for this and other side effects.
- Bowel problems, including blockage or tears in the bowels that can sometimes lead to death can happen if you receive rituximab with chemotherapy medicines to treat non-Hodgkin's lymphoma. Tell your doctor immediately if you have any abdominal pain during treatment with RIABNI.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with RIABNI:

Before starting treatment, make sure your doctor knows if you are taking or have recently taken any other medicines (including those you have bought for yourself from a pharmacy, supermarket or health store). This is extremely important, as using more than one medicine at the same time can strengthen or weaken their effect. RIABNI should not be used with other drugs unless your doctor has told you it is safe to do so.

How to take RIABNI:

Your doctor has prescribed RIABNI after carefully studying your case. Other people may not benefit from taking this medicine, even though their problems may seem similar to yours.

Where may I receive the infusion:

Your doctor or Amgen Entrust™ Patient Support Programs will help you to decide where you will receive the infusion. The Entrust™ Infusion Network consists of clinics located across Canada that are staffed by qualified healthcare professionals specially trained in the administration of RIABNI

infusions. Information about the about Entrust™ Patient Support Program can be obtained by calling Victory® by Amgen Entrust™ at t 1.888.706.4717.

Usual dose:

The usual dose of RIABNI is based on your body surface area which your doctor will calculate for you.

RIABNI is not taken by mouth but given through an intravenous line. An intravenous line, or I.V., is a thin, plastic tube placed in a vein in your hand or arm. When RIABNI is given intravenously, it is called an infusion.

A healthcare professional in a healthcare facility will give you RIABNI as prescribed by your doctor. Your first RIABNI infusion may take most of the day. Usually the remaining infusions will take less time.

Overdose:

It is unlikely that you will receive too much RIABNI as you will be closely monitored by Healthcare Professionals during your infusion. However, if you suspect you received too much RIABNI contact your healthcare professional and poison control centre immediately.

If you think you, or a person you are caring for, have taken too much RIABNI, contact a healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose of RIABNI, contact your healthcare professional immediately. Your healthcare professional will decide when you should receive your next dose.

What are possible side effects from using RIABNI?

These are not all the possible side effects you may feel with taking RIABNI. If you experience any side effects not listed here, tell your healthcare professional.

The most common possible unwanted effects are infusion related events, and happen to more than 30% of patients treated with rituximab:

- Fever and chills
- Nausea, vomiting, fatigue (feeling tired or weak), headache, skin rash, redness of the skin, itchiness, wheezing or tightness in the chest, shortness of breath, difficulty breathing, sensation of the tongue or throat swelling, throat irritation, rhinitis (runny nose), temporary low blood pressure, flushing, dizziness on standing up, fast heartbeat, chest pain, pain where the non-Hodgkin's lymphoma is located.

If these unwanted effects occur, it is most common within 30 minutes to 2 hours after starting the first infusion, but may also occur after the infusion has finished. The symptoms are usually mild to moderate, and can be easily treated. Rarely, these reactions can be severe. These unwanted effects are less common after the first treatment.

These unwanted effects can be prevented or managed by:

- Slowing or interrupting your infusion of RIABNI. The treatment can be restarted once the symptoms have resolved.
- Giving a fever reducer, such as **TYLENOL®**, and an antihistamine, such as **BENADRYL®** and a steroid such as prednisone which can be given for allergic reactions, before each infusion of RIABNI. Sometimes additional medications are needed to be given to treat these unwanted effects.

Additionally:

- Your doctor may instruct you not to take your blood pressure medication 12 hours before and delay taking until after your infusion of RIABNI is complete. Please ask your doctor for specific instructions.
- Because some of the medications given with RIABNI may cause some dizziness or sleepiness, you should arrange for someone else to drive you home after each treatment.

There are also possible unwanted effects which could be serious but occur less commonly:

- chest pain, fast or irregular or uneven heart beat.
- decreased of the white blood cells, red blood cells and platelets in the blood, infection and bleeding.
- rapid destruction of cells sometimes leading to kidney, heart or breathing problems (Tumour Lysis Syndrome).
- redness or blistering of the skin and the inside of the mouth.
- recurrence of Hepatitis B infection. Signs and symptoms of Hepatitis B include mild fever, feeling of sickness, fatigue, loss of appetite, joint and/or abdominal pain and yellowing of whites of the eyes, skin and tongue.
- increasing weakness on one side of the body, clumsiness or falls, trouble with thinking or memory, changes in mood, change in vision.

If you have been given RIABNI in combination with chemotherapy, the following additional unwanted effects may occur:

- Sudden loss of speech, weakness or numbness of part or all of one side of the body, loss of vision or blurred vision, unexplained dizziness and/or sudden falls.
- Herpes zoster also known as shingles. Symptoms of shingles include itching, tingling or severe burning pain with red patches that develop into blisters and are grouped in a cluster usually on the trunk of the body.

Please consult your doctor, nurse or pharmacist for possible unwanted effects that may be caused by CHOP, CVP or FC chemotherapy.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
COMMON			
New fever or if your temperature becomes higher than 38°C		√	
Shortness of breath, difficulty breathing, wheezing, coughing		√	
Symptoms of infection that include: <ul style="list-style-type: none"> - Fever, temperature at 38°C or higher - Sore throat - Cough - Any redness or swelling - Pain when you pass your urine 		√	
Any bleeding or unusual bruising		√	
Skin rash, itching, hives or sore joints		√	
Swelling of the face, lips, mouth or throat which may cause difficulty in swallowing or breathing, swelling of the hands, feet or ankles		√	
Symptoms of Hepatitis B such as mild fever, feeling of sickness, fatigue, loss of appetite, joint and/or abdominal pain and yellowing of whites of the eyes, skin and tongue		√	
UNCOMMON			
Chest pain, fast heart rate or an irregular or uneven heart rate		√	
Kidney problems such as lower back or side pain, swelling of feet or lower legs, numbness or tingling in feet or hands		√	
Redness or blistering of the skin and the inside of the mouth		√	√
Sudden loss of speech, increasing weakness or numbness of part or all of one side of the body, loss of vision or blurred vision, unexplained dizziness and/or clumsiness or sudden falls, trouble with thinking or memory, changes in mood, change in vision, change in mental status (for example, confusion), seizures		√	√
Symptoms of shingles such as itching, tingling, or severe burning pain with red patches that develop into blisters and are grouped in a cluster usually on the trunk of the body		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store vials in a refrigerator at 2°C to 8°C. Protect from light. Do not freeze or shake.

Keep out of reach and sight of children.

If you want more information about RIABNI:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website www.amgen.ca, or by calling 1-866-502-6436.

This leaflet was prepared by Amgen Canada Inc.

Last Revised:

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

^{Pr}**RIABNI**[™] *pronounced ree AB nee*

rituximab for injection

Rheumatoid Arthritis & Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Read this carefully before you start taking RIABNI and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about RIABNI.

RIABNI is a biosimilar biologic drug (biosimilar) to the reference biologic drug RITUXAN[®]. A biosimilar is authorized based on its similarity to a reference biologic drug that was already authorized for sale.

Serious Warnings and Precautions

Several side effects are associated with RIABNI, some may be severe and life-threatening. This drug should only be used by health professionals experienced in treating rheumatoid arthritis in a setting where medication and supportive care measures are immediately available in the event of an allergic reaction during administration (see **DOSAGE AND ADMINISTRATION [4]**).

- Serious infusion reactions can happen during your infusion or within 24 hours after your infusion of RIABNI.
- Recurrence of hepatitis B virus infection has occurred in patients who show evidence of the virus in a blood test. It is advised that all patients be tested for hepatitis B virus infection before starting treatment with RIABNI.
- Serious, including fatal infections can occur during or following treatment with RIABNI. A rare brain infection called JC virus causing progressive multifocal leukoencephalopathy (PML) and death has been reported in patients with autoimmune diseases treated with rituximab. It is hard to predict who will get PML, but it is more common in people with weakened immune systems.
- Severe skin reactions such as Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) have been reported very rarely. Some cases have resulted in death.
- Serious and potentially fatal cardiovascular events have been reported rarely following treatment with rituximab.

What is RIABNI used for?

- RIABNI (also known as rituximab) is an injectable medicine that is used to reduce signs and symptoms of rheumatoid arthritis (in combination with methotrexate).
- RIABNI in combination with glucocorticoids or “steroids” is also used to reduce inflammation associated with severe Granulomatosis with Polyangiitis (GPA, also known as Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) and helps to control your disease.

What is Rheumatoid Arthritis?

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints. Characteristics of RA include redness, swelling, pain, and limited movement around joints of the hands, feet, elbows, knees and neck. It is considered an autoimmune disease, a disease which produces antibodies against its own immune system or against its own body proteins.

What is Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)?

GPA/MPA are disorders that causes blood vessel inflammation (vasculitis). GPA/MPA are characterized by inflammation associated with autoantibodies called ANCA (anti-neutrophil cytoplasm antibodies). ANCA contribute to inflammation that damages the blood vessel walls in different tissues and organs in the body. The signs and symptoms of vasculitis vary depending on which blood vessels/organ systems are affected.

How does RIABNI work?

B-cells are an important element in the immune system, helping the body to fight off infection. However, in diseases such as RA and GPA/MPA, the immune system acts abnormally leading to an attack on normal healthy tissue such as the joints. In GPA/MPA patients, the immune system can attack the respiratory tract [sinuses, nose, trachea (windpipe), and lungs], kidneys, eyes, nerves and skin.

RIABNI is a monoclonal antibody. Antibodies are proteins which are produced to bind to another protein called an antigen. RIABNI binds to an antigen on the surface of a type of white blood cell, the B lymphocyte. When RIABNI binds to the surface of this cell, it causes the cell to die.

What are the ingredients in RIABNI?

Medicinal ingredients: rituximab

Non-medicinal ingredients: hydrochloric acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection.

RIABNI comes in the following dosage forms:

Liquid concentrate for intravenous (IV) administration.

Who should take RIABNI?

RIABNI is used to reduce signs and symptoms of moderate-to-severe rheumatoid arthritis in people who have tried other medicines called TNF antagonists, which have either stopped working or have not worked well enough. RIABNI is taken together with another medicine called methotrexate. When taken with methotrexate, RIABNI has been shown to reduce the rate of progression of joint damage as measured by x-ray.

RIABNI is also used in the treatment of severe Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). RIABNI is taken together with other medicines referred to as glucocorticoids or "steroids". RIABNI has been shown to reduce inflammation and helps to control your disease.

Do not use RIABNI if:

If you are allergic to rituximab or proteins of similar origin or any other non-medicinal ingredient in RIABNI or if you have ever had a rare infection of the brain called progressive multifocal leukoencephalopathy (PML) you should not take RIABNI.

RIABNI is not recommended unless patients' moderate-to-severe rheumatoid arthritis has not been controlled with medicines called TNF antagonists.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take RIABNI. Talk about any health conditions or problems you may have, including if you:

- ever had a bad reaction to rituximab or any of the non-medicinal ingredients.
- are allergic to other medications, food or dyes
- have a history of heart disease, heart attack or stroke
- are taking any other medicines (including those not prescribed by the doctor). If you are taking or took another biologic medicine called a TNF antagonist or a DMARD (disease modifying anti-rheumatic drug). If you are taking medication to reduce blood pressure. If you are planning to be immunized with a vaccine during or after the completion of your RIABNI therapy
- have a pre-existing lung disease as you may have a greater chance of breathing difficulties during your RIABNI treatment infusion
- have a history of hepatitis B or current hepatitis B infection
- have a history of chronic or recurrent infection
- are pregnant or plan on becoming pregnant or are breast-feeding a child

Other warnings you should know about:

- Rituximab has not been studied in pregnant or breast-feeding women. If you are pregnant or breast-feeding, be sure to discuss with your doctor whether RIABNI is right for you. Women in whom there is a possibility of conceiving a child should avoid becoming pregnant and use effective contraceptive methods during and up to 12 months after treatment with RIABNI.
- RIABNI is an infusion (“drip”) which is given intravenously (into your veins). Some patients being given rituximab have some side effects while the infusion is being given. If you notice any difficulty breathing, feel hot or shivery, have hives or an itchy rash, tell the person giving you the infusion immediately. These effects mainly occur with the first infusion of RIABNI. If you develop any of these symptoms, the infusion will be slowed down or stopped for a while. Some patients will need to take an antihistamine or acetaminophen. When these symptoms go away, or improve, the infusion can be continued.
- If you have ever had heart disease (i.e. angina, palpitations, or heart failure) or a history of breathing problems, your doctor will take special care of you during therapy with RIABNI.
- The cells that are killed by RIABNI help to fight infection. RIABNI should not be given to people who have an active infection. Tell your doctor if you think you may have an infection, even a mild one like a cold, before he gives you the medicine. Also, please tell your doctor if you have a lot of infections or suffer from severe infections.
- You might get infections more easily following RIABNI therapy. It is very important to tell your doctor if you get any symptoms of an infection, for example fever, cough, sore throat, burning pain when passing urine, or you start to feel weak or generally unwell.
- In some cases, patients who have had hepatitis B might have a repeat attack of hepatitis. Tell the doctor if you think you have had hepatitis in the past.

- Infection with hepatitis B virus causes inflammation of the liver which may show as mild fever, feeling of sickness, fatigue, loss of appetite, joint and/or abdominal pain and yellowing of whites of the eyes, skin and tongue. If you experience any of these symptoms immediately contact your doctor. If you show evidence of hepatitis B virus infection you may be referred to a liver disease expert for ongoing monitoring and management.
- RIABNI is not to be used in patients with active hepatitis B viral disease. Tell your doctor if you think you have hepatitis B.
- Live viral vaccines should not be given with RIABNI. Your doctor will check if you should have any vaccines before or after you receive RIABNI.
- Cases of Progressive Multifocal Leukoencephalopathy (PML) have been reported following use of rituximab for the treatment of autoimmune diseases, including RA. PML is a condition that causes nerve damage within the brain. Tell your doctor immediately if you have memory loss, trouble thinking, difficulty with walking, clumsiness, falls or weakness on one side of the body, changes in mood or loss of vision. Your doctor will check if you need to see a neurologist.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with RIABNI:

Before starting treatment, make sure your doctor knows if you are taking or have recently taken any other medicines (including those you have bought for yourself from a pharmacy, supermarket or health store). This is extremely important, as using more than one medicine at the same time can strengthen or weaken their effect. RIABNI should not be used with other drugs unless your doctor has told you it is safe to do so.

How to take RIABNI:

Your doctor has prescribed RIABNI after carefully studying your case. Other people may not benefit from taking this medicine, even though their problems may seem similar to yours.

Before the infusion is given you will be given medicines to prevent or reduce possible reactions to RIABNI.

RIABNI is not taken by mouth but given through an intravenous line. An intravenous line, or I.V., is a thin, plastic tube placed in a vein in your hand or arm. When RIABNI is given intravenously, it is called an infusion.

Where may I receive the infusion:

Your doctor or Amgen Entrust™ Patient Support Programs will help you to decide where you will receive the infusion. The Entrust™ Infusion Network consists of clinics located across Canada that are staffed by qualified healthcare professionals specially trained in the administration of RIABNI infusions. Information about the about Entrust™ Patient Support Program can be obtained by calling Enliven® by Amgen Entrust™ at 1-877-936-2735.

Usual dose:***Rheumatoid Arthritis***

Each course of treatment is made up of two separate infusions which are given at least 2 weeks apart. Repeated courses of treatment with RIABNI are possible. Depending on the signs and symptoms of your disease, your doctor will decide when you should receive more RIABNI.

Granulomatosis with Polyangiitis and Microscopic Polyangiitis

RIABNI is administered as a weekly intravenous infusion for 4 weeks.

Overdose:

It is unlikely that you will receive too much RIABNI as you will be closely monitored by Healthcare Professionals during your infusion. However, if you suspect you received too much RIABNI contact your healthcare professional and poison control centre immediately.

If you think you, or a person you are caring for, have taken too much RIABNI, contact a healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose of RIABNI, contact your healthcare professional immediately. Your healthcare professional will decide when you should receive your next dose.

What are possible side effects from using RIABNI?

These are not all the possible side effects you may feel with taking RIABNI. If you experience any side effects not listed here, tell your healthcare professional.

The most common possible unwanted effects are infusion related events:

- Fever and chills
- Nausea, vomiting, fatigue (feeling tired or weak), headache, skin rash, hives, redness of the skin, itchiness, wheezing or tightness in the chest, shortness of breath, difficulty breathing, sensation of the tongue or throat swelling, throat irritation, rhinitis (runny nose), temporary low blood pressure, high blood pressure, flushing, dizziness on standing up, fast heartbeat, pain in the mouth/throat, swelling of the hands and feet.

If these unwanted effects occur, it is most common within 30 minutes to 2 hours after starting the first infusion, but may also occur after the infusion has finished. The symptoms are usually mild to moderate, and can be easily treated. Rarely, these reactions can be severe. These unwanted effects are less common after the first treatment.

These unwanted effects can be prevented or managed by:

- Slowing or interrupting your infusion of RIABNI. The treatment can be restarted once the symptoms have resolved.
- Giving a fever reducer, such as **TYLENOL®**, and an antihistamine, such as **BENADRYL®** before each infusion of RIABNI. Sometimes additional medications are needed to be given to treat these unwanted effects.

Additionally:

- Your doctor may instruct you not to take your blood pressure medication 12 hours before and delay taking until after your infusion of RIABNI is complete. Please ask your doctor for specific instructions.
- Because some of the medications given with RIABNI may cause some dizziness or sleepiness, you should arrange for someone else to drive you home after each treatment.

In addition to the unwanted effects described above, there are certain adverse events identified which are specific to GPA/MPA patients, namely muscle spasms, increases in liver enzymes and nose bleeds.

There are also possible unwanted effects which could be serious but occur less commonly:

- Some patients get infections after treatment. Often these are colds but could be pneumonia or urinary infections. Some other effects might occur, but are less likely, including: pain in the tummy, back, chest, muscles and/or joints, at the infusion site, feeling unwell, changes in blood pressure, changes in heart rate, diarrhea, indigestion, cramp, dizziness, tingling or numbness, anxiety or nervousness, cough, watery or itchy eyes, runny or itchy nose, sweating, sinusitis.
- Some patients also have some changes to blood tests including a fall in the number of red cells, white cells or both. Severe but rare reactions, in particular severe breathing difficulties and severe skin reactions including blistering, could be fatal. This is why your doctor will watch you closely, and why it is important for you to tell your doctor immediately if you experience any difficulty in breathing and any skin reactions.
- Some patients also have increasing weakness on one side of the body, clumsiness or falls, trouble with thinking or memory, changes in mood, change in vision. You should report these to your doctor immediately.

If you are receiving RIABNI in combination with other medicines, some of the side effects you may experience may be due to the other medicine.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
COMMON			
New fever or if your temperature becomes higher than 38°C		√	
Shortness of breath, difficulty breathing, wheezing, coughing		√	
Symptoms of infection that include: <ul style="list-style-type: none"> - Fever, temperature at 38°C or higher - Sore throat - Cough - Any redness or swelling - Pain when you pass your urine 		√	
Any bleeding or unusual bruising		√	
Skin rash, itching, hives or sore joints		√	
Swelling of the face, lips, mouth or throat which may cause difficulty in swallowing or breathing, swelling of the hands, feet or ankles		√	
Symptoms of Hepatitis B such as mild fever, feeling of sickness, fatigue, loss of appetite, joint and/or abdominal pain and yellowing of whites of the eyes, skin and tongue		√	
UNCOMMON			
Changes in blood pressure, changes in heart rate		√	
Redness or blistering of the skin		√	√
Increasing weakness on one side of the body, clumsiness or falls, trouble with thinking or memory, changes in mood, change in vision		√	
Sudden loss of speech, increasing weakness or numbness of part or all of one side of the body, loss of vision or blurred vision, unexplained dizziness and/or clumsiness or sudden falls, trouble with thinking or memory, changes in mood, change in vision, change in mental status (for example, confusion), seizures		√	
Symptoms of shingles such as itching, tingling, or severe burning pain with red patches that develop into blisters and are grouped in a cluster usually on the trunk of the body		√	
Kidney problems such as lower back or side pain, swelling of feet or lower legs, numbness or tingling in feet or hands		√	
Redness or blistering of the skin and inside the mouth		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store vials in a refrigerator at 2°C to 8°C. Protect from light. Do not freeze or shake.

Keep out of reach and sight of children.

If you want more information about RIABNI:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website www.amgen.ca, or by calling 1-866-502-6436.

This leaflet was prepared by Amgen Canada Inc.

Last Revised: